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applications in the prevention, diagnosis, and treatment of a wide range of diseases. However, before
nanoparticulate agents can be brought into clinical use, they must first be developed, optimized, and evaluated
in animal models. In the typical pre-clinical paradigm, almost all of the optimization is done at the in vitro
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how a nanoparticle will perform in animal studies. Therefore, a method that allows many agents to be
evaluated in a single animal subject would allow for much more efficient and predictive optimization of
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we are successfully able to use inductively coupled plasma mass spectrometry (ICP-MS) to quantitatively
determine a nanoparticle's blood clearance kinetics, biodistribution, and tumor delivery. This approach was
applied to evaluate both passive and active tumor targeting, as well as metabolically directed targeting of
nanoparticles to low pH tumor microenvironments. Importantly, we found that these in vivo measurements
could be made for many nanoparticle formulations simultaneously, in single animals, due to the high-order
multiplexing capability of mass spectrometry. This approach allowed for efficient and reproducible
comparison of performance between different nanoparticle formulations, by eliminating the effects of subject-
to-subject variability. In the future, we envision that this "higher-throughput" evaluation of agents at the in
vivo level, using ICP-MS multiplex analysis, will constitute a powerful tool to accelerate pre-clinical evaluation
of nanoparticles in animal models.
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ABSTRACT 
 
ICP-MS ANALYSIS OF LANTHANIDE-DOPED NANOPARTICLES: A 
QUANTITATIVE AND MULTIPLEXING APPROACH TO INVESTIGATE 
BIODISTRIBUTION, BLOOD CLEARANCE, AND TARGETING 
 
 
Samuel Crayton 
 
Andrew Tsourkas, Ph.D. 
 
The rapidly progressing field of nanotechnology promises to revolutionize healthcare in 
the 21st century, with applications in the prevention, diagnosis, and treatment of a wide 
range of diseases. However, before nanoparticulate agents can be brought into clinical 
use, they must first be developed, optimized, and evaluated in animal models. In the 
typical pre-clinical paradigm, almost all of the optimization is done at the in vitro level, 
with only a few select agents reaching the level of animal studies. Since only one 
experimental nanoparticle formulation can be investigated in a single animal, and in vivo 
experiments have relatively higher complexity, cost, and time requirements, it is not 
feasible to evaluate a very large number of agents at the in vivo stage. A major drawback 
of this approach, however, is that in vitro assays do not always accurately predict how a 
nanoparticle will perform in animal studies. Therefore, a method that allows many agents 
to be evaluated in a single animal subject would allow for much more efficient and 
predictive optimization of nanoparticles. We have found that by incorporating lanthanide 
tracer metals into nanoparticle formulations, we are successfully able to use inductively 
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coupled plasma mass spectrometry (ICP-MS) to quantitatively determine a nanoparticle’s 
blood clearance kinetics, biodistribution, and tumor delivery. This approach was applied 
to evaluate both passive and active tumor targeting, as well as metabolically directed 
targeting of nanoparticles to low pH tumor microenvironments. Importantly, we found 
that these in vivo measurements could be made for many nanoparticle formulations 
simultaneously, in single animals, due to the high-order multiplexing capability of mass 
spectrometry. This approach allowed for efficient and reproducible comparison of 
performance between different nanoparticle formulations, by eliminating the effects of 
subject-to-subject variability. In the future, we envision that this “higher-throughput” 
evaluation of agents at the in vivo level, using ICP-MS multiplex analysis, will constitute 
a powerful tool to accelerate pre-clinical evaluation of nanoparticles in animal models. 
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Chapter 1: Introduction to Nanoparticle Diversity, Applications, 
Delivery, and Detection 
1.1 Introduction 
Extensive research is currently underway on a global scale to develop 
nanotechnology for applications in the prevention, diagnosis, and treatment of disease. 
Such innovations have the potential to revolutionize healthcare in the 21st century by 
improving quality of life, extending life expectancy, and reducing healthcare costs.1 
Already, nanoparticles platforms are being applied to diverse fields including 
regenerative medicine,2 vaccines,3 imaging,4, 5 surgery,6 and drug delivery.7, 8 Given the 
variety of materials used in nanoparticle synthesis, the breadth of their applications, and 
growth of active targeting molecules, the number of distinct nanoparticle formulations is 
truly astronomical. 
In order to evaluate the performance of any nanoparticle formulation, a central 
consideration is what amount of nanoparticles (or nanoparticle payload) has reached the 
particular site of interest. It is also important to examine the amount of nanoparticles 
delivered to off-target tissues, since this can lead to increased toxicity in drug delivery 
studies and diminished contrast in imaging studies. Additionally, it is helpful to examine 
the blood clearance profile for any nanoparticles under investigation, since this will 
influence nanoparticle delivery to both the target of interest and other locations.  
There are a number of approaches to assessing nanoparticle concentrations in 
vitro and in tissue or blood samples. They range from direct and quantitative methods, 
such as radiolabeling, to indirect and qualitative surrogates, like the rate of tumor growth 
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following nanoparticle administration. The nanoparticle detection technique chosen by 
the investigator is influenced by a number of factors including convenience, cost, and 
level of detail required. Ideally, every evaluation of nanoparticle performance would 
include quantitative and absolute determination of nanoparticle particle concentration at 
the site of pathology, in off-target locations, and in the blood. However, the gold standard 
for such measurements (radiolabeling) can be inconvenient for many investigators, due to 
the special handling requirements of radioactive materials and quarantine considerations 
of exposed animal subjects. Consequently, it is common for investigators to rely on semi-
quantitative measurements such as whole-animal and ex vivo fluorescence measurements. 
A convenient and cost-effective alternative to radiolabeling that provides quantitative 
measurements of biodistribution and blood clearance could make these data more 
accessible to nanoparticle investigators. 
Inherent in any nanoparticle study is also the comparison of delivery between two 
or more formulations. For example, a passive targeting study might seek to optimize 
some nanoparticle property (such as size, shape, charge, surface coating, or elasticity), 
which requires comparison of multiple formulations that vary across the property of 
interest. Or an active targeting study might compare the actively targeted agent to a 
negative control that lacks the targeting ligand. Conventionally, these comparisons would 
be made by administering each agent in a separate cohort of animals. The major 
drawback to this approach, however, is the large animal-to-animal experimental 
variability of in vivo studies. A convenient way to compare agents while controlling for 
subject-to-subject variability is to employ a ratiometric/multiplex approach, whereby two 
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or more agents are administered simultaneously to a single subject, and a “signal” from 
each one can be independently resolved. 
Even when radiolabeling is used to trace a nanoparticle’s biodistribution and 
blood clearance, it is usually only feasible to examine one nanoparticle formulation in a 
single sample or animal. It is possible to employ a ratiometric approach with 
radiolabeling, using gamma emitters with resolvable energies9 or a combination of 
gamma counting and scintillation,10 but physical restrictions of energy resolution 
ultimately limit the number of compounds that can be simultaneously investigated. 
Herein, we have sought to streamline the evaluation of sets of distinct 
nanoparticle formulations, in vitro and in vivo, with the use of a quantitative and 
multiplex assay for nanoparticle detection. Specifically, we have developed a method 
whereby the concentration of superparamagnetic iron oxide (SPIO) nanoparticles can be 
quantitatively determined using inductively coupled mass spectrometry (ICP-MS) of a 
lanthanide metal tracer incorporated into the nanoparticle. Importantly, the concentration 
of each lanthanide metal can be determined independently of other lanthanides present in 
the sample. Therefore, it is possible to simultaneously administer multiple SPIO 
formulations, with distinct physicochemical properties, to a single animal subject and 
orthogonally assess their blood clearance, biodistribution, and passive delivery to a tumor 
xenograft (Chapter 2). Investigation into the versatility of this system found that it could 
be easily extended to a number of other commonly used imaging and therapeutic 
nanoparticle constructs, such as liposomes, polymersomes, dendrimers, and gold 
nanoparticles (Chapter 3). The technique was then applied to compare the active targeting 
capability of SPIO formulations directed against distinct tumor markers (Chapter 4). 
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Finally, a novel pH-sensitive SPIO nanoparticle was engineered for the detection of 
acidic tumor microenvironments, and the ICP-MS based method was used to evaluate its 
performance in vivo (Chapter 5). In this chapter, extensive background is provided on the 
mechanisms of active and passive nanoparticle delivery, pH mediated delivery and 
imaging, commonly used nanoparticle platforms, and typical methods of nanoparticle 
detection and imaging in vivo. 
1.2 Background 
1.2.1 Passive and Active Targeting of Nanoparticle Platforms 
1.2.1a Overview 
As a nascent tumor develops, it will reach a stage in which the nutrient and waste 
exchange through its local vasculature is insufficient to sustain its accelerated growth 
profile.11 Thereafter, the tumor initiates the process of angiogenesis, in order to form new 
blood vessels and allow for continued growth. Often these rapidly generating blood 
vessels possess an abnormal basement membrane and an increased density of pericytes 
associated with the proliferating endothelial cells.12 Consequently, the tumor neo-
vasculature exhibits an increased level of permeability to macromolecular components. 
Additionally, actively growing tumors often have disorganized and disrupted lymphatic 
vessels, resulting in poor lymphatic drainage and impaired clearance of material from the 
tumor interstitium.11 This combination of leaky vasculature and inefficient lymphatic 
drainage results in a phenomenon known as the enhanced permeability and retention 
(EPR) effect. EPR is a driving force for nanoparticles to preferentially accumulate in 
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regions of malignancy and is consistently exploited in studies of nanoparticle-based 
imaging and therapeutic agents. Tumor accumulation derived solely from the 
nanoparticle’s blood residence time and the EPR effect is commonly referred to as 
passive targeting. Methods to improve nanoparticle tumor delivery, through specific 
interactions with malignant cells or extracellular components, are termed active targeting. 
Figure 1.1 depicts tumor delivery by the EPR effect and further enhancement through 
active targeting.  
 
Figure 1.1 Schematic of the enhanced permeability and retention (EPR) effect (passive 
targeting) followed by nanoparticle binding to tumor cell receptor (active targeting)13 
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1.2.1b Passive Targeting 
Passive targeting of nanoparticle formulations is their preferential, but non-
specific, accumulation at a tumor site secondary to the EPR effect. Even with a highly 
permeable tumor vasculature, many passes through the circulation are required in order 
for a large amount of nanoparticles to extravasate at the tumor. Therefore, a central 
component of passive delivery is the design of nanoparticles with long in vivo circulation 
times. One major obstacle to passive tumor delivery is the reticuloendothelial system 
(RES), also commonly known as the mononuclear phagocyte system (MPS), which 
efficiently clears nanoparticulate material from blood circulation.14 Accordingly, 
nanoparticle formulations must be engineered to minimize interaction with the cells of 
the RES. It is known that many properties of a nanoparticle (e.g. size, shape, surface 
charge, hydrophilicity, and specific coating material) all influence the nanoparticle’s 
interaction with blood and cellular components, thereby affecting circulation time. 15  
The hydrodynamic diameter of a nanoparticle has a very strong influence on 
circulation time and passive nanoparticle delivery.16 Specifically, nanoparticles smaller 
than 5 nm are under the renal filtration threshold and are very rapidly cleared from 
circulation. Blood circulation time and passive delivery by EPR is usually optimized for 
nanoparticle sizes in the 10 – 100 nm range, where interaction with the RES is 
minimized. Once the nanoparticle size begins to exceed 100 nm, interaction with the RES 
increases again and extravasation through capillary fenestrations becomes impaired.17 
Also critically important to nanoparticle circulation time and passive tumor 
delivery by EPR is surface charge. Previous studies have demonstrated that prolonged 
blood circulation, and therefore, optimal tumor delivery is achieved with nanoparticles 
displaying a neutral to mildly negative surface charge.14, 18 When the surface charges 
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becomes overly negative, excessive association with phagocytic cells of the 
reticuloendothelial system (RES) decreases circulation time,14, 18 and it has been 
commonly reported that positively charged nanoparticles are cleared very rapidly due to 
local electrostatic interactions near the injection site 19.  
Specific properties of the nanoparticle coating material (e.g. hydrophilicity) also 
influence nanoparticle circulation time. Since many groups have demonstrated that 
incorporation of polyethylene glycol (PEG) into the surface of nanoparticles helps avoid 
opsonization and increases circulation times,15, 20, 21 nanoparticle PEGylation is a very 
popular method to impart in vivo stealth properties.22 Although PEGylation increases a 
nanoparticle’s circulation time by minimizing its interactions with the RES, it may also 
impair the nanoparticle’s ability to interact with tumor cells, thereby limiting uptake via 
endocytic pathways. 23, 24 This potential drawback also must be considered when 
designing nanoparticles for active targeting studies, so as not to have the nanoparticle’s 
PEG brush mask or bury the active targeting ligand. 
1.2.1c Active Targeting Strategies 
 Active targeting is a nanoparticle delivery strategy whereby affinity ligands on the 
agent’s surface bind to specific receptors or biomarkers within the tumor. It is important 
to note that successful active targeting still relies on efficient extravasation of the 
nanoparticles through the permeable tumor endothelium. Therefore, the nanoparticle’s 
physicochemical properties, which influence blood circulation and passive delivery by 
the EPR effect, are still critically important in the design of actively targeted 
nanoparticles. Once delivered to the tumor, however, actively targeted agents possess 
several key advantages. While completely passive targeting is dependent on poor 
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lymphatic drainage in order to achieve nanoparticle retention at the tumor site, active 
targeting also exploits specific binding to tumor receptors.25 Thus, actively targeted 
nanoparticles can accumulate at higher concentrations compared to passively targeted 
formulations, which are more easily washed out of the tumor interstitial compartment.  
Also, depending on the type and surface density of ligands on the nanoparticle, it 
is possible for the actively targeted agent to be internalized once it becomes bound.26, 27 
Unlike individual antibodies, nanoparticles have varying degrees of multivalency, which 
further increases the likelihood of cellular internalization.28, 29 For drug delivery 
applications with membrane permeable drugs, nanoparticle delivery to the interstitial 
compartment can be sufficient to achieve a therapeutic dose. However, membrane 
impermeable payloads, such as hydrophilic small molecules, proteins, peptides, or 
nucleic acids, require the nanoparticle to deliver them into the cell. Also, when 
nanoparticles are internalized within cells, they payload is more efficiently trapped within 
the tumor region and cell surface becomes available for interaction with additional 
nanoparticles, resulting in greater payload delivery to the tumor. For these reasons, active 
targeting strategies, whereby nanoparticles are engineered to specifically bind to tumor 
cells and become internalized, have the potential to enhance diagnostic and therapeutic 
potential. 
1.2.1d Specific Active Targeting Biomakers Examined 
A number of actively targeted agents for diagnosis and treatment of cancer are 
currently in clinical use and an even greater number are currently being investigated. 
They range in scale from radiolabeled small molecules such as 18F-fluorodeoxyglucose 
for PET imaging of tumor metabolic activity,30 short peptide analogs like 111In-
9 
 
pentetreotide for neuroendocrine tumor imaging,31 to antibodies such as 131I-anti-CD20 
for treatment of recurrent B-cell lymphoma,32 to nanoparticle assemblies for magnetic 
resonance imaging of tumors.33 Various specific receptors have been targeted including 
folate,34 transferrin,35 EGFR,36 IL2,37 and many others. In addition to directly targeting 
surface receptors on malignant cells, contrast agents have been developed for to detect 
neovascularization38, 39 and apoptosis,40, 41 two phenomena associated with tumorigenesis. 
In Chapter 4, three specific active targeting receptor/ligand pairs will be examined and 
background on these is provided below: 
HER2/neu Receptor and Affibody Ligand 
 Human epidermal growth factor receptor 2 (HER2/neu) is a surface receptor 
tyrosine kinase involved in signal transduction pathways of cell growth and 
differentiation.42 It is overexpressed in approximately 30% of breast cancers, where it 
correlates with increased tumor aggressiveness and metastatic potential.43, 44 HER2/neu 
may also be overexpressed in ovarian cancer,45 colorectal cancer,46 and aggressive forms 
of endometrial carcinoma.47 For these reasons, HER2/neu was identified as a promising 
target for tumor active targeting strategies, and an anti-HER2/neu monoclonal antibody 
(trastuzumab, Herceptin) is used clinically in the treatment of HER2 positive breast 
cancers.48 For nanoparticle active targeting, one very promising ligand for HER2 
targeting is the HER2/neu affibody. Affibodies are an attractive class of alternative 
scaffold proteins derived from a 58-amino acid portion of staphylococcal protein A.49 
They possess a high degree of specificity (similar to antibodies) but have a smaller 
molecular weight of approximately 6.6 kDa (similar to phage-derived peptides).50, 51 The 
HER2/neu affibody has high specificity and pM affinity for the HER2/neu receptor, and 
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has been utilized for several nanoparticle-based studies, with a high degree of targeting 
success.52-54 
αVβ3 Integrin and Cyclic RGD Ligand 
 αVβ3 integrin serves as a receptor for extracellular matrix proteins with exposed 
arginine-glycine-aspartate (RGD) motifs, including fibronectin, vitronectin, lamin, and 
collagen.55-57 Integrin binding facilitates cellular migration along these matrix proteins of 
the intercellular space and basement membrane.58, 59 It is expressed at low levels on 
epithelial and mature endothelial cells, but is overexpressed on activated endothelial cells 
associated with the neovascularization of tumors.60-62 Interestingly, in tumor xenograft 
models αVβ3 integrin can be overexpressed both on the malignant cells, themselves, and 
on host-derived proliferating endothelial cells.63 Therefore, synthetic cyclic RGD 
containing peptides are an attractive candidate for active targeting of rapidly growing and 
metastatic tumors. In fact, radiotracers based on cyclic RGD are being investigated for 
radiotherapy of αVβ3 integrin positive tumors and imaging with single photon emission 
computed tomography (SPECT) and positron emission tomography (PET).64-66 
HSP47 and LDS Affinity Peptide 
 Heat shock protein 47 (HSP47) is a collagen binding protein belonging to the 
serine protease inhibitor (serpin) family.67 Its expression is upregulated during a cellular 
stress response to noxious stimuli including high temperature, heavy metal exposure, and 
oxidative stress.68 HSP47 is overexpressed in a range of human cancers including oral 
squamous cell carcinoma,69 gastric cancer,70 pancreatic ductal carcinoma,71 lung cancer,72 
and colonic adenocarcinoma secondary to ulcerative colitis.73 The ligand chosen to target 
HSP47 was a small peptide affinity ligand called “LDS”, based on its first three residues. 
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LDS was derived from phage display panning against HSP47 and its binding to HSP47 
positive tumor cells has been demonstrated.74 
1.2.2 pH Imaging 
 Besides passive nanoparticle delivery (Chapter 2) and conventional 
receptor/ligand based active targeting (Chapter 4), another increasingly popular strategy 
is to target local metabolic changes associated with malignancy. In Chapter 5, we present 
a novel pH-sensitive SPIO nanoparticle and evaluate its performance in vivo using a 
lanthanide tracer. Accordingly, this section contains background information on tumor 
pH alterations and pH imaging agents. 
1.2.2a Tumor pH Alterations  
In healthy mammalian tissues, acid-base homeostasis is maintained through a delicate 
balance between acid production and removal.  A pH regulatory mechanism is necessary 
since acids are an invariable side product of both aerobic and anaerobic metabolism.  In 
the case of aerobic metabolism, sugar is metabolized to pyruvate, which in the presence 
of oxygen is oxidized by the mitochondria to CO2 and H2O.  CO2 is then transported 
outside the cell where it is hydrated by carbonic anhydrases to form bicarbonate plus a 
free proton, H+.  In the case of anaerobic metabolism, i.e. in the absence of oxygen, 
pyruvate is reduced to lactic acid and is subsequently exported from cells.  Once in the 
extracellular space, acids diffuse from the site of production to the blood, where they are 
buffered by an open and dynamic CO2/HCO3- system. 
Although the physiological mechanisms responsible for stabilizing the intra- and 
extracellular pH are quite robust, many pathological conditions including cancer have 
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been associated with an increase in tissue acidity.  This sub-physiological pH is thought 
to arise from the increase in glycolysis, seen in nearly all invasive cancers (even under 
aerobic conditions), and poor perfusion, due to a chaotic and heterogeneous 
microvasculature in the tumor microenvironment.  Interestingly, it has been observed that 
even in the absence of glycolysis the extracellular pH can still reach values as low as 
6.65;75 however, it has been hypothesized that elevated glycolysis may still be needed for 
“hyperacidity”.76  Numerous studies have shown that the extracellular pH of human and 
animal tumors can reach values approaching 6.0, which is likely not possible without 
elevated glycolysis.77, 78 The critical importance of identifying pathologies with sub-
physiologic pH stems from studies that show low pH stimulates in vitro invasion and in 
vivo metastases.79, 80 This has led to the development of numerous techniques and 
imaging strategies for measuring pH in vivo. 
1.2.2b Absolute pH Imaging 
In recent years, numerous methods have been developed that allow for the non-
invasive assessment of tissue pH, most of which are based on magnetic resonance.81 One 
common technique relies on the 31P MR resonance of phosphate.82 Since intracellular 
inorganic phosphate (Pi) concentrations are higher than extracellular concentrations and 
the intracellular volume fraction is greater than 50%, the chemical shift of endogenous Pi 
is generally thought to reflect intracellular pH. Extracellular pH of tumors can also be 
separately measured using exogenous agents such as 3-aminopropylphosphate (3-APP).83 
3-APP is a non-toxic, membrane impermeant compound that has a pH-dependent 
chemical shift, 1 ppm per pH unit, in the physiological range. 
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Exogenous agents have also been developed with pH-sensitive 19F resonances.84, 85  
The almost complete lack of endogenous 19F resonances in normal tissues combined with 
the high gyromagnetic ratio and large chemical shift dispersion of 19F compounds has 
been reported to result in improved signal-to-noise and resolvable pH-dependent 
chemical shifts, compared with 31P MRS of 3-APP.  However, drawbacks of 19F 
approaches include the instability of fluorinated compounds and the inability to 
simultaneously measure other metabolic compounds.81 
Since the 1H nucleus offers the highest inherent sensitivity for MR detection and 
because it is possible to image the spatial distribution of tissue pH with pH-sensitive 1H 
resonances, numerous groups have employed imidazole-based compounds such as IEPA 
to measure pH in vivo.86-89 IEPA is non-toxic, membrane impermeant, and has few 
interfering background resonances. The drawback of using IEPA, however, is that the 
chemical shift is only 0.7 ppm over the entire titration range, which generally means that 
imaging must be conducted under (high) field strengths that are not available in most 
clinics. An alternative 1H MR imaging method exploits the pH-dependent magnetization 
transfer (CEST) between bulk phase water and either endogenous protein amide groups 
or exogenous probe molecules.90, 91 pH-dependent gadolinium-based relaxation agents 
can also be used;92-94 however, both of these approaches require an accurate 
determination of probe concentration, which is difficult to achieve in vivo. 
Recently, magnetic resonance imaging of pH has also been performed using 
hyperpolarized 13C-labeled bicarbonate.95  Specifically, pH was imaged from the ratio of 
signal intensities of hyperpolarized bicarbonate (H13CO3-) and 13CO2.  The spatial 
distribution of 13CO2 and H13CO3- was imaged in a mouse tumor model with an image 
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resolution of 16 x 16 voxels, each measuring 2 x 2 x 6 mm, on a 9.4T MR. This clearly 
represents another step towards the ultimate goal of imaging pH in human clinical 
pathologies; however, advancements must still be made to improve the spatiotemporal 
resolution of MR spectroscopy on 1.5T scanners before these techniques are adopted for 
routine clinical use.  
1.2.2c Relative pH Imaging 
A complimentary approach to absolute pH imaging MRS (where the pH is 
determined by the chemical shift of the probe) or CEST (where changes in pH influence 
the chemical exchange kinetics) is to detect regions of relatively abnormal pH by 
designing agents that preferentially accumulate in these regions. That is, the identity of 
the signal is not influenced by pH, but the biodistribution of the agent is influenced by 
pH. In this respect, such an agent has much in common with a classic receptor/ligand 
actively targeted molecule; the agent washes into the tumor through the enhanced 
permeability of the tumor vasculature and then is preferentially retained at the tumor site 
through pH mediated alterations in the nanoparticle’s physicochemical properties. 
One such targeting moiety is pH low insertion peptide (pHLIP).96-98 At neutral or 
basic pH this peptide exists in equilibrium between an unstructured aqueous 
conformation and a conformation bound to the surface of lipid bilayers. As pH falls 
below 7.0, the equilibrium is directed towards a transmembrane helical conformation 
such that the affinity of pHLIP for cell membranes is approximately 20 times higher at 
low pH. Once inserted across a cell membrane at low pH, it can remain in place on the 
order of days. This pH-sensitive peptide has subsequently been used to produce pH 
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sensitive contrast agents. An optical agent consists of pHLIP directly conjugated to 
fluorescent dye (e.g. Cy5.5), and has been used in animal models to detect tumors and 
visualize tumor margins in mock surgical procedures.99 A PET agent was constructed by 
pHLIP conjugation to 64CuDOTA. Studies using mouse xenografts of two human prostate 
cancer cell lines demonstrated the PET agent avidly concentrated at the tumor site in a 
pH dependent manner.100 Beyond pHLIP agents, recently, a pH sensitive MR contrast 
agent has been reported that consists of magnetic nanoparticles encapsulated by PEG-
PAE diblock copolymer.101 The composite particle is stable in aqueous environments at 
physiologic pH and higher, but upon exposure to pH less than 7.0, the PAE polymer 
block is protonated, leading to destabilization of the construct and precipitation of the 
magnetic nanoparticles in situ. Once micro-precipitation occurs at the tumor site, the MR 
signal is amplified and diffusion of the agent out of tumor becomes more difficult. 
1.2.3 Diversity of Nanoparticle Platforms and Properties 
 There are many different nanoparticle architectures, built from a wide array of 
materials, possessing great variation across a range of physicochemical parameters. In 
order to optimize nanoparticle characteristics, improve nanoparticle performance in 
animal models, and identify specific agents to bring to clinical testing, a method allowing 
convenient and quantitative detection of multiple agents in a single animal would be 
valuable. Chapters 2 and 3 demonstrate how ICP-MS multiplex analysis can be adapted 
to a wide range of nanoparticle platforms in vivo. Accordingly, background on these 
specific nanoparticle constructs is provided in the following section. 
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1.2.3a Superparamagnetic Iron Oxide (SPIO) Nanoparticles 
 SPIO nanoparticles typically consist of a magnetite (Fe3O4) and/or maghemite 
(γFe2O3) iron core and a hydrophilic surface coating.33 In the presence of an external 
magnetic field, the magnetic moments of the SPIO align with the field and enhance the 
local magnetic flux. This effect allows them to influence both the longitudinal and 
transverse relaxation of surrounding protons. While the iron oxide core is responsible for 
generating magnetic contrast, the hydrophilic coating is used to improve the solubility, 
biocompatibility, and stability of the iron oxide nanoparticles. A variety of biocompatible 
polymers have been employed as the coating, including PEG and PLGA, and 
polysaccharides, such as dextran.33, 102 Varieties of surface modifications (including 
attachment of targeting ligands) can subsequently be applied to SPIO, depending on the 
particular application. 
 
Figure 1.2. Illustration of dextran stabilized superparamagnetic iron oxide (SPIO), with 
metal core in brown and dextran chains in blue. 
 
 Clinical use of SPIO nanoparticles as MR contrast agents began in the 1980’s. 
Since SPIO nanoparticles often exhibit uptake in the organs of the RES, they are well 
suited to aid in delineation of both primary tumors of the liver103 as well as metastatic 
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lesions.104  Furthermore, since SPIO nanoparticles gain access to the lymphatic drainage 
of tumors and lymph nodes contain a high number of phagocytic cells, SPIO can be used 
to survey for lymph node metastases, which aids in cancer staging and therapeutic 
planning.105-107 Although this application is promising, the ultimate goal is to utilize SPIO 
nanoparticles for cellular and molecular imaging applications, allowing for the detection 
of malignancies prior to metastasis. 
 Detection of non-RES primary tumors with SPIO nanoparticles is currently 
impeded by the sensitivity limitations associated with many MR contrast agents. There 
are numerous approaches for improving SPIO nanoparticle sensitivity, including the 
optimization of SPIO magnetic properties, SPIO targeting methods, MR pulse sequences, 
MR hardware, and signal post-processing techniques. For example, incorporation of 
hetero-metals such as manganese into the iron core108-110 has been shown to increase 
relaxivity, and loading multiple SPIO into single nanovesicles111-113 increases the signal 
of each individual particle. Other groups have used a self-amplification approach114 to 
boost the local concentration of SPIO at sites of interest, while others are developing 
activatable probes,115, 116 in order to increase contrast by lowering background signal. 
1.2.3b Liposomes and Polymersomes 
 Liposomes are small artificial bilayer vesicles composed of either naturally 
occurring lipids or a number of commercially available synthetic products. The natural or 
synthetic phospholipids have a hydrophobic lipid “tail” and a polar “head” constructed 
from various glycerylphosphate derivatives. Due to their amphiphilic nature, when 
phospholipid molecules are dispersed in aqueous media they can self-assemble into 
spherical, closed structures consisting of an aqueous core surrounded by a highly ordered 
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phospholipid bilayer. Consequently, liposomes can encapsulate hydrophilic compounds 
in their aqueous cores and intercalate hydrophobic compounds in their lipid bilayers. 
 Liposomes vary widely in size, number of lamellae, surface charge, permeability, 
and bilayer rigidity, depending on the preparative technique, synthetic conditions, and 
types of lipids used. Their sizes range over three orders of magnitude, from tens of 
nanometers to tens of micrometers. These structural parameters affect the behavior of 
liposomes both in vitro and in vivo. Therefore, it is critical to carefully select the 
liposome constituents and preparative technique for the intended application. For 
example, conventional liposomes are rapidly cleared from the circulation by the 
phagocytic cells of the RES. Therefore, for in vivo applications, steps such as pegylation 
or steric stabilization, must be taken to prolong circulation time.117, 118 The coat has been 
shown to inhibit serum protein binding on the liposomal surface, thereby reducing RES 
sequestration, complement activation, and destabilization of the liposomal membranes. 
Incorporation of cholesterol into the phospholipid membrane has also been shown to 
improve liposome stability.119 
Polymersomes, by contrast, are self-assembled nanovesicles composed of 
amphiphilic synthetic block copolymers. Most commonly polyethylene oxide (PEO) is 
used as the hydrophilic block.  This creates a relatively intert, brush-like outer shell, 
which  imparts “stealth” characteristics to the polymersomes and allows them to 
effectively avoid the reticuloendothelial system.120  Compared to liposomes, 
polymersomes are far more robust, have lower membrane permeability, greater stability, 
and can be finely tuned through polymer selection to yield vesicles with diverse 
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functionality. Combined with their high stability, polymersomes have been found to 
exhibit long circulation times and low toxicity.120 
The improved stability of polyersomes largely stems from the higher molecular 
weight of the diblock copolymers and the presence of a thick hydrophobic domain, 
typically ~8-10 nm.  This is significantly larger than the hydrophobic domain of most 
liposomes, which are typically ~3 nm in thickness.121 However, increased membrane 
thickness generally leads to decreased membrane fluidity and deformability, bringing the 
mechanical properties of polymersomes closer to viral capsids than liposomes. 
Both liposomes and polymersomes are attractive platforms for imaging and drug 
delivery because payloads can be encapsulated within the vesicles and delivered to sites 
of interest. Furthermore, sequestering the payload from direct exposure to the blood can 
prevent it from being damaged by circulating enzymes or causing excess toxicity. For 
example, when liposomes are used to encapsulate imaging agents, they help overcome 
the rapid clearance, non-specific cellular interaction, and toxicity of free contrast, all of 
which result in images of diminished contrast and resolution.122 Polyermersomes, as well, 
are easily transformed into imaging agents through the encapsulation of hydrophilic 
contrast material (e.g. Gd-DTPA, fluorescent dyes) within the aqueous core and/or 
hydrophobic fluorescent dyes within the membrane.  
Nanovesicles can also be combined with active targeting strategies to direct 
encapsulated drugs or contrast agents to specific organs or pathologies. Targeted delivery 
of liposomes in vivo has been achieved by covalent and non-covalent coupling of site-
directing ligands (such as monoclonal antibodies, proteins, vitamins, peptides, and 
glycolipids) to the surface of liposomes.123 For example, PEG-shielded liposomes 
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functionalized with cyclic RGD have been used to target the antivascular agent 
combretastatin A4 to tumor vasculature.124 The exterior surface of polymersomes can 
also be readily functionalized with biologically active ligands for targeting 
applications.125 
1.2.3c Dendrimeric Nanoparticles 
 Dendrimers are highly uniform, spheroid polymeric nanostructures that 
repeatedly branch outward from an inner mulitmeric core. They are usually produced in 
an iterative sequence of reaction steps, where each generation results in an exponential 
increase in molecular weight and a geometric increase in volume.126 For imaging 
applications, PAMAM dendrimers are most commonly used, and they range in size from 
about 1 nm to just over 13 nm, depending on the generation.127 PAMAM dendrimers 
possess an ethylenediamine core and display amino groups on the surface, which provide 
convenient reactivity for surface modifications.128-131 For drug delivery applications, it is 
also possible to encapsulate molecules inside interior cavities of a high generation 
dendrimer.132 
 Dendrimers possess many structural parameters, including base material, size, 
shape, branching, length, and surface functionality,133 that can all affect the dendrimer’s 
performance as an imaging or therapeutic platform. For example, smaller generation 
dendrimers are subject to rapid renal elimination, with blood half-lives of only a few 
minutes.134 Those with charged or hydrophobic surfaces are also rapidly cleared from 
circulation, but tend to accumulate in the liver.135 However, dendrimers with a neutral or 
hydrophilic surface, such as PEG, can exhibit blood half-lives reaching many hours.135 
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1.2.3d Gold Nanoparticles 
The use of gold nanoparticles in biological applications began in 1971 when 
Faulk and Taylor invented the immunogold staining procedure for electron 
microscopy.136 Gold nanoparticles which are typically sized between 0.5 and 250 nm, 
have been prepared in a wide variety of shapes including spherical, 137, 138 rods, 139, 140 and 
barbells.141 Gold has also been used as a thin shell-coating for a dielectric core.142 Their 
straightforward synthesis, excellent stability, and the ease of functionalization with 
targeting ligands have permitted the use of gold nanoparticles in both imaging and 
therapeutic applications. 
Gold nanoparticles can be used with multiple imaging platforms for in vivo 
molecular imaging. For instance, gold nanoparticles complexed with a thiol-PEG coating 
and targeted with anti-EGFR single chain antibody fragments have been used to target 
tumors in vivo using surface enhanced Raman spectroscopy (SERS).143 Gold 
nanoparticles are also being investigated as X-ray and computed tomography (CT) 
contrast agents. Recently, 1.9 nm gold nanoparticles, administered intravenously in a 
mouse tumor model, allowed for high resolution imaging of the tumor, blood vessels, and 
kidneys.144 Since gold nanoparticles exhibit greater X-ray attenuation than iodine-based 
contrast agents, it was even possible to visualize microvasculature and neovasularization 
within the tumor. Beyond imaging applications, gold nanorods are also being investigated 
as therapeutic photothermal agents. Specifically, small axial diameter nanorods, delivered 
to an animal tumor, serve as highly efficient absorbers of near infrared light.145 When 
short IR laser pulses are applied to the tumor volume, the laser energy is converted to 
heat, leading to ablation of the lesion.146 
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1.2.4 Detection and Imaging Modalities 
 There are numerous modalities to detect, quantify, and image nanoparticle 
formulations in vitro, in vivo, and ex vivo. Each method has its own unique advantages 
and disadvantages, which compels the investigator to select a modality that best suits the 
particular application. A partial list of detection and imaging modalities, along with their 
strengths and weaknesses is provided in table 2.1. 
Table 1.1. Common Nanoparticle Detection and Imaging Modalities  
Method Advantages Disadvantages / 
Limitations 
Quantitative Multiplex 
Nuclear 
PET/SPECT 
Very High 
Sensitivity, 
Functional 
Information 
Poor Resolution, Ionizing 
Radiation, Agent 
Requires EHRS Handling 
Yes Possible 
2-3 
Optical / 
Fluorescence 
High Sensitivity, 
Ease of Use 
Lower Resolution, Altered 
or Prevented by Tissue 
Type/Depth 
Semi Yes 
MR / MRS High 
Resolution, 
Anatomical and 
Functional 
Information 
Low Contrast Sensitivity, 
Long Scan Time, Low 
Temporal Resolution, 
Expensive 
Yes* Possible 
Mass 
Spectrometry 
High Sensitivity Ex Vivo Only Yes Yes 
CT / X ray High 
Resolution, 
High Temporal 
Resolution 
Very Low Contrast 
Sensitivity, Ionizing 
Radiation 
Yes* Possible 
Ultrasound Widely 
Available, High 
Temporal 
Resolution, 
Inexpensive 
Lower Resolution, 
Contrast is Intravascular 
Only, Altered or 
Prevented by Tissue 
Type/Depth 
No No 
Histology High 
Resolution, 
Functional and 
Structural 
Information 
Ex Vivo, Sample 
Preparation 
Semi Yes 
* These modalities provide quantitative data, but calculation of exogenous agent 
concentration is usually semiquantitative 
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1.2.4a Nuclear and Radiolabel Detection and Imaging 
 The “gold standard” of pharmacokinetic and pharmacodynamic measurements is 
the use of radionuclide tracers. Radiolabeling provides absolute quantitation of tracer 
concentrations and very high (pM) sensitivity.147 Although there are several mechanisms 
of nuclear decay (e.g. alpha, beta, gamma, positron emission, electron capture, isomeric 
transition, and internal conversion), radiotracer signals largely fall into two categories: 
gamma or beta emitters. Gamma radiation passes through soft tissue samples with little 
attenuation and can be quantified with minimal sample preparation using a gamma 
counting instrument. Beta particles, however, require indirect counting, which 
necessitates more sample preparation. Specifically, the sample is dissolved in a liquid 
scintillation solution, containing a scintillant that absorbs the beta particle’s energy and 
emits light for detection.  
The earliest experiments studying the in vivo biodistribution and clearance of 
nanoparticle formulations relied on radiolabeling. The long-lived radionuclides 3H, 14C, 
and 125I were used to trace the activity of small molecule payloads incorporated into 
nanoparticles.148-150 More recently, the γ emitters 111In and 99mTc have gained popularity 
as nanoparticle radiolabels, since they have relatively mild labeling procedures and can 
be used for in vivo imaging (SPECT) followed by ex vivo measurements of 
biodistribution. For PET imaging of nanoparticle formulations, 64Cu is most commonly 
used. 
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Table 1.2. Common Radionuclides for Nanoparticle Investigation  
Radionuclide Decay Mode Half Life 
1H β 12.35 years 
14C β 5730 years 
18F β+ 109.77 minutes 
32P β 25.4 days 
64Cu β+ 12.7 hours 
99mTc γ 6.00 hours 
111In γ 2.83 days 
125I γ 60.14 days 
131I β 8.02 days 
 
One major benefit of the metal radiotracers is the versatility available for 
incorporating the tracer into the nanoparticle formulation. Direct radiolabeling can be 
accomplished through reduction of disulfide bonds followed by introduction of the 
metal.151, 152 More typically, a chelator (e.g. DTPA,153, 154 HYN-IC,155, 156 or DOTA157) is 
used to bind the metal. The chelator may be covalently conjugated to the surface of the 
nanoparticle, face the aqueous core,158, 159 or be buried within a hydrophobic domain160, 
161
 (e.g. bilayer of a liposome or core of a micelle). For vesicular structures such as 
liposomes and polyersomes, a preformed metal-chelator complex can be encapsulated 
within the aqueous core.162, 163 It is possible to incorporate the chelator into the 
monomeric/block co-polymer material prior to nanoparticle assembly,164 covalently 
conjugate the chelator to a previously assembled nanoparticle,165 or non-covalently attach 
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a chelator functionalized moiety (e.g. protein or peptide) to the nanoparticle surface.166 
Addition of radiolabels to nanoparticles may have a minimal or significant impact on the 
agent’s pharmacokinetics, depending on the location of the radiolabel within the 
nanoparticle (i.e. core versus surface) and the fractional increase in nanoparticle size 
upon radiolabeling. 
The major limitation to radiolabeling, for the purposes of nanoparticle 
characterization, is the relative lack of multiplexing capability. A two-label ratiometric 
approach is well established using a low and high energy gamma emitter (e.g. 125I and 
111In).9, 167 A triplex assay is conceivable by adding a beta emitter detected separately by 
scintillation, but would then require separate preps and measurements to obtain the 
information. Higher order multiplexing (achievable by optical instrumentation in vitro or 
ICP-MS ex vivo) is unlikely to be feasible. Another, smaller consideration is the special 
handling requirements for radioactive material and animals. Laboratory handling of 
radionuclides is by no means “difficult”; but its inconvenience decreases the frequency of 
its use, and an alternative method of absolute quantification of nanoparticle concentration 
in biological samples, without radioactivity, may lead more investigators to acquire such 
data. 
1.2.4b Optical and Fluorescence Detection and Imaging 
Optical and fluorescence detection of nanoparticles is arguably the most 
convenient and widely used approach. Fluorescence is usually imparted to a nanoparticle 
by incorporation of either an organic dye or inorganic fluorophore (i.e. quantum dot). 
Many different small molecule organic fluorophores, spanning the visible and infrared 
spectrum, have been successfully used with nanoparticles, including: fluoresceins, 
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cyanines, rhodamines, and specific commercial dye lines like Alexa Fluor, DyLight, and 
BODIPY. The fluorophores can be incorporated by covalent conjugation or encapsulation 
within an aqueous or hydrophobic core. The labeled nanoparticles can then be imaged at 
the whole animal level or in ex vivo specimens. Multiplexing of fluorophores with 
resolvable excitation and emission spectra is possible, as evidenced by multi-color flow 
cytometry.168 However, applying this principle at the tissue, organ, and animal level is 
more difficult since a large region of the visible spectrum is unsuitable for fluorescence 
measurements in complex or thick samples (see below). 
 Perhaps the biggest limitation of fluorescence detection and imaging of 
nanoparticles are issues associated with tissue penetration and interference. Specifically, 
both the incident excitation radiation and the emitted signal are subject to attenuation as 
they pass through biological tissue. Since light scattering decreases as 1/λ4 and photon 
absorption by endogenous oxygenated and deoxygenated hemoglobin reaches a minimum 
in the near infrared (NIR) spectral window,169 tissue penetration is wavelength dependent 
– with longer wavelengths suffering less attenuation than shorter wavelengths. 
Nevertheless, even the brightest and most red-shifted organic fluorphores are limited to 
approximately 5 cm of tissue penetration.170 This distance limit is suitable for small 
animal work, but is limiting for human applications other than those involving exposed 
tissue (e.g. superficial soft tissue and skin,171 fluorescence assisited surgery,172 or 
endoscopic methods).173  
 Another significant drawback of fluorescence detection of nanoparticles is its 
restriction to semi-quantitative measurements. That is, the concentration of the 
fluorophore, and therefore the nanoparticle, cannot be calculated from its signal, due to a 
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number interfering variables present in biological samples. For example, the peak 
excitation/emission wavelength, extinction coefficient, and quantum yield can vary with a 
number of parameters including local chemical environment, exposure time, and 
temperature. Fluorescence quenching, either from other molecules of the same 
fluorophore or endogenous absorbers, leads to significant non-linearity. Tissue thickness, 
density, composition, and auto-fluorescence also all influence signal, even with ex vivo 
sampling. 
1.2.4c Magnetic Resonance Detection and Imaging 
Magnetic resonance approaches are capable of obtaining an extremely diverse 
array of structural and functional information in vivo (see also the pH imaging section 
above). Generally speaking, the functional information is often extracted in one of three 
ways. First, in magnetic resonance spectroscopy (MRS) the chemical shift of a particular 
resonance may change with variations in some physiologic parameter. In this manner, the 
varying 31P resonance of 3-APP is used to deduce extracellular pH.83 Secondly, 
alterations in the metabolic environment of tissues can be deduced using the ratio of the 
signals from two or more metabolites in an MRS study. For example, studies have found 
that a high choline / N-acetyl aspartate is commonly observed in brain tumors.174 Thirdly, 
chemical exchange saturation transfer (CEST) measurements detect the transfer of 
magnetization between two pools in chemical exchange, leading to signal amplification, 
signals that can be “switched” on and off, and detection of physiologic stimuli by 
alterations they cause in the CEST effect.175 
 Measuring the absolute concentration of a particular resonance or metabolite with 
magnetic resonance methods is much more difficult, although significant progress has 
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been and continues to be made for endogenous metabolites.176 With regard to 
determination of nanoparticle concentrations, however, absolute quantification is not yet 
possible. Since the concentration of nanoparticles delivered in vivo is not very large 
compared to the sensitivity of MR methods, direct detection of a nanoparticle’s resonance 
is difficult. Instead, nanoparticles imaged by MR are usually detected indirectly through 
their interaction with bulk water protons. For example, Gd3+ can be incorporated into 
nanoparticles with metal chelators, much the same as metal radionuclides can.177 The 
gadolinium ion’s seven unpaired electrons provide a conduit through which bulk water 
protons can transfer energy, allowing their longitudinal relaxation rate to be increased. 
This in turn leads to a stronger (brighter) signal on T1-weighted images for voxels 
containing the nanoparticle. SPIO nanoparticles contain iron oxide crystals, which 
generate disturbances in the local magnetic field surrounding the nanoparticles. This in 
turn causes accelerated de-phasing of the bulk water magnetization following a 90° 
radiofrequency pulse, which leads to a weaker (darker) signal on T2-weighted images. 
With SPIO or Gd3+ doped nanoparticles, it is possible to estimate nanoparticle 
concentration using a calibration curve with a tissue phantom. However, accurate 
absolute quantification is difficult since many specific properties of the tissue and pulse 
sequence will influence the signal obtained. Furthermore, detection by this method is not 
amenable to multiplexing. 
1.2.4d Inductively Coupled Plasma – Mass Spectrometry (ICP-MS) 
Detection 
 ICP-MS is an analytical method allowing for the rapid and sensitive (1 ppt to 1 
ppb) detection of a wide range of metal species in a sample. The basic instrument design 
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places a mass spectrometer downstream of an inductively coupled plasma source. The 
ICP is generated by introducing a small number of electrons into an argon gas stream and 
then applying radiofrequency radiation to cause rapid oscillation of the free electrons. 
Collisions between the electrons and argon atoms result in ionization, producing Ar+ and 
additional electrons. A steady state is quickly reached, resulting in electro-neutral plasma 
with a temperature significantly greater than a chemical flame. 
 In order to analyze a sample containing complex material, such as blood or tissue, 
the material must first be digested with nitric or hydrochloric acid to produce a more 
homogenous liquid. The sample is then nebulized and introduced into the plasma stream, 
where the extremely high temperature leads to atomization, and subsequent ionization, of 
the material. The metals ions of the sample are then fed from the plasma into a 
conventional mass spectrometer (usually quadrupole, or less frequently, time of flight). 
Importantly, the concentration of each metal ion being investigated can be simultaneously 
acquired with a single measurement.  
 ICP-MS multiplexing is already being successfully applied to in vitro 
immunoassays.178 Specifically, a polymer tag containing multiple lanthanide metal 
chelates is attached to the Fc portion of antibodies.179 In this manner, each specific 
antigen/antibody is associated with a specific lanthanide metal. In vitro multiplex analysis 
has been applied for a variety of cell surface biomarkers180, 181 and growth and 
transcription factors in cell lysates.178 Very recently (May 2011) the massively-parallel 
nature of ICP-MS multiplex analysis was demonstrated with simultaneous “mass 
cytometric” analysis of more than 30 cell markers.182 
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 Another recent development in ICP-MS instrumentation is laser ablation LA-ICP-
MS, which offers three considerable advantages over conventional ICP-MS. First, the 
original sample can be analyzed directly (i.e. without chemical digestion) by ablating the 
sample with a pulsed laser beam and sweeping the aerosol directly into the plasma. 
Secondly, LA-ICP-MS can be conducted with much smaller amounts of material. 
Specifically, micrograms samples can be analyzed, versus milligrams for conventional 
ICP-MS (i.e. the entire sample is microgram quantity; the amount of lanthanide need only 
be parts per billion concentration within the sample). Thirdly, the laser pulses can be 
scanned across a solid sample, allowing for a mass “image” to be generated for an organ 
or tumor with heterogeneously distributed nanoparticles. 
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Chapter 2: Development of ICP-MS Analytical Method to Quantify 
SPIO Nanoparticle Clearance and Organ Concentration  
2.1 Abstract 
Recent advances in material science and chemistry have led to the development of 
nanoparticles with diverse physicochemical properties, e.g. size, charge, shape, and 
surface chemistry. Evaluating which physicochemical properties are best for imaging and 
therapeutic studies is challenging not only because of the multitude of samples to 
evaluate, but also because of the large experimental variability associated with in vivo 
studies (e.g. differences in tumor size, injected dose, subject weight, etc.). To address this 
issue, we have developed a novel lanthanide-doped nanoparticle system and analytical 
method that allows for the quantitative comparison of multiple nanoparticle compositions 
simultaneously. Specifically, SPIO with a range of different sizes and charges were 
synthesized, each with a unique lanthanide dopant. Following the simultaneous injection 
of the various SPIO compositions into tumor-bearing mice, inductively coupled plasma 
mass spectroscopy (ICP-MS) was used to quantitatively and orthogonally assess the 
concentration of each specific SPIO composition in serial blood samples and the resected 
tumor and organs. This approach provides a simple, cost-effective, and non-radiative 
method to quantitatively compare tumor localization, biodistribution, and blood clearance 
of more than 10 nanoparticle compositions simultaneously, removing subject-to-subject 
variability.  
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2.2. Introduction 
 Over the past decade, interest in the development of nanoparticles for clinical 
applications, such as diagnosis and drug delivery, has increased exponentially, along with 
the number of specific nanoparticle formulations reported in the literature.1-5 Given the 
variety of nanomaterials from which they can be constructed, the array of 
physicochemical properties they can possess, and the assortment of specific molecular 
processes that can be targeted in vivo, the number of potential nanoparticle combinations 
is truly astronomical.  
 For most nanoparticle applications, a crucial research question is how much of the 
nanoparticle formulation (and thus imaging or therapeutic payload) reaches the tissue of 
interest. However, since determining this information directly and quantitatively is often 
impractical, indirect or semi-quantitative methods are usually employed. For example, 
relative nanoparticle delivery may be inferred from fluorescence intensity, imaging 
contrast, or alterations in tumor growth rate. However, since nanoparticle delivery is only 
one of several variables affecting fluorescence intensity, imaging contrast, and tumor 
growth rate, they cannot be assumed to represent nanoparticle delivery.  
The “gold standard” for quantitative determination of biodistribution and blood 
clearance is through incorporation of a radioisotope within the compound of interest. 
Given the large number of radioisotopes to choose from, a compound can usually be 
radiolabeled by replacement of a stable isotope, ensuring the label has minimal impact on 
the behavior of the compound. Radiolabeling also has the advantage of being very 
sensitive. However, one major drawback to the use of radiolabeling is the special 
handling and containment protocols required when working with radioactivity. Therefore, 
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a quantitative approach that does not require special laboratory precautions could make 
measurements of clearance and biodistribution more accessible. 
Another, perhaps even more important, research question is how does one 
nanoparticle’s delivery to a tissue of interest compare to another’s. Whether comparing a 
new investigational agent to a negative control or optimizing a specific set of 
nanoparticles, such data are indispensable for development of better nanoparticle 
formulations and progression to clinical use. Beyond the difficulties of obtaining 
quantitative data for an individual nanoparticle’s biodistribution, there are also problems 
using this data to compare nanoparticle formulations due to the large experimental 
variability of in vivo studies. A convenient way to compare agents while controlling for 
subject-to-subject variability is to employ a ratiometric or multiplex approach, whereby 
two or more agents are administered simultaneously to a single subject, and a “signal” 
from each one can be independently resolved. It is possible to employ a multiplex 
approach with radiolabeling, using gamma emitters with resolvable energies6 or a 
combination of gamma counting and scintillation,7 but physical limitations of energy 
resolution ultimately limit the number of compounds that can be simultaneously 
investigated. 
In order to address these limitations, a method was designed that would allow for 
the quantitative determination of biodistribution and blood clearance of multiple 
nanoparticle formulations in a single animal (Figure 2.1). Specifically, lanthanide metals 
were doped into the iron cores of superparamagnetic iron oxide (SPIO) nanoparticless. 
Multiple lanthanide-labeled nanoparticles were then injected in individual animals 
simultaneously. Inductively coupled mass spectrometry (ICP-MS) was then used to 
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detect parts-per-billion (ppb) concentrations of the lanthanide metals, independent of one 
another, in tissue and blood. Since lanthanide and other heavy metals (e.g. gold, silver, 
etc.) do not naturally exist within animal subjects, the concentration of the lanthanide 
metals unambiguously represents the concentration of its associated nanoparticle. This 
“ICP-MS multiplex” approach should provide a sensitive and straightforward method for 
quantitatively comparing the biodistribution and blood clearance of multiple nanoparticle 
formulations simultaneously, without the disadvantages of radioactivity and subject-to-
subject variability. 
 
Figure 2.1 Schematic of the ICP-MS based multiplex method for determining biodistribution and blood 
clearance. (A) Nanoparticles of varying physicochemical properties are combined into a single solution. 
Each type of nanoparticle is associated with a unique lanthanide metal; either by encapsulation or chelation 
(for example, the large and neutral particle contains Gd while the small and negative particle contains Ho). 
The concentration of each lanthanide metal in the injected solution is measured by ICP-MS and the 
combined solution is injected intravenously into the animal. (B) Blood samples are drawn at various times 
post-injection and following the final blood draw, the animal is sacrificed and the tumor and other organs 
are excised and rinsed in water. The blood and tissue samples are weighed and digested with nitric acid, 
and then the concentration of each lanthanide metal is determined by ICP-MS. 
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2.3 Materials and Methods 
 
Synthesis of Dextran Stabilized Lanthanide Doped SPIO 
 
Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the 
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran. 8 Briefly, 
25 g of dextran T-10 (Pharmacosmos A/S, Holbaek, Denmark), was dissolved in 500 mL 
dH2O and heated to 80°C for 1 hour. The solution was then allowed to cool to room 
temperature and continued to mix overnight. Subsequently, a solution of 1.85 g FeCl3, 
0.73 g FeCl2, and 0.125 g LnCl3•6H2O (Ln = Ho, Eu, Er, Sm, or Gd) in 25 mL dH2O was 
prepared and decanted into the dextran solution. The combined solution was cooled on 
ice and degassed with N2 for 90 min. While keeping the solution stirring on ice and under 
N2, an automated syringe pump was then used to introduce 15 mL of concentrated 
NH4OH to the solution over 5 hours. The resulting black viscous solution was removed 
from the N2 atmosphere, heated to 90°C for 1 hour, cooled overnight, and centrifuged at 
20,000 RCF for 30 minutes to remove large aggregates. Free iron, lanthanide, and 
dextran were removed by diafilitration across a 100 kDa membrane and the Ln-SPIO 
were brought to a final volume of ≈40 mL at 10 mg Fe/mL.  
 This 40 mL of dextran SPIO at an iron concentration of 10 mg/mL was then 
combined with an equal volume of 10 M NaOH and mixed for 10 minutes. 80 mL of 
epichlorohydrin was then added and the solution was vigorously stirred at room 
temperature overnight. Epichlorohydrin crosslinks the dextran coating within the Ln-
SPIO particle and chemically activates the dextran surface for conjugation. The solution 
was then briefly centrifuged to allow phase-separation into an aqueous black SPIO layer 
and a clear layer of unreacted epichlorohydrin, which was removed. The SPIO layer was 
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quickly purified via extraction in isopropanol. Specifically, the Ln-SPIO material was 
combined with 5 volumes of isopropanol and the mixture was vigorously shaken. Brief 
centrifugation of the mixture resulted in a layer of precipitated salt, an Ln-SPIO layer, 
and an isopropanol layer (containing any remaining epichlorohydrin). The SPIO layer 
was then isolated and combined with an equal volume of concentrated NH4OH and 
gently stirred for 24 hours at room temperature, resulting in an aminated nanoparticle 
surface. After the reaction, the Ln-SPIO was purified by diafiltration across a 100 kDa 
membrane and was 0.2 µm filtered to remove any oversized material. Finally, to ensure 
complete purification of the Ln-SPIO from excess salt and lanthanide ions, the 
nanoparticles were magnetically purified on MACS LS columns using a MidiMACS 
magnet (Miltenyi Biotec, Auburn, CA, USA). 
 To prepare SPIO with different surface charges, aminated Ln-SPIO formulations 
were reacted overnight with varying amounts of succinic anhydride (0 – 1 M) in 0.1 M 
sodium bicarbonate buffer and subsequently purified by isopropanol precipitation. 
Nanoparticles with distinct size distributions were obtained by differential centrifugation. 
Specifically, iterative centrifugation at 10,000 RCF for 10 minutes, resulted in a final 
nanoparticle pellet enriched for larger sizes. Smaller nanoparticles were obtained by 
magnetic depletion (i.e. the flow-through of a MACS LS column was collected). 
Necessarily, this resulted in SPIO without magnetic properties, but selected for smaller 
nanoparticles, since particularly small iron cores do not have magnetic properties.  
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Nanoparticle Physicochemical Characterization 
Ln-SPIO stock samples were diluted in deionized water and deposited on 200-
mesh carbon coated copper grids (Polysciences, Warrington, PA, USA) for TEM imaging 
with a JEOL 1010 transmission electron microscope operating at 80 kV. Mean iron core 
size was determined by measuring 100 individual nanoparticles. The presence of 
lanthanide metal incorporated into SPIO nanoparticles, versus the background solution, 
was assessed by energy dispersive X-ray spectroscopy (EDS) mapping using a JEOL 
2010F. Stock samples of Ln-SPIO nanoparticles, dendrimers, polymersomes, and 
liposomes were diluted into pH 7.4 phosphate buffered saline for determination of the 
hydrodynamic diameter by dynamic light scattering (DLS). Measurements were acquired 
with a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the non-
invasive back-scatter (NIBS) mode. For zeta potential measurements, stock samples of 
Ln-SPIO were diluted into either 10 mM HEPES buffered water at pH 7.4 or phosphate 
buffered saline at pH 7.4 and then mean nanoparticle zeta potential was measured using a 
Zetasizer Nano-ZS. For Ln-SPIO nanoparticles, the transverse (r2) and longitudinal (r1) 
relaxivities were measured using a Bruker mq60 tabletop MR relaxometer operating at 
1.41 T (60 MHz).  
 
Nanoparticle Stability Assays 
The stability of the nanoparticles was measured as the amount of lanthanide 
leakage that could be observed in serum. Nanoparticles were incubated in 100% fetal 
bovine serum (FBS) at 37°C with shaking. Aliquots were removed at 1, 2, 4, 6, and 24 
hours and applied to a 4,000 MWCO centrifugal filter device to collect any free metal in 
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the filtrate. Lanthanide concentrations were measured by ICP-MS in the original 
nanoparticle stock and in the filtrates, allowing for calculation of percent of lanthanide 
leakage. 
 
Cell Culture and Tumor Model 
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided 
by Mark Greene, PhD, FRCP, University of Pennsylvania) were cultured and maintained 
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin at 37°C and 5% CO2. Approximately 6-week 
old female nu/nu nude mice (Charles River Laboratory, Charles River, MA, USA) were 
maintained in accordance with the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. Mice were anesthetized via isoflurane and T6-17 cells were 
injected subcutaneously into the back right flank (2 x 106 cells in 0.2 mL PBS). Tumors 
were grown until the longest dimension was approximately 8 mm. 
 
Quantitation of Tumor Delivery, Biodistribution, and Blood Concentration by ICP-MS 
Three animal cohorts, each containing 3 animals, were used for multiplex 
experiments, as outlined in Table 2.1. Each nanoparticle formulation was injected at a 
dose of 10 mg Fe / kg body weight (for a total iron load of 30 mg/kg in each mouse) in 
200 µL of injected solution. 
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Table 2.1 Summary of animal injection groups (n=3 for all groups). 
 
Experimental 
Cohort 
Number of 
Particles Co-
injected 
Description 
Negative Zeta 
Potential 
3 -20.8 mV, -12.2 mV, -5.2 mV SPIO (all ≈ 28 
nm) 
Positive Zeta 
Potential 
3 +3.6 mV, +10.0 mV, +14.3 mV SPIO (all ≈ 28 
nm) 
Size 3 15.52 nm, 29.05 nm, 70.72 nm SPIO (all ≈ -20 
mV) 
 
For each experimental group, prior to injection, a nanoparticle aliquot was saved 
for inductively coupled plasma mass spectrometry (ICP-MS) determination of lanthanide 
concentration in the injected material. Following nanoparticle injection, 10 µL blood 
samples were collected from each animal, using the tail-nick method, at times of 1, 2, 4, 
7, and 24 hours post-injection. After the final blood draw, the animals were sacrificed and 
the tumors, livers, spleens, kidneys, hearts, and lungs excised. 
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain, 
NY, USA) and trace metal grade nitric acid and aqua regia was purchased from Fisher 
Scientific (Pittsburg, PA, USA). All dilutions were done using in-house deionized water 
(≥18 MΩ-cm) obtained from a Millipore water purification system. 
The pre-injection solutions, blood, tumor, and organ samples were analyzed for 
158Gd (gadolinium), 147Sm (samarium), 153Eu (europium), and 165Ho (holmium), using an 
Elan 6100 ICP-MS (Perkin Elmer, Shelton, CT, USA)  at the New Bolton Center 
Toxicology Laboratory, University of Pennsylvania, School of Veterinary Medicine, 
Kennett Square, PA, USA. The samples were weighed into Teflon PFA vials (Savillex, 
Minnetonka, MN, USA) and digested overnight with 70% nitric acid at 70° C.  0.1 mL of 
2 ppm 159Tb (terbium) was added to each of the digested samples and the mixtures were 
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diluted with deionized water to a final volume of 10 mL. The lanthanide concentration of 
each sample was measured using a calibration curve of aqueous standards at 0.01, 0.1, 
1.0, and 10 ppb for each metal.  
The performance of the instrument and accuracy of the results were monitored by 
analyzing a reagent blank and bovine serum control serum (Sigma) prior to analysis of 
the samples. Also, standard reference material (Peach Leaves 1547) obtained from 
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with 
known values of iron and rare earth elements was analyzed with each batch of samples. 
For each nanoparticle formulation, the percent injected dose per gram of tissue, 
was calculated as [Ln]sample / ([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration 
in the sample (blood, tumor, or organ tissue), [Ln]inj is the lanthanide concentration in the 
injected nanoparticle solution, and Minj is the mass of nanoparticle solution injected (0.2 
grams). 
2.4 Results and Discussion 
 
Synthesis of and Characterization of Ln-SPIO 
 
Lanthanide doped superparamagnetic iron oxide (SPIO) nanoparticles were 
prepared by including a small amount of lanthanide metal with the ferric and ferrous salts 
during synthesis. Five different lanthanide metals (Gd, Eu, Ho, Sm, and Er) were 
successfully incorporated into SPIO nanoparticles. Following synthesis and purification 
of each Ln-SPIO formulation, differential centrifugation and chemical surface 
modification were used to generate orthogonal sets of nanoparticles having either fixed 
size and varying surface charge or fixed surface charge and varying size (Table 2.2).  
66 
 
Table 2.2 Physicochemical properties of the nine unique Ln-SPIO formulations . 
Tracer 
Metal 
Hydrodynamic 
Diameter (nm) 
Zeta Potential 
(mV), HEPES, pH 
7.4 
r2  
(mM-1s-1) 
r1 
(mM-1s-1) 
Core Size 
(nm) 
Ln / 
Fe% 
Ho 15.52 -19.6 < 5 < 0.5 5.1 ± 1.9 17.8 
Eu 29.05 -20.7 141.75 9.35 17.4 ± 3.0 1.6 
Gd 70.72 -19.6 214.97 2.26 41.1 ± 10.6 8.0 
Sm 29.84 -20.8 150.41 9.99 19.4 ± 3.9 1.7 
Eu 28.61 -12.2 137.18 9.10 19.2 ± 3.5 2.9 
Gd 26.06 -5.2 123.66 11.79 15.9 ± 2.7 2.0 
Sm 29.16 +3.6 142.38 9.22 19.8 ± 3.8 1.7 
Gd 27.29 +10.0 106.76 10.31 15.1 ± 2.6 2.0 
Eu 29.47 +14.3 176.58 8.87 18.6 ± 3.8 2.9 
 
Specifically, to investigate the effect of surface charge, 6 nanoparticle 
formulations were generated, each with a hydrodynamic diameter of approximately 28 
nm but with zeta potentials ranging from -20.8 mV to +14.3 mV (Figure 2.2 A). Since it 
was hypothesized that negatively and positively charged nanoparticles could not be 
combined in a single injection due to electrostatic aggregation, these nanoparticles were 
divided into two sets, one with three negatively charged nanoparticles and one with 3 
positively charged nanoparticles. Consequently, only three different Ln-SPIO cores were 
necessary (Gd, Eu, and Sm) for each of these studies. To investigate the effect of size, 
three nanoparticle formulations were generated, each with a zeta potential of 
approximately -20 mV, but with sizes of 15.52 nm, 29.05 nm, and 70.72 nm (Figure 2.2 
B).  
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Figure 2.2 Dynamic light scattering (DLS) size distributions for Ln-SPIO nanoparticles. (A) The six 
nanoparticle formulations used to investigate the effect of zeta potential on nanoparticle biodistribution and 
blood clearance have near-equivalent size distributions. (B) The three nanoparticle formulations that were 
used to isolate the effect of size on nanoparticle biodistribution and blood clearance have distinct size 
distributions (each with zeta potential ≈ -20 mV). 
 
The mean core size for each formulation of Ln-SPIO was determined by 
transmission electron microscopy (Table 2.2) and the core morphology was examined 
(Figure 2.3 A-D). Consistent with SPIO previously synthesized by co-precipitation,8 the 
medium and large size formulations have cores consisting of multiple individual crystals, 
resulting in a heterogeneous appearance. 
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Figure 2.3 TEM images of Ln-SPIO: Representative TEM images of (A) Sm-SPIO (core size, CS = 
19.4±3.9nm, hydrodynamic diameter, HD = 29.84nm), (B) Eu-SPIO (CS = 19.2±3.5nm, HD = 28.61nm), 
(C) Gd-SPIO (CS = 15.9±2.7nm, HD = 26.06nm) and (D) Ho-SPIO (CS = 5.1±1.9nm, HD = 15.52nm). All 
scale bars are 100 nm. 
Energy dispersive X-Ray spectroscopy (EDS) was used to further confirm that 
each lanthanide metal was incorporated into the iron core. Specifically, when examining 
the nanoparticles under transmission electron microscopy, EDS regions of interest placed 
in the background (i.e. not containing any nanoparticles) yielded signatures of ions of the 
buffer (Na, Cl) and the TEM grid itself (Cu), but no lanthanide was detectable in the 
background solution. When the EDS region of interest was moved onto a group of 
nanoparticles, very large Fe signatures were detected, as well as signatures corresponding 
to the specific lanthanide that was used for that synthesis (Figure 2.4). EDS examination 
of conventional SPIO nanoparticles yielded only iron signatures without any lanthanide 
peaks. 
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Figure 2.4 EDS spectra of background (Grid), iron only SPIO (Fe), and Ln-SPIO doped with either Eu, 
Sm, Ho, or Gd, demonstrating specific incorporation of each lanthanide metal into the nanoparticle core. 
 
MR imaging following a multiplex injection of SPIO nanoparticles provides little 
information, since the contribution of each individual nanoparticle formulation cannot be 
de-convoluted. Nevertheless, with the exception of Ho-SPIO, it was found that each Ln-
SPIO nanoparticle used in the studies possessed magnetic relaxivities that were 
comparable to un-doped dextran SPIO (Table 2.2). The Ho-SPIO used in the size study 
had negligible magnetic relaxivity due to the method in which it was processed to obtain 
the small size. Prior to processing, the Ho-SPIO had relaxivities similar to the other Ln-
SPIO formulations. 
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To ensure that the lanthanide metals within the core of each SPIO formulation 
would not readily leach/leak from the nanoparticle following intravenous injection, the 
stability of each Ln-SPIO was evaluated in serum (Figure 2.5). Upon exposure to 100% 
serum for 24 hours at 37°C, each Ln-SPIO nanoparticle experienced less than 0.5% 
leakage of lanthanide metal into the bulk solution. In fact, for two of the Ln-SPIO (Sm 
and Eu) the amount of leakage was below the limit of detection (≈ 0.2%).   
 
 
Figure 2.5 Stability of various lanthanide doped nanoparticles, assayed by percent of lanthanide leakage 
observed after 24 hours of incubation in 100% serum at 37°C. 
 
Effect of Surface Charge on SPIO Biodistribution 
 The surface charge of the nanoparticle (with a fixed hydrodynamic diameter of 
approximately 28 nm) was found to have a significant impact on passive tumor delivery 
(Figure 2.6). Specifically, the mildly negative SPIO formulation (-12.2 mV in 10 mM 
HEPES) was found to have the highest tumor delivery at 2.05 % injected dose / gram 
tumor 24 hours post-injection. Zeta potentials closer to neutrality (-5.2 mV and +3.6 mV) 
had somewhat lower tumor delivery of 1.37 and 1.23 % ID/g, while more extreme 
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negative values (-20.8 mV) resulted in even less tumor delivery (1.09 % ID/g). The 
moderate and extreme positive values of zeta potential, at +10.0 mV and +14.3 mV, 
resulted in the poorest tumor delivery (0.84 and 0.29 % ID/g, respectively). 
 
Figure 2.6 Effect of SPIO surface charge on passive nanoparticle delivery to T6-1 flank tumors, 24 hours 
post-injection (reported as percent injected dose per gram tumor tissue). 
  
Nanoparticle accumulation in other organs (liver, spleen, kidney, lungs, and heart) 
was also examined 24 hours post-injection (Figure 2.7). Large uptake was observed in 
organs of the reticuloendothelial system (RES), with liver concentrations ranging from 
25-45 % ID/g and spleen concentrations ranging from 13-40 % ID/g. The lungs, kidney, 
and heart all showed modest uptake in the range of 0.5-2 % ID/g, with the notable 
exception of the heart delivery of the three positively charged SPIO nanoparticles. It was 
found that each positively charged SPIO had significantly elevated delivery to the heart, 
in the range of 5-7 % ID/g. These data were confirmed with a second set of mice. It was 
also found that at 5 minutes post-injection, the concentration of +14.3 mV SPIO 
nanoparticles in a washed heart specimen was 12.2 % ID/g, while its concentration in the 
blood at 5 minutes was only 2.3 % ID/g. 
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Figure 2.7 Effect of SPIO surface charge on biodistribution, at 24 hours post-injection.  
 Finally, the blood clearance profile for each surface charge was investigated 
(Figure 2.8). Similar to the results observed for tumor delivery, the -12.2 mV SPIO 
demonstrated the longest blood circulation time, while the more neutral formulations (-
5.2 mV and +3.6 mV) had a shorter circulation time. The more positively charged 
particles exhibited very rapid clearance, with the +14.3 mV formulation’s blood 
concentration falling to 1.1 % ID/g in the first hour post-injection. 
 
Figure 2.8 Effect of SPIO surface charge on blood clearance. 
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It should be noted that the absolute value of a zeta potential measurement is 
highly dependent on the identity and ionic strength of the buffer in which it is measured. 
The zeta potentials (as measured in pH 7.4, 10 mM HEPES, with no additional salt) of 
the 6 nanoparticle formulations tested in this investigation were -20.8, -12.2, -5.2, +3.6, 
+10.0, and +14.3 mV. A low ionic strength buffer was selected to measure zeta potential 
for this study in order to highlight relatively small differences in surface charge. In this 
buffer, the -5.2 mV and +3.6 mV formulations should be considered close to neutral; the -
12.2 mV and +10.0 mV are mildly negative and positive, respectively; the remaining two 
formulations have more significant negative and positive charges. 
Previous studies have demonstrated that prolonged blood circulation, and 
therefore, optimal tumor delivery by the enhanced permeability and retention (EPR) 
effect is achieved with nanoparticles displaying a neutral to mildly negative surface 
charge.9, 10 When the surface charges becomes overly negative, excessive association 
with phagocytic cells of the reticuloendothelial system (RES) decreases circulation time9, 
10
 and it has been commonly reported that positively charged nanoparticles are cleared 
very rapidly due to local electrostatic interactions near the injection site.11  
The results obtained in the two zeta potential experimental cohorts are consistent 
with this general literature consensus, and the tumor delivery was found to correlate well 
with blood circulation time, consistent with passive delivery by EPR. Specifically, the 
mildly negative surface charge of -12.2 mV yielded the longest circulation time and 
greatest tumor delivery. More neutral formulations resulted in slightly lower, but still 
significant, circulation time and tumor delivery. Excessively negative SPIO (-20.7 mV) 
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displayed still more rapid clearance and decreased tumor delivery, while moderately and 
strongly positive formulations had poor circulation time and tumor delivery. 
As expected, a large amount of the injected material, for all surface charges, was 
found in the liver and spleen. However, the two surface charges that yielded the greatest 
tumor delivery (-5.2 mV and -12.2 mV) exhibited the least liver uptake. The more 
significantly negative formulation (-20.7 mV) had a larger liver uptake, consistent with 
stronger association with Kupffer cells and clearance by the liver. Given its relatively 
large mass, the liver represents a major mechanism by which nanoparticles are removed 
from circulation, and since nanoparticles removed from circulation by the liver cannot 
end up delivered to the tumor, it was reasonable to observe the liver concentration as 
roughly inversely related to tumor delivery.  
The relatively high concentration (≈ 6% ID/g) of positively charged nanoparticles 
observed in the heart 24 hours post-injection was an unexpected finding that is likely due 
to a “first pass effect”, since the right chambers of the heart are the first organ that the 
nanoparticles reach after intravenous injection. In fact, washed heart tissue sampled at 5 
minutes post-injection contained 12.2% ID/g. Since the nanoparticle concentration in the 
blood at 5 minutes post-injection was only 2.3% ID/g, the high concentration of 
nanoparticles detected in the heart cannot be attributed to residual blood in the chambers. 
The results are consistent with a rapid initial interaction of the positively charged 
nanoparticles with the endocardium, followed by approximately half of this initial load 
being washed away during the next 24 hours.  
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Effect of Nanoparticle Size on SPIO Biodistribution 
 
 The hydrodynamic diameter of SPIO nanoparticles (with a fixed zeta potential of 
approximately -20 mV) was also found to influence their passive tumor delivery (Figure 
2.9 A). Specifically, the smallest formulation of 15.52 nm yielded the greatest tumor 
delivery at 1.61 % ID/g, the medium sized formulation of 29.05 nm resulted in a lower 
delivery at 1.29 % ID/g, and the largest formulation of 70.72 nm demonstrated the lowest 
delivery at 1.06 % ID/g. Similarly to the negatively charged SPIO tested in the previous 
cohort of animals, all nanoparticle sizes demonstrated significant RES uptake (28 – 42 % 
ID/g in the liver and 18 – 38 % ID/g in the spleen) and more modest uptake in the heart, 
lungs, and kidneys (0.5 – 2 % ID/g, Figure 2.9 B). 
 
Figure 2.9. Effect of SPIO hydrodynamic diameter on tumor delivery and biodistribution. (A) Passive 
nanoparticle delivery to T6-17 flank tumors for three distinct SPIO size distributions. (B) Nanoparticle 
uptake in other organs as a function of size. 
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The blood clearance of the three different sizes tested proved especially 
interesting (Figure 2.10). While the 29.05 nm, -20.7 mV nanoparticle exhibited a similar 
circulation profile as it did in the previous cohort of animals, both the smaller 
nanoparticle (15.52 nm) and the larger nanoparticle (70.72 nm) exhibited more prolonged 
circulation.  
 
Figure 2.10 Effect of SPIO hydrodynamic diameter on blood clearance. 
Previous studies have shown that there is a window, roughly between 5 nm and 
100 nm, in which nanoparticle blood circulation time and passive tumor delivery by EPR 
is maximized.12-15 If the construct is too small, it can be rapidly and efficiently cleared 
through the kidneys, but if too large (>200 nm), it is efficiently trapped by cells of RES 
organs.16 All three SPIO sizes tested were comfortably above the renal filtration 
threshold, so it was not surprising to observe an inverse relationship between nanoparticle 
size and tumor delivery. 
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However, unlike in the zeta potential studies, the tumor delivery was not observed 
to be strictly correlated to circulation time (the largest SPIO, at 70.72 nm, demonstrated 
the lowest tumor delivery, despite having intermediate circulation time). It is possible that 
the 70.72 nm SPIO exhibit greater blood concentrations (especially at early time points) 
because their larger size makes extravasation into tissue (including the tumor) more 
difficult, but the size is not yet large enough to result in excessive interaction with cells of 
the RES. It has also been demonstrated that diffusion-based penetration into tumors is 
strongly dependent on nanoparticle size.17 It is likely the larger, 70.72 nm formulation, 
was not able to efficiently diffuse through the tumor tissue and, therefore, experienced a 
greater “wash out” effect over the 24 hours of the study. 
2.5 Improved Statistical Power of Multiplex (Ratiometric) Data 
 One of the most promising aspects of this multiplex ICP-MS approach to 
measuring biodistribution and blood clearance is the robust statistical power inherent in 
injecting all nanoparticle formulations one wishes to compare into a single animal. In 
vivo studies often exhibit a high degree of experimental variability (e.g. differences in 
tumor size, subject weight, and physiology). When each nanoparticle formulation is 
injected alone, comparison between formulations must be made with unpaired statistical 
tests, which often necessitates a larger number of animals in order to detect statistically 
significant differences in the performance of two or more nanoparticles. However, when 
each nanoparticle is simultaneously administered to all animals, subject-to-subject 
variability is effectively removed by the use of paired statistics. For example, the absolute 
tumor delivery of two particular nanoparticle formulations might be highly variable 
between three animals, confounding attempts to compare the formulations. However, if in 
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each given subject, one nanoparticle is observed to have higher tumor delivery than the 
other, one can more easily conclude that formulation is superior. 
 Looking at the statistical analysis of the experimental cohort (3 animals) 
investigating the effect of nanoparticle size, between the 6 organs investigated for 3 sizes, 
there were 18 head-to-head statistical comparisons that could be made. Treating the data 
as unpaired, using P < 0.05 as the criterion, 6 of the comparisons were statistically 
significant; treating the data as paired, 15 of the possible 18 comparisons demonstrated 
statistical significance. To highlight a particular data set, the average kidney delivery of 
the 15.52 nm, 29.05 nm, and 70.72 nm sizes were 1.74, 1.29, and 1.16 % ID/g, 
respectively, each with a standard deviation of 0.26 – 0.29 % ID/g. These small 
differences in nanoparticle concentration could not be deemed statistically different (P 
values ranging from 0.06 to 0.59) from one another if the data are treated as unpaired. 
However, given that in a given animal, the 15.52 nm nanoparticle always had the greatest 
concentration, followed by 29.05 nm, and then 70.72 nm, paired statistics indicated that 
each concentration was statistically different (P values ranging from 0.002 to 0.022). 
However, it should not be assumed that paired statistics (compared to unpaired) always 
necessarily result in a lower P value. In the experimental cohort investigating the effect of 
nanoparticle surface charge, there were several instances in which unpaired statistics 
would have produced P values less than 0.05 (which can always occur by chance when 
such a large number of comparisons are made) but paired analysis resulted in a P value 
greater than 0.05. The consequence of using paired statistics, therefore, is simply an 
increase in statistic power (i.e. a more accurate estimation of whether the difference is 
“real” can be obtained with a smaller sample size).  
79 
 
2.6 Conclusion 
 A synthetic protocol to stably incorporate lanthanide metals into the core of SPIO 
nanoparticles, without abolishing their magnetic properties, has been developed. The 
lanthanide dopant can be used as a unique tracer atom, allowing the sensitive and 
quantitative detection of the nanoparticles by ICP-MS, both in vitro and in vivo, without 
interference from endogenous signals. When distinct lanthanide metals are incorporated 
into nanoparticles with distinct physicochemical properties, ICP-MS allows for the 
concentration of each nanoparticle formulation to be measured independently of other 
formulations that may be present in the solution or tissue of interest. As a proof of 
principle, this ICP-MS multiplex approach was used to evaluate the effect of nanoparticle 
size and surface charge on tumor delivery, biodistribution, and blood clearance in vivo. 
The results obtained were consistent with the general literature consensus about these 
properties and only required a small number of experimental animals, due to the inherent 
and robust statistical power of a multiplex (ratiometric) approach. Furthermore, it is 
envisioned that the ICP-MS multiplex analysis described could prove to be a powerful 
future research tool in the investigation of other nanoparticle formulations with diverse 
physicochemical properties and active targeting capabilities, while allowing for 
nanoparticle standardization. 
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Chapter 3: Generalization of ICP-MS Analytical Method to Other 
Nanoparticle Formulations and Validation of Multiplex Data 
3.1 Abstract 
 The previous chapter outlined an analytical protocol for stably incorporating 
lanthanide metals into the iron core of superparamagnetic iron oxide (SPIO) 
nanoparticles and then using ICP-MS to quantify of the biodistribution and blood 
clearance of multiple lanthanide-doped SPIO simultaneously administered to a single 
animal. The method used for lanthanide incorporation (i.e. co-precipitation of iron and 
lanthanide) was unique to SPIO. However, much greater utility can be gained if 
lanthanide multiplex analysis could be applied to a wider range of nanoparticle 
formulations. In this chapter, liposomes, polymersomes, dendrimers, and gold 
nanoparticles were examined. With the exception of gold nanoparticles, incorporation of 
the metal was accomplished using the chelator DTPA. In the case of the nanovesicles, the 
lanthanide was chelated to DTPA and then encapsulated within the aqueous core. For the 
dendrimers, DTPA was covalently conjugated to the nanoparticle surface. The gold 
nanoparticles do not require an additional dopant, since the gold itself serves as an 
orthogonal, non-endogenous tracer. Given that the most commonly used methods to 
radiolabel macropharmaceuticals and nanoparticles exploit radionuclide-chelate 
complexes, the successful use of chelators to incorporate the tracer lanthanide 
demonstrates that the ICP-MS multiplex approach can be conveniently substituted for 
radiolabeling in biodistribution and clearance studies.  
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3.2 Introduction 
 Given the variety and versatility of nanoparticle based carrier systems, it is not 
surprising that there is tremendous research interest to develop nanoparticles into imaging 
and therapeutic agents. Radionuclides play a major role in such studies since they provide 
quantitative information and have very high sensitivity. For example, gamma emitters 
such as 111In and 99mTc or positron emitters such as 18F and 64Cu can be used as the 
source of signal when designing nanoparticle based contrast agents for SPECT1-3 and 
PET4-6 studies, respectively. For therapeutic studies of drug carrying nanoparticles, these 
and other radionuclides such as 125I can also serve as tracers, in order to determine the 
level of payload delivery to the site of interest as well as assess off-target toxicity. 
Furthermore, radionuclides such as 188Re,(7, 8) 90Y,(9) 131I,(10) and 225Ac(11, 12) can 
themselves provide the therapeutic effect (i.e. radiopharmaceutical nanoparticles). 
 Within the nanoparticle field, as well as the larger research community, there is a 
great deal of experience working with radionuclides for imaging, tracing, and 
radiotherapy. There are two very common ways to associate radionuclides with 
nanoparticles. One is encapsulation, where a metal or non-metal radionuclide is non-
covalently confined to the interior of the nanoparticle. For example, liposomes and 
polymersomes possess and aqueous core capable of confining radionuclides13, 14 (as well 
as many other materials including fluorophores and pharmaceuticals). The other common 
approach is to covalently attach a chelator, such as DTPA or DOTA, to the nanoparticle 
and then bind a metal radionuclide to the chelator.15, 16 Less commonly, nanoparticles are 
formed using radiolabeled precursors.17 
 Radiolabeling is the “gold standard” for evaluating an agent’s pharmacokinetics 
and biodistribution and the incorporation of metal radionuclides into nanoparticles and 
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other macromolecules is well established practice. We sought to employ the same 
common methods (i.e. encapsulation and chelation) to incorporate lanthanide tracers into 
nanoparticles, thereby allowing for quantitative measurement of blood clearance and 
tumor delivery using ICP-MS. However, unlike radiolabeling, an ICP-MS based 
approach should allow for high level multiplexing of these measurements in single 
animals. For further validation, we sought to confirm that the blood clearance profiles 
and tumor delivery data obtained with the ICP-MS multiplex injection approach was both 
reproducible across a range of injection pools and agreed with data obtained for 
conventional single agent injection. 
3.3 Materials and Methods 
 
Synthesis of PAMAM (G3)−DOTA−Ho and PAMAM (G5)-DOTA-Pr 
 
10 mg of PAMAM G3 dendrimer (ethylenediamine core, generation 3, 
Dendritech, Midland, MI, USA) was dissolved in 4 mL of sodium bicarbonate buffer (0.1 
M, pH 9.5) and reacted with 35 mg of DOTA-NHS-ester (Macrocyclics, Dallas, TX, 
USA) for 10 hours. The pH of the solution was maintained at 9.5 over the course of the 
reaction by addition of NaOH. The PAMAM−DOTA was purified by centrifugal filter 
devices (Amicon Ultra-4, 5000 MWCO, Millipore, Billerica, MA). The purified 
PAMAM−DOTA conjugates were mixed with 18 mg of HoCl3•6H2O in 0.1 M citrate 
buffer (pH 5.6) overnight at 42°C. Finally, the dendrimer was purified from free Ho3+ 
with 5000 MWCO centrifugal filter devices. PAMAM (G5)-DOTA-Pr was prepared 
using an analogous procedure, substituting PAMAM-G5 in the place of PAMAM-G3 and 
PrCl3•6H2O for HoCl3•6H2O. In order to ensure the two dendrimer formulations were 
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negatively charged, each was reacted overnight with 1 M succinic anhydride in 0.1 M 
sodium bicarbonate buffer and then purified by centrifugal filtration. 
 
Preparation of DOTA−Ce Encapsulating Polymersomes 
DOTA-Ce was prepared by dissolving 303 mg of DOTA (Macrocyclics) in 3 mL 
of citrate buffer (0.1 M, pH 5.6) and reacting with 223.8 mg of CeCl3•7H2O for 10 hours. 
The reaction solution was maintained at pH 6.0 with NaOH. Polymersomes were 
prepared by dissolving 20 mg of PEO-PBD block copolymer (polyethyleneoxide[600 
Da]-block-polybutadiene[1200 Da], Polymer Source, Dorval, Quebec, Canada) in 
chloroform in a glass vial and then evaporating the solvent using a stream of N2 gas. 
After further drying under vacuum overnight, the residual polymer film was hydrated 
with 1 mL DOTA-Ce aqueous solution in a 65 °C water bath for 30 min and then 
sonicated for another 1 h at the same temperature. Polymersomes were subjected to ten 
freeze–thaw–vortex cycles in liquid nitrogen and warm H2O (65 °C), followed by 
extrusion 21 times through two stacked 100 nm Nuclepore polycarbonate filters using a 
stainless steel extruder (Avanti Polar Lipids, Alabaster, AL). Unencapsulated DOTA-Ce 
was removed via size-exclusion chromatography using Sepharose CL-4B (Sigma-
Aldrich, St. Louis, MO, USA) and polymersomes were further purified through repeated 
washing on centrifugal filter devices (Amicon Ultra-4, 100K MWCO, Millipore). Any 
remaining positively-charged surface amino groups were then blocked by carboxylation 
with succinic anhydride. 
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Preparation of DOTA−Dy Encapsulating Liposomes 
DOTA-Dy was prepared by dissolving 303 mg of DOTA in 3 mL of citrate buffer 
(0.1 M, pH 5.6) and reacting with 226.2 mg of DyCl3•6H2O for 10 hours. The reaction 
solution was maintained at pH 6.0 with NaOH. For liposome synthesis, hydrogenated soy 
phosphatidylcholine (HSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (mPEG2000-DSPE) 
were obtained from Avanti Polar Lipids. 10 mg of 55 mol% HSPC/40 mol% 
CHOL/5 mol% mPEG2000-DSPE mixture was dissolved in chloroform in a glass vial, 
followed by evaporation of the solvent with a stream of N2 gas and further drying under 
vacuum for at least 4 hours. DOTA-Dy encapsulating liposomes were then synthesized 
and purified with a procedure analogous to the preparation of DOTA-Ce encapsulating 
polymersomes. 
 
Preparation of PEG-coated Gold Nanoparticles 
 Gold nanoparticles were prepared according to a protocol established by 
Turkevich.18 Briefly, 200 ml of aqueous 0.01% (w/v) HAuC14 was brought to a boil and 
then 7 ml of aqueous 1% (w/v) sodium citrate was added. The color of the solution 
initially changed to a grayish-black and then to red within a few minutes. The solution 
was allowed to cool at room temperature and then filtered through a 0.2 µm pore size 
nylon filter system. The AuNPs were then coordinated with HS – PEG (5K) – OCH3 
(Sigma Aldrich) at a mass ratio of 8:1 HS – PEG - OCH3:Au. After 2 hours of constant 
stirring, the AuNP solution was then purified from excess reactants using 50K MWCO 
centrifugal filter devices. 
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Nanoparticle Physicochemical Characterization 
Stock samples of dendrimers, polymersomes, liposomes, and gold nanoparticles 
were diluted into pH 7.4 phosphate buffered saline for determination of the 
hydrodynamic diameter by dynamic light scattering (DLS). Measurements were acquired 
with a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the non-
invasive back-scatter (NIBS) mode. For zeta potential measurements, stock samples were 
diluted into phosphate buffered saline at pH 7.4 and then mean nanoparticle zeta potential 
was measured using a Zetasizer Nano-ZS. 
 
Nanoparticle Stability Assays 
The stability of the nanoparticles was measured as the amount of lanthanide 
leakage that could be observed in serum. Nanoparticles were incubated in 100% fetal 
bovine serum (FBS) at 37°C with shaking. Aliquots were removed at 1, 2, 4, 6, and 24 
hours and applied to a 4,000 MWCO centrifugal filter device to collect any free metal in 
the filtrate. Lanthanide concentrations were measured by ICP-MS in the original 
nanoparticle stock and in the filtrates, allowing for calculation of percent of lanthanide 
leakage. 
 
Cell Culture and Tumor Model 
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided 
by Mark Greene, PhD, FRCP, University of Pennsylvania) were cultured and maintained 
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin at 37°C and 5% CO2. Approximately 6-week 
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old female nu/nu nude mice (Charles River Laboratory, Charles River, MA, USA) were 
maintained in accordance with the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. Mice were anesthetized via isoflurane and T6-17 cells were 
injected subcutaneously into the back right flank (2 x 106 cells in 0.2 mL PBS). Tumors 
were grown until the longest dimension was approximately 8 mm. 
 
Quantitation of Tumor Delivery, Biodistribution, and Blood Concentration by ICP-MS 
Two animal cohorts, each containing 3 animals, were used for multiplex 
experiments, as outlined in Table 3.1. In the first experimental groups, which investigated 
a single type of SPIO, the nanoparticles were injected at a dose of 10 mg Fe / kg body 
weight in 200 µL of injected volume. In the second experimental group, which included a 
variety of additional nanoparticle platforms, the SPIO was injected at 10 mg Fe / kg body 
weight and the other formulations were injected at concentrations so that all tracer metal 
concentrations (lanthanide or gold) were approximately equal to that of the SPIO 
samples, ≈ 34 ppm, in 200 µL of injected solution. 
 
Table 3.1. Summary of animal injection groups (n=3 for each groups). 
Experimental 
Cohort 
Number of 
Particles Co-
injected 
Description 
Single Particle 1 -20.8 mV, 29.8 nm SPIO  
Additional 
Platforms 
7 Gd-DTPA, G3 and G5 dendrimers, AuNP, SPIO, 
liposome, polymersome 
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For each experimental group, prior to injection, a nanoparticle aliquot was saved 
for inductively coupled plasma mass spectrometry (ICP-MS) determination of lanthanide 
concentration in the injected material. Following nanoparticle injection, 10 µL blood 
samples were collected from each animal, using the tail-nick method, at times of 1, 2, 4, 
7, and 24 hours post-injection. After the final blood draw, the animals were sacrificed and 
the tumors, livers, spleens, kidneys, hearts, and lungs excised. 
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain, 
NY, USA) and trace metal grade nitric acid and aqua regia was purchased from Fisher 
Scientific (Pittsburg, PA, USA). All dilutions were done using in-house deionized water 
(≥18 MΩ-cm) obtained from a Millipore water purification system. 
The pre-injection solutions, blood, tumor, and organ samples were analyzed for 
158Gd (gadolinium), 147Sm (samarium), 153Eu (europium), 165Ho (holmium), 166Er 
(erbium), 161Dy (dysprosium), 140Ce (cerium), 141Pr (praseodymium), and 197Au (gold) 
using an Elan 6100 ICP-MS (Perkin Elmer, Shelton, CT, USA)  at the New Bolton 
Center Toxicology Laboratory, University of Pennsylvania, School of Veterinary 
Medicine, Kennett Square, PA, USA. The samples were weighed into Teflon PFA vials 
(Savillex, Minnetonka, MN, USA) and digested overnight with 70% nitric acid (or aqua 
regia for gold containing samples) at 70° C.  0.1 mL of 2 ppm 159Tb (terbium) was added 
to each of the digested samples and the mixtures were diluted with deionized water to a 
final volume of 10 mL. The lanthanide (or gold) concentration of each sample was 
measured using a calibration curve of aqueous standards at 0.01, 0.1, 1.0, and 10 ppb for 
each metal.  
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The performance of the instrument and accuracy of the results were monitored by 
analyzing a reagent blank and bovine serum control serum (Sigma) prior to analysis of 
the samples. Also, standard reference material (Peach Leaves 1547) obtained from 
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with 
known values of iron and rare earth elements was analyzed with each batch of samples. 
For each nanoparticle formulation, the percent injected dose per gram of tissue, 
was calculated as [Ln]sample / ([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration 
in the sample (blood, tumor, or organ tissue), [Ln]inj is the lanthanide concentration in the 
injected nanoparticle solution, and Minj is the mass of nanoparticle solution injected (0.2 
grams). 
3.4 Results and Discussion 
 
Generalization of ICP-MS Multiplex Method with Additional Nanoparticle Platforms 
  
In order to demonstrate the generalizability and versatility of the ICP-MS 
multiplex approach, orthogonal metals were incorporated into a wide range of 
nanoparticle platforms and their tumor delivery and blood clearance was examined. 
Specifically, the small molecule Gd-DTPA, PAMAM dendrimers of generation 3 and 5, 
PEG coated gold nanoparticles, SPIO, a polymersome, and a liposome were all 
synthesized and conjugated to or encapsulated with orthogonal metals (Table 3.2).  
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Table 3.2 Size and zeta potential of the nanoparticles used in the multiplatform study. 
 
Particle Tracer Metal Hydrodynamic 
Diameter (nm) 
Zeta Potential (mV), 
PBS, pH 7.4 
Gd-DTPA Gd -- -- 
G3 Dendrimer Ho 4.2 -0.38 
G5 Dendrimer Pr 6.1 -7.58 
Gold NP Au 26.0 -1.31 
SPIO Er 33.3 -9.55 
Polymersome Ce 82.5 -4.08 
Liposome Dy 93.8 -1.35 
 
The hydrodynamic diameter of these formulations was then measured in PBS, 
along with their surface charge (zeta potential), using DLS and electrophoretic mobility. 
Due to its very small size, the individual Gd-DTPA complex, however, is not amenable 
to DLS measurement. These results are reported in Table 3.2. All nanoparticle 
formulations possessed a neutral to moderately negative surface charge, making them 
compatible for co-injection. This group of nanoparticles spanned a wide range of sizes, 
from approximately 4 to 95 nm (Figure 3.1).  
 
Figure 3.1. Size distributions of the nanoparticles (G3 and G5 dendrimer, gold (Au), SPIO, 
polymersome, and liposome) used in the multiplatform study. 
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The stability of the dendrimer chelates and nanovesicle formulations was also 
confirmed by incubation in 100% serum for 24 hours at 37°C. It was found that less than 
0.4% of the lanthanide metal was released from the dendrimer chelates into the bulk 
solution, and less than 1.5% of the lanthanide metal encapsulated within the liposome and 
polymersome was released into the bulk solution (Figure 3.2). 
 
Figure 3.2 Stability of various lanthanide doped nanoparticles, assayed by percent of lanthanide leakage 
observed after 24 hours of incubation in 100% serum at 37°C. 
 
These 7 formulations were simultaneously injected and their tumor delivery 
(Figure 3.3 A) and blood clearance (Figure 3.3 B) were evaluated. The small molecule 
Gd-DTPA and smallest particle (G3 dendrimer, 4.2 nm) had tumor delivery at or below 
the detection limit of 0.17% ID/g at 24 hours, and were entirely cleared from circulation 
in the first hour post-injection. Interestingly, the G5 dendrimer, with a size only slightly 
larger than the G3 dendrimer (6.1 nm) exhibited the greatest tumor delivery at 4.36% 
ID/g and a prolonged circulation time, with 5.83% ID/g still circulating at 24 hours post-
injection. The significantly larger PEG-coated gold nanoparticle also demonstrated very 
robust tumor delivery at 4.00% ID/g and significantly lower clearance than any other 
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formulation tested, with 15.20% ID/g remaining in circulation 24 hours post-injection. 
The SPIO nanoparticle had tumor delivery and blood circulation times comparable to the 
studies in the previous chapter. The polymersome and liposome yielded lower tumor 
delivery (0.35% ID/g and 1.00% ID/g, respectively), and correspondingly, faster blood 
clearance.  
 
Figure 3.3 ICP-MS multiplex analysis of biodistribution and blood clearance for seven different 
compounds injected simultaneously. (A) Tumor delivery and (B) blood clearance profiles for a variety of 
lanthanide doped nanoparticle formulations, spanning a range of sizes, including small molecules, 
dendrimers, gold nanoparticles, SPIO nanoparticles, polymersomes, and liposomes. 
 
The small molecule Gd-DTPA and the G3 dendrimer both had undetectable tumor 
delivery at 24 hours post-injection and had been cleared from circulation in the first hour 
post-injection. This is consistent with previous reports of G3 dendrimer’s rapid 
clearance.19 Since both of these formulations are less than 5 nm in diameter, they are 
efficiently removed from circulation by renal filtration, and while they may display 
dynamic wash-in at the tumor site, their small size allows for efficient wash-out and, 
subsequently, poor tumor delivery at the 24 hour time point. 
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 It has been reported that G5 dendrimer exhibits a significantly longer circulation 
time compared to G3,20 as the G5 dendrimer’s small increase in size begins to impair 
renal filtration. In this study, the addition of the chelator DOTA, and surface modification 
with succinate (to neutralize the positive charge of a native PAMAM dendrimer) also 
contributes to increased size for the G5 formulation. The long circulation time observed 
in this study, and consequent high tumor delivery, was likely due to the formulation being 
too large for renal clearance, but still being small enough to avoid significant RES 
interaction. 
 The PEG-coated gold nanoparticle also exhibited very long circulation time and 
high tumor delivery. This was not unexpected since a PEG coating often confers “stealth” 
properties to nanoparticles21 and many gold nanoparticle formulations have been reported 
to have relatively long circulation times.22 The ≈ -20 mV, ≈ 30 nm SPIO demonstrated 
similar clearance and tumor delivery as it did in the previous experimental cohorts. 
Compared to the SPIO nanoparticles, the liposome and polymersome each displayed 
more rapid clearance and, consequently, lower tumor delivery.  
 
Validation of Multiplex Approach across Multiple Experimental Cohorts 
 
A central assumption for all of the multiplex injection experiments is that the 
different nanoparticle formulations do not interact with each other, so that tumor delivery, 
biodistribution, and blood clearance observed in a multiplex injection are the same as 
they would be if each formulation were injected separately. The experimental cohorts 
used in this investigation, as well as the previous chapter, were specifically designed to 
test and validate this assumption (see table 3.3). A specific form of SPIO nanoparticle (≈ 
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30 nm hydrodynamic diameter and ≈ -20 mV zeta potential, represented with bold text in 
table 3.3) was present in the multiplex injection of 3 different animal cohorts (negative 
zeta potential, size, and additional platforms), allowing for comparison of clearance and 
tumor delivery for this nanoparticle across a range of injection conditions. It should be 
noted that the zeta potential reported for the SPIO nanoparticle in Table 3.2 (-9.55 mV) 
was measured in isotonic phosphate buffered saline; zeta potential measured in 10 mM 
HEPES yielded ≈ -20 mV. Also, this formulation of SPIO was injected alone, in order to 
explicitly compare tumor delivery and clearance to the values obtained in the different 
multiplex injections. 
 
Table 3.3 Summary of animal injection groups from this and previous chapter that all 
contain a specific SPIO formulation (n=3 for all groups). 
 
Experimental 
Cohort 
Number of 
Particles Co-
injected 
Description 
Single Particle 1 -20.8 mV, 29.8 nm SPIO  
Negative Zeta 
Potential 
3 -20.8 mV, -12.2 mV, -5.2 mV SPIO (all ≈ 28 
nm) 
Size 3 15.52 nm, 29.05 nm, 70.72 nm SPIO (all ≈ -20 
mV) 
Additional 
Platforms 
7 Gd-DTPA, G3 and G5 dendrimers, AuNP,  
33 nm, ≈ -20 mV SPIO, liposome, polymersome 
 
 The tumor delivery of this SPIO formulation conserved across animal cohorts is 
summarized in Figure 3.4. For each injection condition tested, the tumor delivery was 
very similar (1.09 – 1.29 % ID/g), and no two conditions were statistically different (P 
values ranging from 0.33 to 0.85).  
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Figure 3.4 Comparison of tumor delivery of a single SPIO nanoparticle formulation (≈ 29 nm, ≈ -20 
mV) that was injected across multiple studies. No statistical difference is found between tumor delivery 
obtained when the same SPIO formulation is injected alone, with SPIO of other charges, with SPIO of 
other sizes, or with various other nanoparticle platforms. 
Blood circulation profiles are compared in Figure 3.5; again, the four injection 
conditions tested resulted in similar clearances, with overlapping error bars.   
 
Figure 3.5 Validation of the ICP-MS multiplex method by comparing blood clearance of a single SPIO 
nanoparticle formulation (≈ 29 nm, ≈ -20 mV) injected alone, with SPIO of other charges, with SPIO of 
other sizes, or with various other nanoparticle platforms.  
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 As previously stated, in order for the ICP-MS multiplex method to provide 
reliable data, it is important that the particular formulations that are co-injected together 
do not exhibit interactions with each other, so that in the co-injection they behave as they 
otherwise would if injected alone. In general, three potential sources of nanoparticle 
interaction should be considered: hydrophobic interactions, electrostatic interactions, and 
molecular specific interactions. For this particular investigation, all nanoparticle 
formulations possessed a significantly hydrophilic surface, and no nanoparticles 
possessed any specific ligands or receptors. In order to avoid electrostatic interactions, 
when the effect of nanoparticle surface charge was evaluated, the study was split into two 
separate injections (one with the three negatively charged particles, and one with the 
three positively charged particles). It is also worth noting that at no time, for any of the 
experimental groups, was any aggregation visibly observed when the individual 
formulations were combined to form the multiplex solution. Given that each nanoparticle 
would be “multivalent” for any possible type of interaction, macroscopic aggregation or 
precipitation would be expected if nanoparticle interaction had occurred. 
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3.5 Conclusion 
 In addition to precipitating lanthanide metals into the core of SPIO nanoparticles, 
it is also possible to incorporate lanthanides into liposomes, polymersomes, and 
dendrimeric formulations using either encapsulation or chelation. Therefore, it is 
envisioned that any nanoparticle formulation amenable to labeling with a metal 
radionuclide would also be suitable for labeling with an ICP-MS lanthanide tracer. Some 
other types of nanoparticles (e.g. gold and silver nanoparticles) inherently contain an 
ICP-MS metal tracer, without any further need for labeling. In addition to providing a 
quantitative method of detection with high sensitivity, ICP-MS tracers provide two 
potential befits over conventional radiolabeling. Namely, they have the ability to easily 
multiplex a large number of signals in a single fluid or tissue sample while avoiding the 
hazards of handling radioactivity. Consequently, ICP-MS based multiplex analysis can be 
applied to a very wide variety of nanoparticle and macropharmaceutical formulations and 
allows for “higher throughput” evaluation of the pharmacokinetics and biodistribution of 
such agents in animals models. 
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Chapter 4: Extension of ICP-MS Multiplex Method to Compare 
Actively Targeted SPIO Nanoparticles 
4.1 Abstract 
Given the rapidly expanding library of pathology biomarkers (e.g. tumor 
receptors) and targeting scaffolds (e.g. antibodies, single chain antibody fragments, small 
affinity peptides, etc.), the number of actively targeted nanoparticle formulations is 
growing exponentially. In most studies, the goal is to maximize the concentration of 
diagnostic or therapeutic nanoparticle payload delivered to a site of interest in vivo, while 
minimizing delivery in other locations. Given the difficulty and expense of in vivo animal 
testing, it is generally not feasible to examine a large number of specific nanoparticle 
candidates in vivo. This often leads to the investigation of only the single formulation that 
performed best in vitro. However, nanoparticle delivery in vivo is dependent on many 
variables, many of which cannot be adequately assessed with in vitro cell-based assays. 
Consequently, the development of actively targeted nanoparticles could be greatly 
facilitated and expedited by a method that allows for many formulations (including 
control formulations) to be evaluated in a single animal. It is hypothesized that the ICP-
MS multiplex approach developed in chapters 2 and 3 to examine passive nanoparticle 
delivery could be naturally extended to fill this role. 
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4.2 Introduction 
Rapid advancements in nanotechnology have resulted in the development of 
nanoparticle formulations for a myriad of biological applications extending from 
diagnostic cell tracking to improved delivery of therapeutic agents. Given the limitless 
ability to modify the physicochemical properties of nanoparticles to fit specific areas of 
interest, it is expected that their utility will only continue to increase. Recently, there has 
been especially significant growth in the application of nanoparticles to cancer 
diagnostics and drug delivery. This growth is a direct result of the numerous advantages 
that nanoparticles provide to this field; including, but not limited to: the ability of 
nanoparticles to extravasate at a tumor, the high therapeutic and diagnostic “payloads” 
that can be incorporated into nanoparticles, and their favorable toxicity profiles resulting 
from reduced agent accumulation in healthy tissue.1-3 
So far, the majority of clinical trials for nanoparticles have focused on passive 
delivery to the tumor. That is, a nanoparticle’s physicochemical properties are optimized 
for long blood residence time, which allows for a high percentage of uptake into tumors 
via the enhanced permeability and retention (EPR) effect.4 While this strategy has 
demonstrated that nanoparticle-encapsulated drug has improved efficacy and reduced 
side-effects (compared to free drug), an increased focus has recently been placed on 
further improving these nanoparticles with active targeting strategies. Indeed, many 
studies have shown that active targeting of nanoparticles can increase the dose of 
therapeutic delivered to a tumor and also improve the intra-tumoral localization of 
delivered nanoparticles.5, 6 Furthermore, a nanoparticle’s surface may display multiple 
copies of a particular targeting ligand (multivalency), and this has been shown to increase 
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binding avidity, increase the rate of internalization, and ultimately improve therapeutic 
efficacy and/or image contrast.7-11  
One particular class of nanoparticles that has become increasingly dependent on 
targeted delivery is superparamagnetic iron oxide (SPIO) nanoparticles (NPs). SPIO NPs 
are an attractive magnetic resonance (MR) contrast agent, providing T2*-weighted 
contrast enhancement in MR imaging applications. Due to their good biocompatibility, 
strong contrast enhancement, and their ability to generate functional data concomitant 
with anatomic information, SPIO are avidly being evaluated as molecular imaging 
agents. In this role, they are used to report the expression level of target cell-surface 
receptors in order to improve the specificity of disease detection.  To date, affinity 
ligands have been used to deliver SPIO NPs to a range of different sites including tumor 
cells,12,13 tumor vasculature,14,15 atherosclerotic lesions,16-18 and many others.19-24 
However, while SPIO NPs have seen extensive biological applications, their full 
transition to the clinic as molecular imaging agents has been slow to develop, due to the 
relatively high concentrations of SPIO NPs needed to generate detectable MR contrast in 
an area of interest.  
Often, pathologies present with several possible biomarkers that may be viable 
targets. For example, breast cancers may overexpress the estrogen receptor, progesterone 
receptor, and/or the Her2/neu (ErbB2) receptor.25 As nanoparticles continue to progress 
toward greater clinical use, it is important to identify which molecular targets result in the 
best in vivo tumor delivery (for a particular tumor type). Importantly, the optimal 
molecular target and nanoparticle composition for nanoparticle delivery in vivo may not 
be accurately reflected in assays conducted in vitro. For example, it has been shown that 
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affinity ligands with very high affinity do not necessarily result in the best tumor 
targeting, since tight binding at the tumor periphery slows diffusion of the agent within 
the tumor and can block extravasation of additional agent.26 Furthermore, the addition of 
targeting ligands to a nanoparticle’s surface can alter its physicochemical properties, thus 
potentially altering its circulation properties and affecting its ability to reach a tumor. 
Despite the large potential for incongruity between nanoparticle performance in vitro 
and in vivo, most often investigators choose the identity of the active targeting ligand and 
then optimize the ligand surface density, along with other nanoparticle physicochemical 
properties, based on in vitro data. Subsequently, this “optimal” formulation is generally 
evaluated in one cohort of subjects, while one or more negative control (non-targeted) 
nanoparticle formulations are examined in other cohorts. However, when nanoparticles 
are evaluated in separate animal cohorts, the large animal-to-animal variability 
characteristic of in vivo studies makes nanoparticle improvement more difficult to 
observe. The primary reason for the lack of optimization at the in vivo stage, and the use 
of a large number of animals, is the lack of a feasible “higher throughput” method for 
accurately comparing different nanoparticles in vivo. In chapters two and three, we 
introduced a non-radiative, quantitative, and multiplex method for assessing nanoparticle 
pharmacokinetics and biodistribution, demonstrating its ability to compare passive 
delivery for a wide range of nanoparticle types and physicochemical properties. Herein, 
this method is extended to include the evaluation of actively targeted SPIO NPs.  
For this work, we have selected three targets of interest: the HER2/neu receptor, heat 
shock protein 47 (HSP47) and αVβ3 integrin. Each of these receptors has been shown to 
have a high association with cancer, and each has been used as a target in therapeutic 
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studies.27-30 Additionally, each of these targets has ligands that can be used to actively 
target SPIO NPs. Specifically, HER2 affibody, cyclic RGD, and the LDS affinity peptide 
were selected as ligands for targeting HER2/neu, αvβ3 integrin, and HSP47 
respectively.31-36 As described in chapter 2, a set of four lanthanide-doped SPIO 
nanoparticles (Ho, Sm, Gd, and Eu) were synthesized. HER2 affibody, cyclic RGD, and 
LDS peptide were conjugated to the Ho-, Sm-, and Gd-SPIO, respectively. The Eu-SPIO 
lacked a targeting ligand and served as a negative control nanoparticle formulation. ICP-
MS multiplex analysis can then be used to trace each actively targeted formulation 
simultaneously in a single sample. 
4.3 Materials and Methods 
 
Materials 
 
Azido-dPEG4-NHS ester was purchased from Quanta BioDesign Ltd. (Powell, 
OH). NIH/3T3 cells that were engineered to stably express the Her2/neu receptor (T6-17) 
were kindly provided by Dr. Mark Greene, MD/PhD (University of Pennsylvania). All 
other reagents were purchased from Thermo Fisher Scientific (Waltham, MA) unless 
otherwise noted. 
 
Synthesis of Dextran Stabilized Lanthanide Doped SPIO 
 
Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the 
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran 37. 
Briefly, 25 g of dextran T-10 (Pharmacosmos A/S, Holbaek, Denmark), was dissolved in 
500 mL dH2O and heated to 80°C for 1 hour. The solution was then allowed to cool to 
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room temperature and continued to mix overnight. Subsequently, a solution of 1.85 g 
FeCl3, 0.73 g FeCl2, and 0.125 g LnCl3•6H2O (Ln = Ho, Eu, Sm, or Gd) in 25 mL dH2O 
was prepared and decanted into the dextran solution. The combined solution was cooled 
on ice and degassed with N2 for 90 min. While keeping the solution stirring on ice and 
under N2, an automated syringe pump was then used to introduce 15 mL of concentrated 
NH4OH to the solution over 5 hours. The resulting black viscous solution was removed 
from the N2 atmosphere, heated to 90°C for 1 hour, cooled overnight, and centrifuged at 
20,000 RCF for 30 minutes to remove large aggregates. Free iron, lanthanide, and 
dextran were removed by diafilitration across a 100 kDa membrane and the Ln-SPIO 
were brought to a final volume of ≈40 mL at 10 mg Fe/mL.  
 This 40 mL of dextran SPIO at an iron concentration of 10 mg/mL was then 
combined with an equal volume of 10 M NaOH and mixed for 10 minutes. 80 mL of 
epichlorohydrin was then added and the solution was vigorously stirred at room 
temperature overnight. Epichlorohydrin crosslinks the dextran coating within the Ln-
SPIO particle and chemically activates the dextran surface for conjugation. The solution 
was then briefly centrifuged to allow phase-separation into an aqueous black SPIO layer 
and a clear layer of unreacted epichlorohydrin, which was removed. The SPIO layer was 
quickly purified via extraction in isopropanol. Specifically, the Ln-SPIO material was 
combined with 5 volumes of isopropanol and the mixture was vigorously shaken. Brief 
centrifugation of the mixture resulted in a layer of precipitated salt, an Ln-SPIO layer, 
and an isopropanol layer (containing any remaining epichlorohydrin). The SPIO layer 
was then isolated and combined with an equal volume of concentrated NH4OH and 
gently stirred for 24 hours at room temperature, resulting in an aminated nanoparticle 
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surface. After the reaction, the Ln-SPIO was purified by diafiltration across a 100 kDa 
membrane and was 0.2 µm filtered to remove any oversized material. Finally, to ensure 
complete purification of the Ln-SPIO from excess salt and lanthanide ions, the 
nanoparticles were magnetically purified on MACS LS columns using a MidiMACS 
magnet (Miltenyi Biotec, Auburn, CA, USA). 
 
Cloning of HER2-Affibody and LDS Recombinant Protein into pTXB1 Vector 
The nucleotide and corresponding amino acid sequences for the HER2 affibody 
and LDS affinity peptide are provided in Figures 4.1 and 4.2, respectively. 
Complementary oligonucleotides comprising the HER2-Affibody or LDS coding 
sequence flanked at both ends by 15 base sequences homologous to the desired restriction 
sites of the destination vector were ordered from Integrated DNA Technologies 
(Coralville, IA). To improve subsequent affinity column cleavage, an additional 9 base 
pairs encoding a “MRM” amino acid sequence were included in the oligonucleotides at 
the C-terminal end of both sequences.  The full nucleotide and amino acid sequence for 
the HER2-Affibody and AHNP can be found in Figure x. Oligonucleotides were 
incubated together at a final concentration of 5 µM and hybridized at room temperature 
for 30 minutes. The resulting sequence was agarose gel purified and directly ligated with 
gel-purified NdeI-XhoI double digested pTXB1 vector (New England Biolabs, Inc) via 
the CloneEZ kit (Genscript). Insertion of the HER2-Affibody and AHNP sequences was 
verified by DNA sequencing using the T7 promoter as the sequencing primer. 
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GTG GAT AAC AAA TTT AAC AAA GAA ATG CGC AAC GCG TAT TGG GAA ATT 
              Val    Asp  Asn  Lys    Phe  Asn    Lys   Glu   Met    Arg  Asn    Ala   Tyr    Trp    Glu   Ile 
 
GCG CTG CTG CCG AAC CTG AAC AAC CAG CAG AAA CGC GCG TTT ATT CGC 
              Ala    Leu  Leu    Pro  Asn    Leu  Asn   Asn    Gln   Gln   Lys   Arg    Ala    Phe   Ile   Arg 
 
AGC CTG TAT GAT GAT CCG AGC CAG AGC GCG AAC CTG CTG GCG GAA GCG 
              Ser   Leu   Tyr   Asp   Asp   Pro   Ser    Gln    Ser     Ala   Asn   Leu   Leu   Ala   Glu   Ala 
 
AAA AAA CTG AAC GAT GCG CAG GCG CCG AAA ATG CGC ATG 
                          Lys    Lys   Leu   Asn   Asp   Ala    Gln   Ala    Pro   Lys    Met  Arg  Met 
Figure 4.1 Nucleotide and corresponding amino acid sequence of the HER2-Affibody. 
The additional base pairs added to improve affinity column cleavage are shown in bold.  
 
 
 
 
CTG GAT AGC CGC TAT AGC CTG CAG GCG GCG ATG TAT ATG GCG ATG 
                  Leu   Asp   Ser    Arg   Tyr    Ser   Leu   Gln   Ala    Ala   Met   Tyr   Met   Arg   Met 
 
Figure 4.2 Nucleotide and corresponding amino acid sequence of the LDS peptide. The 
additional base pairs added to improve affinity column cleavage are shown in bold.  
Expression and Purification of HER2-Affibody and LDS Recombinant Protein 
 
The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS 
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an 
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty 
mL of LB medium and grown overnight under the same conditions, and then inoculated 
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a 
final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures 
were allowed to express for 2 hours at 37 °C.  Bacterial cultures were centrifugally 
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM Na-
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HEPES, 0.5 M NaCl, 1 mM EDTA,  pH 8.5) containing 0.75 g/L lysozyme and 50 mM 
phenylmethylsulfonyl fluoride.  Cells were lysed by pulse sonication on ice. Cells were 
centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at -
20 °C.  For the following purification steps, all procedures were run at 4 °C. One mL of 
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography 
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England 
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were 
washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three 
mL of 50 mM MESNA was quickly passed through the column in order to evenly 
distribute the MESNA throughout the chitin beads, and flow was stopped. The column 
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a C-
terminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl, 
pH 8.5) and concentrated to a volume of 500 µL using an Ultracell 3,000 (Millipore, 
Billerica, MA). An analogous experimental protocol was used for the production and 
purification of LDS peptides, with the exception of the IPTG concentrations used for 
induction, which were lowered from 0.5 mM to 0.4 mM final concentration.  
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Figure 4.3 Schematic of EPL-Click conjugation strategy, illustrated with HER2 affibody 
conjugation to Ho-SPIO. Upon cleavage from the chitin affinity purification column, the 
HER2 affibody displays a C-terminal reactive thioester. This C-terminal thioester reacts 
with the N-terminal cysteine of a fluorescent linker peptide (AFP). Towards the C-
terminus of the linker peptide is an azide group. Subsequently a chemoselective “click” 
reaction is carried out between Ho-SPIO displaying alkyne functional groups (ADIBO) 
and the azide group of the HER2-linker adduct. 
 
Expressed Protein Ligation 
Expressed protein ligation was carried about between the thioester containing 
HER2-Affibody/LDS peptide and an azido-fluorescent peptide (AzFP) with an N-
terminal cysteine. The sequence of the AzFP was NH2-CDPEK(5-FAM)DSGK(N3)S-
OH. The K(5-FAM) represents a lysine with a fluorescein covalently attached to its ε-
amino group and the K(N3) represents a lysine with an azido group attached to its ε-
amino group.  The AzFP (0.1 mM) was incubated with approximately 0.01 mM HER2-
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Affibody or LDS. The EPL reaction was mixed overnight at room temperature. For the 
HER2-Affibody, the EPL product and excess AzFPs were separated on a Superdex 30 
chromatography column. For the LDS-peptide, several rounds of washing using Ultracell 
3,000 filtration columns were used to remove unreacted AzFP peptides.  
 
Azide functionalization of Cyclic-RGD 
Cyclic-RGD was incubated with Azido-dPEG12-NHS at 10:1 molar ratios of 
Azide:RGD in DMSO at a final volume of 30 µL. Reactions were incubated at room 
temperature overnight and purified via RGD precipitation in 10x volumes of tert-butyl 
methyl ether followed by centrifugation at 16,000x g for 1 minute. These precipitations 
were performed in triplicate and the resulting conjugate was suspended in a final volume 
of 30 µL DMSO.  
 
ADIBO Modification of SPIO NPs for Click Chemistry 
Surface amines on SPIO NPs were reacted with the amine-reactive ADIBO-
dPEG4-NHS in 0.1 M sodium phosphate buffer, pH 9. ADIBO is an alkyne-containing 
moiety suitable for click conjugation to the azide-containing ligand preparations. 
Specifically, a 138 mM stock of ADIBO-dPEG4-NHS was diluted 100-fold into a 50 µM 
solution of SPIO NPs. All nanoparticle solutions were mixed overnight at room 
temperature. SPIO NPs were purified via superdex 200 chromatography columns (GE 
Healthcare, Piscataway, NJ). The resulting ADIBO-SPIO NPs were incubated with 100 
times molar excess of succinic anhydride to convert all remaining amines to carboxyl 
groups. ADIBO-SPIO NPs were subsequently purified on superdex200 chromatography 
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columns, equilibrated with PBS. For RGD-SPIO and unlabeled SPIO used in flow 
cytometry experiments, SPIO NPs were first labeled with a FITC fluorophore (10:1 
molar ratio of FITC:SPIO) and purified via PD-10 purification columns  before being 
labeled with ADIBO.  
 
Copper-Free Click Conjugation 
ADIBO-SPIO NPs (1 mg/mL) were mixed with fixed concentrations of HER2-
AzFP ligand (2.5 20 µM) and LDS-AzFP (30 µM)  in PBS, pH 7.4 at a final volume of 
100 µL. For RGD-N3, 60 µM of the peptide was incubated with ADIBO-SPIO NPs (1 
mg/mL) in a final volume of 100 µL. Reactions were mixed overnight at room 
temperature and then purified on Superdex 200 chromatography columns equilibrated 
with PBS.   
 
Nanoparticle Physicochemical Characterization 
Stock samples of Ln-SPIO nanoparticles were diluted into pH 7.4 phosphate 
buffered saline for determination of the hydrodynamic diameter by dynamic light 
scattering (DLS) both before and after conjugation to active targeting ligands. 
Measurements were acquired with a Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK) using the non-invasive back-scatter (NIBS) mode. For zeta potential 
measurements, stock samples of Ln-SPIO were diluted into phosphate buffered saline at 
pH 7.4 and then mean nanoparticle zeta potential was measured, both before and after 
conjugation to targeting ligands, using a Zetasizer Nano-ZS. For Ln-SPIO nanoparticles, 
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the transverse (r2) and longitudinal (r1) relaxivities were measured using a Bruker mq60 
tabletop MR relaxometer operating at 1.41 T (60 MHz).  
 
Cell Culture 
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided 
by Mark Greene, PhD, FRCP, University of Pennsylvania) and HeLa cells (purchased 
from ATTC) were cultured and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 
at 37°C and 5% CO2.  
 
Western Blots 
T6-17 and HeLa cells were grown to 80% confluence on 10 cm plate. The plate 
was washed twice with PBS and then incubated on ice for five minutes in 1mL RIPA 
Buffer (Sigma-Aldrich) supplemented with 6M urea. Cells were scraped off the plate and 
clarified by centrifugation. 47 mg of solid tumor was solubilized in 3mL Western Lysis 
Buffer (12.5mM Tris, 4% SDS, pH 8) with a mortar and pestle. Lysate was boiled for 
30min and clarified by centrifugation. Total protein concentrations were determined by 
BCA Assay (Pierce). Concentrations of Hsp47, integrin, and ErbB2 were quantified by 
Western blot. Specifically, 12.5 uL of each sample was loaded into an Any kD TGX gel 
(Bio-Rad) along with four 1:3 serial dilutions. These were quantified on the LiCor 
Odyssey and compared against a standard curve ranging from 800 ng to 10 ng of purified 
Hsp47 (AbCam), Integrin αVβ3 (R&D Systems), or ErbB2 (OriGene). 
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Flow Cytometric Analysis 
Cells (T6-17s or HeLas) were dissociated from culture flasks using PBS-based 
enzyme free dissociation buffer and transferred to sterile 96-well plates at a final 
concentration of 50,000 cells per well. Targeted SPIO conjugates were added to the wells 
for 30 minutes at 37°C at a final concentration 75 µg Fe/mL. Cells were transferred to 1.5 
mL centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3 minutes 
and then resuspending in PBS. Cells were resuspended in 250 µL of PBS and transferred 
to a 96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte Plus 
system (Guava Technologies, Hayward, CA). Flow cytometry data were analyzed using 
FlowJo software (TreeStar Inc., San Francisco, CA). 
 
Cell Relaxation Studies 
T6-17 and HeLa cells were dissociated using PBS-based enzyme free dissociation 
buffer and transferred to sterile 48-well plates at a concentration of 3 x 106 cells per well. 
Actively targeted SPIO conjugates and unlabeled SPIO were incubated with these cells in 
the 48-well plate at a final concentration of 75 µg Fe/mL for 1 hour at 37°C (n=3 for each 
targeting agent). Cells were transferred to 1.5 mL centrifuge tubes and washed in 
triplicate by pelleting cells at 1,000 RCF for 3 minutes and then resuspending in PBS. 
Cells were suspended in a final volume of 300 µL PBS and T2 measurements were taken 
using the benchtop relaxometer. The reciprocal of the T2 relaxation time constant, which 
represents the MR signal of the cell pellet, was calculated, and the reciprocal of the T2 
for cells incubated without nanoparticles (background) was subtracted off. Finally, since 
each Ln-SPIO formulation has a different R2 relaxivity value, the MR signal for each cell 
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pellet was normalized by dividing by the R2 value of the particular Ln-SPIO used, 
resulting in a metric that is proportional to nanoparticle cellular association. 
 
In Vitro ICP-MS Multiplex Assessment of Cell Labeling 
 T6-17 and HeLa cells were dissociated and incubated with actively targeted SPIO 
conjugated and unlabeled SPIO in the same manner as in previous the cell relaxation 
studies, with the notable exception that all SPIO formulations were incubated together 
with cells, rather than each SPIO formulation being incubated separately. Following 
washing to remove unbound nanoparticles, the pellet was resuspended in 100 µL of PBS. 
The lanthanide concentration of Ho, Sm, Gd, and Eu was then determined in each pellet 
and compared to the concentration present in the incubating medium. Data are plotted as 
the ratio of [Ln]pellet / [Ln]incubation medium. 
 
In Vivo Studies 
Approximately 6-week old female nu/nu nude mice (Charles River Laboratory, 
Charles River, MS, USA) were maintained in accordance with the Institutional Animal 
Care and Use Committee of the University of Pennsylvania. Mice were anesthetized via 
isoflurane and T6-17 cells were injected subcutaneously into the back right flank (2 x 106 
cells in 0.2 mL PBS). Tumors were grown until the diameter was approximately 8 mm. 
Ln-SPIO (Ho, Gd, Sm, and Eu) were pooled and injected intravenously at a dose of 3.75 
mg Fe / kg body weight. Prior to injection, an aliquot was saved for ICP-MS 
determination of lanthanide concentration in injected material. 24 hours after nanoparticle 
injection, the animals were sacrificed and the tumors were excised. For each nanoparticle 
118 
 
formulation, the tumor delivery was calculated as a percent injected dose per gram of 
tissue as [Ln]tumor / ([Ln]inj*Minj), where [Ln]tumor is the lanthanide concentration in the 
tumor, [Ln]inj is the lanthanide concentration in the injected nanoparticle solution, and 
Minj is the mass of nanoparticle solution injected (0.2 grams). For evaluation of “base” 
nanoparticles prior to ligand conjugation, one way ANOVA analysis was used to assess 
similarity in tumor delivery for the different Ln-SPIO. 
 
4.4 Results and Discussion 
 
Nanoparticle Physicochemical Characterization 
 Because the size of a nanoparticle formulation influences its 
pharmacokinetics and biodistribution, as examined in chapter 2, it was important to 
ensure that the four Ln-SPIO formulations exhibit very similar size profiles prior to 
targeting ligand conjugation. Therefore, the hydrodynamic diameter of each Ln-SPIO 
formulation was determined by DLS prior to conjugation of active targeting ligands. It 
was found that the peak of the distribution lay between 27.00 nm and 29.07 nm for all 
four formulations (Table 4.1). Furthermore, the size distributions have a very high degree 
of overlap (Figure 4.4), suggesting that the “base” nanoparticles to which the active 
targeting ligands were attached are very similar populations. 
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Table 4.1 Physicochemical properties (hydrodynamic diameter and zeta potential) of Ln-
SPIO formulations before and after conjugation to targeting ligands. Relaxivity values 
were measured prior to conjugation and assumed to be unaffected to conjugation. 
Dopant Ligand Pre-Conj. 
Size nm 
Post-Conj. 
Size nm 
Pre Conj. 
Zeta mV 
Post Conj. 
Zeta mV 
R1 R2 
Eu None 27.00 33.54 -5.63 -10.01 6.2 262.9 
Ho HER2-Aff 28.07 33.47 -4.47 -10.53 10.3 135.2 
Sm RGD 27.77 35.57 -6.09 -6.48 9.2 158.5 
Gd LDS 29.07 34.84 -5.77 -8.61 8.1 172.6 
 
 
 
Figure 4.4 Dynamic light scattering profiles of Ho, Gd, Sm, and Eu doped SPIO 
nanoparticles, prior to conjugation with any targeting ligands. 
 The hydrodynamic diameter of each formulation was subsequently rechecked 
after conjugation of active targeting ligands (Figure 4.5). It was found that each 
formulation increased in size by approximately 5 nm, so that the post-conjugation sizes 
ranged from 33.54 to 35.57. It is likely that the increase in size is due to the addition of 
the various functional groups required for conjugation (i.e. ADIBO, linker peptide, and 
targeting ligand itself). Again, as before ligand conjugation, the size profiles showed a 
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very high degree of overlap, indicating the populations are very similar in size. This 
means it is unlikely that any difference in nanoparticle pharmacokinetics or 
biodistribution observed for the actively targeted agents is the result of size alterations 
secondary to conjugation. 
 Next, since it is critical for the ICP-MS multiplex method that the co-injected 
nanoparticles do not associate or aggregate with one another prior to injection (as 
discussed in chapter 3), DLS measurements were used to rule out the possibility of 
nanoparticle aggregation. Specifically, all four Ln-SPIO formulations (post-conjugation) 
were mixed together in equal amounts and allowed to incubate together for one hour. The 
DLS profile of the mixed solution was then acquired (Figure 4.5). Since the peak size for 
the mixed sample was 38.15 nm and the distribution was very similar to that of each 
individual formulation, it was concluded that no significant association or aggregation 
occurs between the actively targeted formulations prior to injection. 
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Figure 4.5 Dynamic light scattering profiles of each nanoparticle formulation after 
conjugation to its respective targeting ligand. The size profile was also examined in a 
sample where all formulations were combined into a single sample (mixed).  
 
 The zeta potential (surface charge) of a nanoparticle formulation also plays a 
significant role in the pharmacokinetics and biodistribution of nanoparticle platforms (see 
chapter 2). Therefore, the zeta potential of each Ln-SPIO was determined both before and 
after conjugation with active targeting ligands. For the “base” nanoparticles, the aminated 
nanoparticles (which would display a positive surface charge) were first carboxylated 
using succinic anhydride in order to generate a negatively charged surface suitable for 
use in the in vivo check on “base” particle similarity (see below). It was found that the 
carboxylated “base” nanoparticles had zeta potentials ranging from -4.47 mV to -6.09 
mV, which were considered to be very close in value. A slightly greater degree of surface 
charge variation was observed in the nanoparticles after conjugation, however (Table 
4.1). This is a reasonable expectation, since a number of factors influence what the final 
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charge will be (e.g. percentage of amino groups that have undergone conjugation, 
percentage of amino groups that have been carboxylated, and the inherent charge of the 
targeting ligands). It is worth noting that the inherent charges of the targeting ligands 
does not, in itself, explain the small variation seen in surface charge, since at physiologic 
pH the charges on the HER2 affibody, RGD, and LDS are expected to be +3, 0, and 0, 
respectively. It is possible that these differences in nanoparticle surface charge may 
influence the formulations’ blood circulation times, and consequently their tumor 
delivery. However, since this small variation in surface charge was introduced through 
the process of conjugation, it falls within the realm of what we desire to test: how does 
the presence of active targeting ligand effect each nanoparticle’s pharmacokinetics and 
biodistribution.  
 The longitudinal and transverse relaxivities of each Ln-SPIO formulation was also 
determined (prior to ligand conjugation) and is reported in Table 4.1. There is significant 
variation in the magnetic properties for the four Ln-SPIO formulations, which is not 
unexpected since the batch-to-batch variation in magnetic properties is significant for 
traditional dextran SPIO without lanthanide dopant. While it is important to know the R2 
value for each Ln-SPIO in order to normalize its MR signal during in vitro cell 
association assays (see below), agreement between R2 values is not necessary, since MR 
imaging is not a primary goal of this investigation. Nevertheless, it is noteworthy that, as 
seen in the SPIO synthesized in chapter 2, each Ln-SPIO formulation has significant 
magnetic activity. This is helpful since it means that once a set of nanoparticles is 
investigated using the ICP-MS multiplex approach, and a particular formulation that 
results in greatest tumor delivery has been identified, that specific formulation can then 
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be directly administered as a single injection and evaluated for its ability to generate MR 
contrast.  
 
In Vivo Equivalence of Nanoparticle Formulations Prior to Conjugation 
 In order to conclude that differences in tumor accumulation are not due to any 
small differences in the physicochemical properties of the SPIO nanoparticles, it is 
important to demonstrate that the “base” nanoparticles, prior to ligand conjugation result 
in identical tumor delivery. Accordingly, each Ln-SPIO formulation was carboxylated to 
confer an equal negative charge to all formulations (see Table 4.1) and the set of 
nanoparticles was administered intravenously as a single multiplex injection to T6-17 
tumor bearing mice (Figure 4.6). 
 
Figure 4.6 In vivo multiplex ICP-MS analysis of nanoparticle accumulation in T6-17 
tumors (expressed as percent injected dose / gram of tumor tissue) for carboxylated Ln-
SPIO before conjugation to active targeting ligands. ANOVA analysis yielded an F ratio 
of 0.594, corresponding to a P value of 0.636 
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 It was found that the tumor delivery for the four Ln-SPIO formulations ranged 
from 0.99 to 1.22 percent injected dose / gram of tumor tissue. One way analysis of 
variance (ANOVA) statistical testing demonstrated a P value of 0.594, indicating that 
there is no evidence of any meaningful difference in tumor delivery for any formulation 
within the set. Since ANOVA testing does not utilize the pairing information contained in 
multiplex data, a simple t-test (with pairing) was also conducted between the nanoparticle 
with lowest accumulation (Eu) and the one with highest accumulation (Ho). This yielded 
a P value of 0.16; again suggesting that even with the improved statistical power of 
paired analysis, there is no significant difference between the nanoparticle formulations at 
“baseline”.  
 
Assessment of Biomarker Expression by Western Blot 
 In order to assess the level of receptor expression for the three biomarkers 
investigated in this study, Western blots were conducted on T6-17 cells, HeLa cells, and 
excised T6-17 tumors. The blot images are provided in Figure 4.7. 
 
Figure 4.7 Western Blots of T6-17 cells, HeLa cells, and excised T6-17 tumor tissue, 
probing for HER2, αVβ3 integrin, and Hsp47.  
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 First, it was found that the level of HER2 (ErbB2) expression on T6-17 cells was 
very high and significantly greater than the level of expression on HeLa cells. Given that 
T6-17 cells are NIH-3T3 murine fibroblasts engineered to constitutively overexpress 
HER2, this result is expected. The relative abundance of HER2 protein in the excised T6-
17 tumor appears lower than T6-17 cells in vitro. It is possible that this is due to an 
alteration of HER2 expression of the T6-17 cells once organized into a tumor, but it is 
more likely that the relative abundance of HER2 is lower as a result of the large amount 
of non-T6-17 cell derived protein in the tumor (e.g. stromal cells and extracellular matrix 
proteins). Nevertheless, HER2 expression was still clearly evident in the excised T6-17 
tumor lysate. 
 Next, the level of αVβ3 integrin was examined. It was found that the level of 
expression of this biomarker was again higher in T6-17 cells compared to HeLa cells, 
although the degree of difference was much less than with the HER2 receptor. Studies 
have shown integrin αVβ3 expression in NIH/3T3 cells and this expression appears to be 
conserved in T6-17 cells.38, 39 Interestingly, unlike the HER2 receptor relative abundance, 
which drops once the entire tumor is examined, the αVβ3 integrin levels are higher in the 
excised T6-17 tumor compared to the individual cells. This is likely because αVβ3 
integrin is highly overexpressed on activated endothelial cells associated with the 
neovascularization of tumors.40-42 In fact, previous reports have shown that in tumor 
xenograft models αVβ3 integrin can be overexpressed both on the malignant cells, 
themselves, and on host-derived proliferating endothelial cells.43 This makes αVβ3 
integrin a particularly interesting biomarker to compare with HER2. Specifically, even 
though HER2 is more abundant on tumor cells than αVβ3 integrin, targeting αVβ3 integrin 
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might result in increased tumor delivery, since it is expressed elsewhere in the tumor 
tissue. Importantly, this is a comparison that can only be adequately made in vivo, 
demonstrating the utility of being able to use ICP-MS for multiplex analysis in vivo. 
 Finally, levels of Hsp47 were examined. In this case, the expression of this 
biomarker was below the level of detection for both T6-17 and HeLa cells. Although 
there is little literature regarding the expression of Hsp47 on these two cells lines, it is not 
surprising to observe very low levels of expression since Hsp47 is most commonly 
associated with head and neck or gastrointestinal malignancies.27, 29, 44, 45 Interestingly, 
however, Hsp47 expression was clearly detectable in the excised T6-17 tumor. There are 
two potential possibilities to account for this observation. First, it is known that Hsp47 
expression is upregulated during a cellular stress response to noxious stimuli including 
high temperature, heavy metal exposure, and oxidative stress.46 Since the establishment 
of a rapidly growing xenograft tumor is likely to be associated with a hostile local 
environment, it is possible that the T6-17 cells themselves are upregulating their 
expression of Hsp47. Alternatively, cell populations within the tumor other than the T6-
17 cells themselves may be displaying the biomarker. In either case, this again illustrates 
the idea that evaluating active targeting of Hsp47 directed nanoparticles is best done fully 
at the in vivo stage, since expression profiles of the tumor are not the same as those in 
vitro. 
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Flow Cytometric Analysis of Targeted Ln-SPIO 
 
The functionality of HER2-SPIO, LDS-SPIO and RGD-SPIO was subsequently 
assessed by conducting cell-binding assays with the broadly “receptor high” T6-17 cells 
and broadly “receptor low” HeLa cells. Flow cytometric analysis revealed that each 
targeted SPIO formulation successfully labeled T6-17 cells to varying extents, with the 
HER2-SPIO showing the highest degree of cell labeling and the LDS-SPIO showing the 
lowest (Figure 4.8 A). This is generally consistent with the results of the Western blots in 
that strong labeling was observed for the highly expressed HER2 receptor, and a lower 
level of labeling was observed for the less highly expressed αVβ3 integrin. Although 
Hsp47 expression was not detectable on Western blots of T6-17 cells, flow analysis is 
likely to be more sensitive given that each nanoparticle carries multiple fluorophores, 
thereby amplifying the signal. Eu-SPIO nanoparticles that have been reacted with 
ADIBO and carboxylated with succinic anhydride, but have no targeting ligand 
conjugated to them, showed no cell binding when incubated with T6-17 cells (Figure 4.8 
B).  
Based on the relative level of receptor expression between T6-17 and HeLa cells, 
a lower level of cell binding for each ligand is expected on HeLa cells, compared to T6-
17 cells. The flow cytometric data bear this out in the most general sense, with 
undetectable cell binding of each targeted SPIO formulation to the broadly “receptor 
low” control HeLa cells (Figure 4.8 C). However, since flow cytometric measurements 
should have high sensitivity, we would expect that at least a low level of cell binding 
should be observed. Additionally, as expected, no cell binding was detected when 
unlabeled SPIO nanoparticles were incubated with HeLa cells (Figure 4.8 D).  
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Figure 4.8 Flow cytometric analysis of “receptor positive” (T6-17) and “receptor high” 
(HeLa) cells incubated with SPIO nanoparticles. T6-17 cells were incubated with HER2-
SPIO (light solid line), RGD-SPIO (dashed line), and LDS-SPIO (dotted line), with 
varying degrees of cell labeling observed for each ligand (A). No cell labeling is evident 
for the “receptor low” HeLa cells for any of the ligands (C). Additionally, flow 
cytometric analysis was performed for both cell lines incubated with non-targeted SPIO 
and no cell labeling was detected (B and D). 
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MR Comparison of Cell Binding 
In vitro cell binding assays were also carried out by incubating targeted SPIO 
conjugates with T6-17 or HeLa cells for 1 hour at a final concentration of 75 µg/mL Fe 
and examining the T2 relaxivity of cell pellets. This assay provided a more reliable 
measurement for the comparison of cell binding between ligands than flow cytometry 
does, since the fluorescence signal per nanoparticle is not expected to be the same for 
each formulation. For the MR assay, comparison of the level of cell labeling was made 
by using the reciprocal of the T2 relaxation time of the cell pellet as a measure of MR 
signal. The signal was adjusted by the R2 of the particular Ln-SPIO formulation used 
(e.g. Ho-SPIO for the affibody) to yield a normalized MR signal.  
These data follow the same general trend as observed with the flow cytometric 
analysis. HER2 affibody conjugated SPIO exhibit an extremely high level of cell labeling 
on T6-17 cells and much lower labeling on HeLa cells (Figure 4.9). Again, it was not 
surprising that the HER2-SPIO displayed the highest degree of cell binding, since T6-17 
cells have been transfected to overexpress the HER2/neu receptor.47 RGD-SPIO exhibit 
approximately half the level of cell labeling (compared to HER2-SPIO) on T6-17 cells, 
but the level of labeling is clearly well above baseline nonspecific interactions observed 
with blank-SPIO. This level of labeling is also statistically greater than the very low level 
of labeling observed for RGD-SPIO of HeLa cells. Finally, while both cell lines exhibited 
a very low level labeling with LDS-SPIO, although even this low level of cell binding 
can be distinguished from the nonspecific binding of blank-SPIO. 
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Figure 4.9 Labeling of T6-17 and HeLa cells with Ho-HER2-SPIO, Sm-RGD-SPIO, Gd-
LDS-SPIO and Eu-blank-SPIO, as assessed by MR relaxometry. Since each Ln-SPIO has 
different magnetic relaxivity, the T2 relaxation signal obtained for each cell pellet was 
normalized by the R2 value of the SPIO formulation and reported as a relative value to 
the signal of the blank formulation. 
 
ICP-MS Comparison of Cell Binding 
 Finally, an ICP-MS in vitro cell binding assay was conducted by simultaneously 
incubating all targeted SPIO conjugates with T6-17 or HeLa cells for 1 hour at a final 
concentration of 75 µg/mL Fe and analyzing the lanthanide concentration of the washed 
cell pellets versus the lanthanide concentration in the incubating medium (Figure 4.10). 
This assay is expected to provide the most reliable data for making comparisons, both 
between ligands and between cell lines, for three reasons. First, each nanoparticle 
formulation’s binding can be quantitatively normalized to the amount of material applied 
to the cells in the assay. Secondly, unlike the MR based assay, the “signal” detected by 
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ICP-MS is linear over a very large dynamic range of nanoparticle concentrations. This is 
especially important at low levels of nanoparticle binding, when ICP-MS can detect 
differences in binding that would not translate into a difference in MR signal. Thirdly, 
since this assay multiplexes the measurement of cell binding, many sample-to-sample 
variations (such as non-specific uptake by dead cells) are eliminated.  
 
Figure 4.10 Labeling of T6-17 and HeLa cells with Ho-HER2-SPIO, Sm-RGD-SPIO, 
Gd-LDS-SPIO and Eu-blank-SPIO, as assessed by ICP-MS multiplex analysis. All 
targeted nanoparticle formulations were pooled together and incubated with either T6-17 
or HeLa cells in the presence of serum supplemented culture medium. 
 
 The ICP-MS multiplex data again bear out the same general conclusions as the 
flow cytometric and MR-based assays. First, for each ligand, the level of binding to the 
“receptor high” T6-17 cells is greater than the level of binding to the “receptor low” 
HeLa cells. Secondly, with respect to T6-17 cell binding, HER2-SPIO demonstrate the 
greatest level of cell labeling, followed by RGD-SPIO, and LDS-SPIO, all of which are 
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distinguishable from the non-specific of blank-SPIO. The major difference that the ICP-
MS cell labeling data suggest is with regard to the absolute level of nanoparticle binding 
to HeLa cells. In the flow cytometric and MR analysis, there was very little cell binding 
observed for any of the ligands to HeLa cells. However, based on the Western blots, it 
can be concluded that while the HeLa cells are “receptor low” compared to T6-17 cells, 
they do not appear to be “receptor negative”. This discrepancy may be partly accounted 
for by the differences in sensitivity and signal linearity between the different modalities. 
Nevertheless, it appears that the flow cytometric results, which should provide a high 
level of sensitivity, will require further investigation in order to ensure the four sets of in 
vitro measurements are all properly reconciled.  
4.5 Conclusion 
 It is possible to synthesize SPIO nanoparticles, doped with a variety of lanthanide 
tracer metals, each with an overlapping size distribution, so that they exhibit equal levels 
of passive tumor accumulation. These Ln-SPIO formulations can then be subsequently 
functionalized with active targeting ligands, such that each targeting ligand is associated 
with a specific lanthanide tracer. ICP-MS analysis can quantify the concentration of each 
lanthanide metal independently and with very high sensitivity, in a single fluid or tissue 
sample. Therefore, it becomes feasible to collect nanoparticle blood residence time, 
tumor delivery, and biodistribution for many actively targeted and negative control 
formulations in a single animal. This represents a powerful tool for nanotechnology 
investigators to more thoroughly evaluate a greater number of nanoparticle formulations 
in vivo, while reducing experiment time, cost, and number of animals. 
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Chapter 5: pH Titratable Superparamagnetic Iron Oxide for 
Improved Nanoparticle Accumulation in Acidic Tumor 
Microenvironments 
 
5.1 Abstract 
A wide variety of nanoparticle platforms are being developed for both the diagnosis 
and treatment of malignancy. While many of these are either passively targeted or rely on 
specific receptor-ligand interactions, metabolically directed nanoparticles can provide a 
complementary approach. It is known that both primary and secondary events in 
tumorigensis alter the metabolic profile of developing and metastatic cancers. One highly 
conserved metabolic phenotype is a state of up-regulated glycolysis and reduced use of 
oxidative phosphorylation, even when oxygen tension is not limiting. This metabolic 
shift, termed the Warburg effect, creates a “hostile” tumor microenvironment with 
increased levels of lactic acid and low extracellular pH. In order to exploit this 
phenomenon to improve the delivery of nanoparticle platforms to a wide variety of 
tumors, a pH-responsive iron oxide nanoparticle was designed. Specifically, glycol 
chitosan (GC), a water-soluble polymer with pH titratable charge, was conjugated to the 
surface of superparamagnetic iron oxide nanoparticles (SPIO) to generate a T2* weighted 
MR contrast agent that responds to alterations in its surrounding pH. When compared to 
control nanoparticles that lack sensitivity to pH, these GC-SPIO nanoparticles 
demonstrated potent pH-dependent cellular association and MR contrast in vitro. In 
murine tumor models GC-SPIO also generated robust T2* weighted tumor contrast, 
which correlated with increased delivery of the agent to the tumor site, as measured 
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quantitatively by inductively coupled plasma mass spectrometry. Importantly, the 
increased delivery of GC-SPIO nanoparticles cannot be attributed to the commonly 
observed enhanced permeability and retention effect alone, since these nanoparticles have 
similar physical properties and blood circulation times as control agents.  
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5.2 Introduction 
Tumor targeting mechanisms that exploit the altered metabolic profile of malignancy 
have been the subject of intense investigation1 since the development of the metabolite 
analogue 2-fluorodeoxy-D-glucose (2FDG) and its use in positron emission tomography 
(PET) imaging over three decades ago.2 One of the attractions of metabolic imaging is 
the ability to detect and target a wide variety of cancers, since many human solid tumors, 
and especially rapidly growing aggressive malignancies, have a unique metabolic profile 
that distinguishes them from normal tissue.3 This altered metabolic state, consistent with 
the Warburg effect, is characterized by increased glucose uptake, up-regulated glycolytic 
metabolism, increased production of lactic acid, and subsequent derangements in cellular 
pH.4, 5 More specifically, the extracellular pH of normal tissue is approximately 7.4, but 
human and animal tumors can often exhibit an extracellular pH lower than 7.0, even 
reaching as low as 6.3.6, 7 
In recent years, numerous methods have been developed that allow for the non-
invasive assessment of tissue pH, most of which are based on magnetic resonance.6 For 
example, magnetic resonance spectroscopy (MRS) using endogenous inorganic 
phosphate (Pi) and exogenously administered 3-aminopropylphosphate (3-APP) can be 
used to simultaneously measure intra- and extracellular pH, respectively.8, 9 Major 
drawbacks of this method are the reliance on the relatively less abundant 31P nucleus and 
the inability to simultaneously acquire the high resolution anatomical information that is 
the hallmark of magnetic resonance (MR) imaging. More recently, exogenous agents 
with pH-dependent proton resonances have been developed.10 While this eliminates the 
need for specialized 31P hardware, the pH sensitive resonance can be difficult to fully 
distinguish from other endogenous signals. Even more recently, pH-sensitive lanthanide 
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chelates have allowed for measurement of pH with a proton resonance completely 
distinct from endogenous signals.11, 12 Even these agents, however, have limited 
sensitivity since the exogenous agent contains the resonance being detected. Greater 
sensitivity could be obtained using a contrast agent that generates signal by interacting 
with many bulk water molecules. Superparamagnetic iron oxide (SPIO) nanoparticles 
have emerged as an attractive class of MR contrast agent that provides T2*-weighted 
contrast enhancement in both active and passive MR imaging applications by 
accelerating the de-phasing of nearby bulk water.13 SPIO nanoparticles could, therefore, 
serve as a strong signal-generating foundation to which pH sensitivity could be imparted. 
Such pH-responsive SPIO nanoparticles would constitute an 1H MR contrast agent that 
exhibits differential localization based on local pH and could facilitate the detection of 
acidic pathologies, including but not limited to malignancy, on conventional high 
resolution anatomic MR images, without the need for specialized hardware. Such regions 
of suspected acidity, detected with pH-responsive SPIO on large field-of-view anatomic 
images, could then be probed by MRS or chemical exchange saturation transfer (CEST) 
methods to generate an absolute pH map. 
pH-responsive polymers, including chitosan,14 poly-amino ester,15 poly-
caprolactone,16 and poly-histidine,17 have been successfully used to generate pH-
mediated drug release in a variety of nanoparticle carriers. Furthermore, SPIO 
nanoclusters coated with a pH-responsive hydrogel have recently yielded nanoparticles 
with pH-dependent relaxivity.18 Therefore, pH-titratable polymers are attractive 
candidates for imparting such functionality to nanoparticles. Accordingly, in this 
investigation, the pH-responsive polymer glycol chitosan (GC, Figure 5.1 A), a polymer 
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of glucosamine with increased water solubility and amino groups with a pKa ≈ 6.5,19 was 
covalently grafted to the surface of dextran stabilized SPIO nanoparticles, to generate 
native GC-SPIO. Sized matched pH-unresponsive SPIO nanoparticles were prepared as 
control agents to distinguish pH-mediated nanoparticle delivery from the enhanced 
permeability and retention (EPR) effect that is commonly observed for nanoparticle 
agents.20-23 Specifically, GC-coated SPIO nanoparticles were chemically modified with 
glycidol (Figure 5.1 B) to block the pH-responsive amino groups, and inherently pH-
unresponsive dextran SPIO nanoparticles (Figure 5.1 C) were also used.  
 
 
Figure 5.1 Molecular structures of nanoparticle polymeric surface coatings. (A) Native GC is a 
linear polymer of D-glucosamine with β-1-4 linkages. The repeated amino groups have aggregate pKa ≈ 
6.5. (B) Glycidol blocked GC is formed by reaction of native GC with glycidol. Alkylation of the amino 
groups renders them no longer titratable near physiologic pH. (C) Dextran is a branched polymer of glucose 
with both α-1-3 and α-1-3 linkages. It does not possess any functional groups that are titratable near 
physiologic pH. 
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All nanoparticle formulations included a lanthanide metal tracer that allowed the 
distribution of the nanoparticles to be tracked quantitatively in vivo. Specifically, during 
the synthesis of the SPIO nanoparticles, a trace amount of lanthanide was doped into the 
iron oxide cores (Gd for the two GC-containing SPIO formulations and Sm for the 
dextran-only SPIO). Energy-dispersive X-ray spectroscopy (EDS) has previously been 
used to confirm the presence and stability of the lanthanide dopant within the iron oxide 
cores of SPIO synthesized in this manner.24 Here, inductively coupled plasma mass 
spectrometry (ICP-MS) was used to assess the biodistribution of the lanthanide tracer 
(and the corresponding SPIO nanoparticle) in a mouse tumor model.  
Numerous studies have shown that nanoparticles (including SPIO) complexed with 
cationic agents such as polylysine, protamine, or cell penetrating peptides (CPPs) are 
rapidly and efficiently internalized by a wide range of cell types.25-28 However, positively 
charged nanoparticles are rapidly cleared from circulation,29 resulting in poor tumor 
delivery. Therefore, positive charge could be used to improve retention in a desired 
microenvironment, provided that the positive charge is not displayed until that 
microenvironment is reached. Accordingly, both the native GC-SPIO and control agents 
exhibit a neutral or negative surface charge at physiologic pH, affording them a lower 
level of cellular interaction and improving blood residence time.30, 31 (Figure 5.2 A). 
Upon exposure to an acidic mircroenvironment, the pH-responsive polymer surface of the 
native GC-SPIO becomes protonated and the surface charge becomes increasingly 
positive. Therefore, it was hypothesized that native GC-SPIO nanoparticles would be 
preferentially retained in acidic microenvrionments compared with analogous pH-
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unresponsive agents, as a result of electrostatic interactions with surrounding tissue 
(Figure 5.2 B).  
 
 
Figure 5.2 Mechanism of enhanced nanoparticle retention in acidic microenvironments. (A) Both native 
GC-SPIO and control nanoparticles exhibit neutral to negative surface charge at physiologic pH due to 
abundant surface hydroxyl groups. For clarity, the hydroxyl groups are not depicted on the native GC-SPIO 
particle. Presence of neutral or negative surface charge diminishes nanoparticle association with blood 
components and normal tissue. (B) Upon exposure to acidic microenvironments, the amino groups of 
native GC-SPIO titrate to yield a positive charge. The newly cationic nanoparticles exhibit electrostatic 
interactions with negatively charged cell membranes and extracellular matrix components in the acidic 
microenvironment, leading to enhanced retention in these areas. 
5.3 Materials and Methods 
 
Materials 
 
The two SPIO coating polymers dextran T10 and glycol chitosan were purchased 
from Pharmacosmos A/S (Holbaek, Denmark) and Wako Chemicals (Richmond, VA, 
USA), respectively. T6-17 murine fibroblasts (a derivative of the NIH/3T3 line) were 
kindly provided by Mark Greene, PhD, FRCP, at the University of Pennsylvania.  The 35 
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mm volume coil used for radiofrequency transmission and reception was purchased from 
Insight Neuroimaging Systems, LLC (Worcester, MA). All other reagents were 
purchased from Sigma Aldrich USA unless otherwise noted. 
 
Synthesis of Dextran Stabilized Lanthanide Doped SPIO 
 
Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the 
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran.24, 28 
Briefly, 50 g of dextran T-10, was dissolved in 100 mL dH2O and heated to 80°C for 1 
hour. The solution was then allowed to cool to room temperature and continued to mix 
overnight. Subsequently, a solution of 3.70 g FeCl3, 1.46 g FeCl2, and 0.25 g 
GdCl3•6H2O or SmCl3•6H2O in 50 mL dH2O was prepared and decanted into the dextran 
solution. The combined solution was cooled on ice and degassed with N2 for 90 min. 
While keeping the solution stirring on ice and under N2, an automated syringe pump was 
then used to introduce 15 mL of concentrated NH4OH to the solution over 5 hours. The 
resulting black viscous solution was removed from the N2 atmosphere, heated to 90°C for 
1 hour, cooled overnight, and centrifuged at 20,000 RCF for 30 minutes to remove large 
aggregates. Free iron, lanthanide, and dextran were removed by diafilitration across a 100 
kDa membrane and the dextran SPIO were brought to a final volume of 40 mL. 
Surface Conjugation of Glycol Chitosan 
 
High molecular weight glycol chitosan was degraded and prepared for grafting to 
dextran SPIO as follows: 10 g of ≈600 kDa GC was dissolved in 200 mL 6M HCl and 
heated to 80°C for 20 minutes. Following incubation, the material was cooled on ice and 
immediately neutralized with the addition of solid sodium carbonate to terminate 
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degradation. Excess solid sodium carbonate was removed by centrifugation and 
diafiltration membranes were used to de-salt the material and discard any GC polymer 
greater than 100 kDa or less than 3 kDa. 
Native glycol chitosan (GC)-SPIO was then prepared as follows: 40 mL of dextran 
SPIO at an iron concentration of 10 mg/mL was combined with an equal volume of 10 M 
NaOH and mixed for 10 minutes. 80 mL of epichlorohydrin was then added and the 
solution was vigorously stirred at room temperature overnight. Epichlorohydrin 
crosslinks dextran chains within a SPIO particle and chemically activates the dextran 
surface for grafting of glycol chitosan. The solution was then briefly centrifuged to allow 
phase-separation into an aqueous black SPIO layer and a clear layer of unreacted 
epichlorohydrin, which was removed. The SPIO layer was quickly purified via extraction 
in isopropanol. Specifically, the SPIO material was combined with 5 volumes of 
isopropanol and the mixture was vigorously shaken. Brief centrifugation of the mixture 
resulted in a layer of precipitated salt, a SPIO layer, and an isopropanol layer (containing 
any remaining epichlorohydrin). The SPIO layer was then isolated and combined with an 
equal volume of 150 mg/mL GC (3 – 100 kDa) in PBS, and gently stirred for 72 hours at 
room temperature. After the reaction, free GC was removed by diafiltration across a 100 
kDa membrane and the final native GC-SPIO was 0.2 µm filtered to remove any 
oversized material. Finally, to ensure complete purification of the GC-SPIO from excess 
GC and to enhance the material’s magnetic properties, the nanoparticles were 
magnetically purified on MACS LS columns using the MidiMACS magnet (Miltenyi 
Biotec, Auburn, CA, USA). 
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Generation of Control SPIO Nanoparticles 
Glycidol GC-SPIO control nanoparticles were produced by direct chemical 
modification of the native GC-SPIO nanoparticle surface. Briefly, native GC-SPIO at 5 
mg Fe/mL in 10 mM pH 5.0 HEPES buffer was combined with an equal volume of 
glycidol and stirred at room temperature overnight. GC-SPIO was then precipitated from 
the solution by the addition of 4 volumes of isopropanol. Since the blocking was 
incomplete after only one round of reaction with glycidol, the addition at 0.2 volumes of 
7.5% sodium bicarbonate was sometimes required to neutralize remaining positive charge 
on the nanoparticle surface and induce precipitation. The solution was centrifuged, the 
supernatant discarded, and the GC-SPIO pellet was resuspended with sonication in the 
original volume of HEPES buffer. Reaction with glycidol was repeated as above 2 more 
times to exhaustively block pH responsive amino groups (subsequent reactions do not 
require bicarbonate to induce precipitation in isopropanol). Finally, sized matched 
dextran SPIO were used as a second pH-unresponsive control nanoparticle formulation. 
In order to best match the size of the dextran SPIO control nanoparticles to the GC 
grafted nanoparticles, the dextran SPIO nanoparticles used as a control were not from the 
same synthesis as the dextran SPIO upon which the GC grafted nanoparticles were 
constructed. Specifically, the rate of NH4OH addition was increased in order to produce 
somewhat larger size dextran SPIO. 
Native GC-SPIO and Control Nanoparticle Physicochemical Characterization 
Each nanoparticle formulation was diluted to a final concentration of 100 µg 
Fe/mL in pH 7.4 phosphate buffered saline for determination of the hydrodynamic 
diameter by dynamic light scattering (DLS). Measurements were acquired with a 
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Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the non-invasive 
back-scatter (NIBS) mode. Samples were further diluted in water and deposited on 200-
mesh carbon coated copper grids (Polysciences, Warrington, PA, USA) for TEM imaging 
with a JEOL 1010 transmission electron microscope operating at 80 kV. Mean iron core 
size was determined by measuring 100 individual nanoparticles. The transverse (R2) and 
longitudinal (R1) relaxivities of the nanoparticle formulations were calculated by plotting 
the reciprocal of the relaxation time (measured using a Bruker mq60 tabletop MR 
relaxometer operating at 1.41 T) versus the iron concentration. For elemental analysis, 
nanoparticles were precipitated with isopropanol, dried under vacuum, and submitted to 
Intertek Analytical Laboratories (Whitehouse, NJ, USA). Since glycol chitosan is the 
only nitrogen containing component of the nanoparticles, the %N of the sample can be 
scaled to %GC, using the empirical formula of glycol chitosan, C8H15O5N. Similarly, 
since dextran is the only carbon containing component (after the carbon content of GC is 
accounted for), the %dextran can be calculated using its empirical formula, C6H10O5. For 
zeta potential pH titrations, 10 mM HEPES buffered water was prepared with pH values 
ranging from 5.90 to 7.65 in 0.25 unit increments. Each nanoparticle formulation was 
diluted to a final concentration of 100 µg Fe/mL in the buffer at each pH and mean 
nanoparticle zeta potential was measured using a Zetasizer Nano-ZS. Stocks of native 
GC-SPIO, glycidol GC-SPIO, and dextran SPIO were synthesized several times 
throughout the course of the study, each time yielding similar physicochemical 
properties.  
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Cell Culture 
T6-17 murine fibroblasts were cultured and maintained in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin at 37°C and 5% CO2. 
 
In Vitro Cellular Association Studies 
For in vitro pH studies, cell culture medium was supplemented with 25 mM 
HEPES buffer and prepared with pH values ranging from 5.90 to 7.65 in 0.25 unit 
increments. Each nanoparticle formulation was incubated in suspension at a 
concentration of 25 µg Fe/mL with 4 x 106 of freshly trypsinized T6-17 cells for 1 hour at 
37°C in a total volume of 0.5 mL buffered medium. Following incubation, unassociated 
nanoparticles were removed by triplicate low-speed centrifugal washes with nanoparticle 
free medium of matching pH. The cell samples were then resuspended in 0.3 mL of PBS 
at pH 7.4 and the T2 relaxation time of the suspensions were measured on the tabletop 
relaxometer.  
 
Cell Pellet MR Imaging 
Following relaxation measurements, the triplicate samples at each pH were 
combined to form a single cell pellet for each pH and nanoparticle formulation. The 
samples were transferred to a 384-well plate and the cells were pelleted to the bottom of 
each well with brief, low-speed centrifugation. The plate was then imaged on a 9.4-T 
magnet interfaced to a Varian INOVA console using a 70 mm inner diameter volume coil 
for radiofrequency transmission and reception. T2*-weighted gradient echo (GEMS) MR 
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images were collected using parameters as follows: repetition time (TR) = 200 ms, echo 
time (TE) = 5 ms, flip angle = 20°, slice thickness = 0.5 mm, field of view (FOV) = 4 cm 
x 4 cm, number of acquisitions = 8, resolution = 256 x 256. 
Contrast Enhanced In Vivo MR Imaging  
Approximately 6-week old female nu/nu nude mice (Charles River Laboratory, 
Charles River, MS, USA) were maintained in accordance with the Institutional Animal 
Care and Use Committee of the University of Pennsylvania. Mice were anesthetized via 
isoflurane and T6-17 cells were injected subcutaneously into the back right flank (2 x 106 
cells in 0.2 mL PBS). Tumors were grown until the diameter was approximately 8 mm 
and pre-contrast tumor images were acquired using a 9.4-T magnet interfaced to a Varian 
INOVA console. T2*-weighted GEMS images were collected using the same parameters 
as for plate images, except slice thickness = 1 mm. Immediately following the pre-
contrast image acquisition, native GC-SPIO or control nanoparticles were administered 
by retro-orbital injection (10 mg/kg Fe in 0.2 mL; Native GC-SPIO n=4, glycidol GC-
SPIO n=4, dextran SPIO n=3). Post-contrast images were collected 24 hours post-
injection under the same imaging parameters used for pre-contrast images. 
MR Image Analysis 
For each animal’s pre- and post-contrast image, three corresponding axial slices 
were selected for analysis. To account for signal variations between images due to mouse 
or RF coil positioning, the relative signal intensity (RSI) of the tumor in each slice was 
calculated by dividing the MR signal of the operator defined tumor region of interest 
(ROI) by that of the adjacent paraspinal muscle. Nanoparticle induced tumor contrast was 
then determined as the RSI ratio for each animal, calculated as the quotient of the post-
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contrast tumor RSI to the pre-contrast tumor RSI. Following statistically significant 
ANOVA analysis for the three nanoparticles’ contrast, individual t-tests were performed.  
Quantitation of Tumor Delivery and Blood Concentration by ICP-MS 
Prior to nanoparticle injection, an aliquot of nanoparticles from each group of 
mice was saved for inductively coupled plasma mass spectrometry (ICP-MS) 
determination of lanthanide concentration (Gd for native and glycidol GC-SPIO and Sm 
for dextran SPIO). Following nanoparticle injection, 10 µL blood samples were collected 
from each animal, using the tail-nick method, at times of 1, 2, 4, 7, and 24 hours post-
injection. Following post-contrast MR imaging, the animals were sacrificed and the 
tumors, livers, and kidneys excised. 
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain, 
NY, USA) and trace metal grade nitric acid was purchased from Fisher Scientific 
(Pittsburg, PA, USA). All dilutions were done using in-house deionized water (≥18 MΩ-
cm) obtained from a Millipore water purification system. 
The pre-injection solutions, blood, and tumor samples were analyzed for 158Gd 
(gadolinium), or 147Sm (samarium) using an Elan 6100 ICP-MS (Perkin Elmer, Shelton, 
CT, USA)  at the New Bolton Center Toxicology Laboratory, University of 
Pennsylvania, School of Veterinary Medicine, Kennett Square, PA, USA. The samples 
were weighed into Teflon PFA vials (Savillex, Minnetonka, MN, USA) and digested 
overnight with 70% nitric acid at 700 C.  0.1 mL of 2 ppm 159 Tb (terbium) was added to 
each of the digested samples and the mixtures were diluted with deionized water to a 
final volume of 10 mL. The lanthanide concentration of each sample was measured using 
a calibration curve of aqueous standards at 0.01, 0.1, 1.0, and 10 ppb for each lanthanide.  
154 
 
The performance of the instrument and accuracy of the results were monitored by 
analyzing a reagent blank and bovine serum control serum prior to analysis of the 
samples. Also, standard reference material (Peach Leaves 1547) obtained from National 
Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with known 
values of iron and rare earth elements was analyzed with each batch of samples. 
The percent injected dose per gram of tissue, was calculated as [Ln]sample / 
([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration in the sample (blood or 
tumor tissue), [Ln]inj is the lanthanide concentration in the injected nanoparticle solution, 
and Minj is the mass of nanoparticle solution injected (0.2 grams). For tumor, kidney, and 
liver accumulation, ANOVA analysis was performed for the three nanoparticle 
formulations. Where differences were detected (tumor and kidney), individual t-tests 
were performed.  
5.4 Results and Discussion 
 
Characterization of Native GC-SPIO and Control Nanoparticles 
 
Since previous studies have identified that the blood circulation times20-23 and, 
consequently, tumor delivery is highly dependent on the size of SPIO nanoparticles, the 
hydrodynamic diameter of the native GC-SPIO and control nanoparticles (i.e. glycidol 
GC-SPIO, and dextran SPIO) was characterized by dynamic light scattering (DLS). Also, 
because of the need to distinguish pH-mediated delivery from a background level of EPR 
delivery, it was necessary to ensure that the native GC-SPIO and control nanoparticles 
had very similar size profiles. The peak sizes of the native GC-SPIO, glycidol GC-SPIO, 
and dextran SPIO were found to be 33.6 nm, 36.1 nm, and 29.8 nm, respectively. Since 
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the glycidol GC-SPIO particles were synthesized by direct chemical blockade of the pH 
sensitive amino groups of the native GC-SPIO, the glycidol GC-SPIO are necessarily 
slightly larger (2.5 nm). Although the size of dextran SPIO can be marginally tuned with 
varied synthetic conditions, these particles are necessarily slightly smaller (3.8 nm) than 
the native GC-SPIO, owing to the latter’s additional GC coating. Given the close 
agreement in peak sizes and DLS size distributions (Figure 5.3) for the three nanoparticle 
formulations, it is assumed that differences in tumor delivery can be attributed to 
differences in the chemistry of their surface coat, as opposed to their hydrodynamic 
diameter.  
 
Figure 5.3 Dynamic light scattering profiles of native GC-SPIO, glycidol GC-SPIO, and dextran 
SPIO nanoparticles in phosphate buffered saline, pH 7.4. 
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In order to examine the morphology of the iron cores of the nanoparticle 
formulations, and ensure their similarity, transmission electron micrographs (TEM) were 
obtained (Figure 2B). The average core sizes of the GC-based SPIO and dextran SPIO 
were found to be 19.8 ± 3.6 nm, and 19.4 ± 3.9 nm, respectively. Since only the surface 
coating was modified between the native GC-SPIO and glycidol GC-SPIO, these two 
formulations have matching core size characteristics. The morphology of iron cores 
appears similar for all three nanoparticle formulations and similar to previously published 
dextran SPIO images.28  
 
Figure 5.4 Transmission electron microscopy (TEM) images of GC-SPIO and dextran SPIO 
demonstrating iron core size and morphology.  
 
The metal and polymer composition of the native GC-SPIO nanoparticles was further 
examined by elemental analysis. Dried nanoparticles were 37.05% C, 2.87% N, 6.09% 
Fe, and 0.17% Gd by weight. Since only GC contains nitrogen, these data and the known 
molecular structure of dextran and GC allow for calculation of nanoparticle composition. 
The native GC-SPIO nanoparticles are, therefore, 6.09% iron, 0.17% gadolinium, 39.08% 
dextran, and 42.02% glycol chitosan. The remainder of the nanoparticles (12.67%) is a 
combination of oxygen in the nanoparticle core and any electrostatically associated salts.  
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 Although comparison of tumor delivery via ICP-MS measurements is not 
influenced by the nanoparticles’ magnetic properties, the comparison of in vivo MR 
tumor contrast certainly is. Therefore, it was important to ensure all three nanoparticle 
formulations had similar values for their relaxivities, especially the R2 relaxivity, which is 
responsible for contrast enhancement on T2* weighted MR images. R2 values (pH 7.4, 
PBS) for the native GC-SPIO, glycidol GC-SPIO and dextran SPIO were measured as 
146.5, 152.3, and 150.4 Fe mM-1 s-1, respectively. The native GC-SPIO demonstrated 
only a minor increase in R2 relaxivity (≈ 5%) as the pH decreased to 5.9, while the 
glycidol GC and dextran SPIO had no pH dependence to their R2 values. Although 
improved relaxivity for the native GC-SPIO at low pH values can further improve pH 
mediated contrast, this is not the primary mechanism by which contrast is generated. 
Rather, titration of the native GC-SPIO surface coat leads to greater accumulation of 
nanoparticles at the tumor. Given the R2 values for all three formulations were very 
similar at physiologic pH, it was concluded that there is no contrast bias for the native 
GC-SPIO.Finally, the surface charge (zeta potential), and its pH dependence, was 
examined for each of the nanoparticle formulations (Figure 5.5). The native GC-SPIO 
nanoparticle was found to have a near-neutral zeta potential (+0.3 mV) at physiologic pH 
= 7.4. It is important for tumor delivery that the native GC-SPIO have little or no positive 
surface charge at normal blood pH, since cationic materials are rapidly cleared from 
circulation, due to local electrostatic interactions, before they could reach a tumor.29 
Next, as the pH was lowered, the zeta potential continually increased and reached a value 
of +4.1 mV at pH = 6.65 and +8.2 mV at pH = 6.15. Therefore, it was confirmed that the 
native GC-SPIO nanoparticles had a surface coat capable of meaningfully sensing a pH 
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drop of 1.0 unit or less. Since a wide variety of cationic materials have been found to 
electrostatically associate with cells25-28, it was expected that the surface properties of the 
native GC-SPIO nanoparticles would allow them to adhere to cells or negatively charged 
cellular matrix components in a pH-dependent manner that is favorable for detection of 
acidic environments. 
 
Figure 5.5. Zeta potential (surface charge) titration of native GC-SPIO, glycidol GC-SPIO and dextran 
SPIO nanoparticles at 100 µg/mL nanoparticle concentration in 10 mM HEPES buffer at various pH. 
 
The pH-dependence of the surface charge was similarly investigated for the 
glycidol GC-SPIO and dextran SPIO nanoparticles (Figure 5.5). At physiologic pH = 7.4, 
the zeta potentials were -2.9 mV and -20.4 mV for the glycidol GC-SPIO and dextran 
SPIO, respectively. Upon lowering of the pH to 6.15, the zeta potentials changed to -1.0 
mV and -20.7 mV. These results indicate that the surface charge of the control 
nanoparticles does not have significant pH dependence; under conditions that lead to an 
increase in the zeta potential of the native GC-SPIO by 7.9 mV, the glycidol GC-SPIO 
increased only 1.9 mV, and the dextran SPIO zeta potential dropped by 0.3 mV (a 
difference within the standard deviation of a given measurement). It should be noted that 
159 
 
the zeta potential of both control nanoparticles remains below 0 mV under every pH 
condition, such that not even an extremely acidic tumor environment would be able to 
induce electrostatic adherence of these nanoparticles.  
It should be noted that the two GC-based nanoparticle formulations have similar 
(close to neutral) surface charge at physiologic pH = 7.4. In fact, their surface charges 
proved similar enough to give them overlapping blood circulation profiles (see below). 
The glycidol GC-SPIO control formulation, therefore, specifically isolates the EPR 
component of tumor delivery from the native GC-SPIO formulation, so that pH-mediated 
improvement can be assessed. The -20 mV dextran nanoparticles, along with dextran 
formulations investigated at other charges,24 have zeta potentials encompassing the 
charge of native GC-SPIO at physiologic pH. Variations in surface charge can lead to 
differences in blood circulation times, and therefore, tumor delivery by EPR. Therefore, 
the dextran formulations make it possible to see if the delivery of native GC-SPIO 
compares favorably to the delivery obtainable by EPR alone, at any surface charge. 
 
Table 5.1 Summary of the physicochemical properties of native GC-SPIO, glycidol GC-SPIO, and 
dextran SPIO nanoparticles.  
 
Particle 
Surface 
Tracer 
Lanthanide 
Mean 
Hydrodynamic 
Diameter (nm) 
Mean 
Core Size 
(nm)* 
Zeta (mV) 
at pH = 
7.4 
Zeta (mV) 
at pH = 
6.15 
R2  
(mM-1s-1) 
R1 
(mM-1s-1) 
Native 
GC 
Gd 33.6 19.8 ± 3.6 +0.3 +8.2 146.5 7.5 
Glycidol 
GC 
Gd 36.1 19.8 ± 3.6 -2.9 -1.0 152.3 7.9 
Dextran Sm 29.8 19.4 ± 3.9 -20.4 -20.7 150.4 10.0 
*Since the glycidol GC-SPIO was generated by direct surface modification of native GC-SPIO, core sizes 
for these formulations are identical. 
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In Vitro pH Dependent Association of Native GC-SPIO 
Following the successful synthesis of the native GC-SPIO, possessing a favorably 
pH-dependent surface charge, as well as size and relaxivity matched pH-independent 
control nanoparticles, the ability of each formulation to label tumor cells in vitro and 
generate in vitro MR contrast was investigated under various pH conditions. Specifically, 
each nanoparticle formulation was incubated in triplicate with T6-17 tumor cells in 
culture medium at a concentration of 25 µg Fe/mL at pH values ranging from 5.9 to 7.65, 
in 0.25 unit increments. Following triplicate washing to remove unassociated 
nanoparticles, the T2 relaxation times of the cell suspensions were measured to access the 
extent of cell association (Figure 5.6).  
 
Figure 5.6 In-vitro association of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO nanoparticles 
with T6-17 cells. Nanoparticles were incubated in triplicate at 25 µg Fe/mL with 4 x 106 T6-17 cells in 
culture medium buffered by 25 mM HEPES. After removal of unassociated nanoparticles, T2 relaxation 
times were collected for each cellular suspension. 
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Interestingly, it was found that cells incubated with native GC-SPIO nanoparticles 
exhibited a pronounced pH-dependence to their T2 relaxation times. At physiologic pH = 
7.4, the native GC-SPIO cells had an average T2 relaxation time of 917 ms that was not 
statistically different from the T2 relaxation times of cells incubated with either control 
nanoparticle or blank cells incubated without nanoparticles. However, when the pH was 
dropped only one quarter of a pH unit to 7.15, the average T2 relaxation time of native 
GC-SPIO incubated cells dropped to 728 ms. Although not a particularly robust T2 value, 
728 ms was statistically different from the values of 950 ms and 927 ms observed for 
cells incubated without nanoparticles or glycidol GC-SPIO control nanoparticles, 
respectively. These results suggest that, under ideal conditions, the pH-titratable native 
GC-SPIO nanoparticles can differentially label cells in microenvironments only 0.25 pH 
units below physiologic value. After another 0.25 unit drop in pH to 6.90, the native GC-
SPIO nanoparticle incubated cells obtained an average T2 value of 553 ms, which was 
statistically different from blank cells and cells incubated with both control nanoparticle 
formulations. With further reductions in the incubation pH, the average T2 value for cells 
incubated with native GC-SPIO continued to decrease, ultimately reaching values of 147 
ms at pH 6.15 and 96 ms at pH 5.90. 
Appropriately, neither the glycidol GC nor dextran SPIO control nanoparticles 
exhibited any meaningful pH-dependence in their cellular association. Although the 
glycidol GC-SPIO cells incubated at very low pH values (5.90 and 6.15) yielded T2 
relaxation times that were statistically different from the value at physiologic pH = 7.4, 
the T2 values at low pH were still greater than 700 ms, indicating a weak signal. Recall 
that native GC-SPIO incubated cells had already reached this relaxation level at pH 7.15. 
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The statistically detectable difference in relaxation for the glycidol GC-SPIO incubated 
cells at the two extremes of pH is likely due to a small population of titratable amino 
groups remaining despite chemical blockade. For the dextran SPIO, there was no 
statistically detectable difference in cell association between the two ends of the pH 
spectrum. 
It is also noteworthy that native GC-SPIO nanoparticles are able to produce T2 
relaxation times under 200 ms in these cell pellet studies at concentrations of only 25 µg 
Fe/mL. For comparison, actively targeted SPIO nanoparticles relying on receptor – ligand 
interactions have been tested under similar conditions and yielded similar T2 relaxation 
times when incubated at concentrations of 150 µg Fe/mL.32 Although such a comparison 
is not exact, these results indicate native GC-SPIO nanoparticles may be able to generate 
contrast of a magnitude similar to receptor targeted SPIO nanoparticles.  
Following measurement of their T2 relaxation times, the cell pellets were 
transferred to a well plate and a T2* weighted MR image was acquired (Figure 4B). For 
the cells incubated with native GC-SPIO, signal loss can already be discerned at a pH of 
7.15, only 0.25 units below physiologic pH. The signal loss becomes more pronounced as 
the incubation pH drops to 6.65 and at pH 6.15 and below the signal is lost entirely under 
these imaging parameters. Importantly, the cells incubated with glycidol GC and dextran 
SPIO control nanoparticles do not exhibit any marked pH-dependence in their MR signal 
intensity. 
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Figure 5.7 Triplicate samples at each pH were combined into a single well of a 384-well plate and a T2* 
weighted MR image was obtained. Pellets with low T2 relaxation times, resulting from the presence of 
nanoparticles, appear with reduced signal intensity in the image.  
 
In Vivo MR Contrast Enhancement of Native GC-SPIO 
The ability of native GC-SPIO to generate MR contrast significantly greater than 
the background EPR effect was confirmed with an in vivo murine tumor model. 
Specifically, T6-17 flank tumors were grown in nude mice to a diameter of 
approximately 8 mm and then either native GC-SPIO or control nanoparticles at a dose of 
10 mg Fe/kg body weight (approximately 0.2 mg of iron per animal) was administered 
intravenously. T2* weighted MR images were acquired immediately prior to injection of 
nanoparticles and 24 hours after injection (Figure 5.8). The post contrast images of the 
native GC-SPIO nanoparticle demonstrated striking relative signal loss in the tumor. In 
the pre-contrast image shown, the tumor is located between iso-intense paraspinal and 
thigh muscles and is not clearly delineated. In the post-contrast image, however, the 
tumor is revealed as a hypo-intense heterogeneous region, with well-defined margins, 
exerting a mass effect against the adjacent paraspinal muscle. The heterogeneity of 
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intensity in the tumor is likely caused by impaired SPIO diffusion and penetration once 
they encounter a micro-region of sufficient acidity, either at the negatively charged 
vascular endothelium or within the tumor interstitium. Alternatively, the heterogeneity 
may reflect variations in extracellular pH within the tumor.33 Neither the glycidol GC nor 
dextran SPIO control nanoparticles yielded significantly visible contrast enhancement 
between pre- and post-contrast images.  
 
Figure 5.8 In vivo pre- and post-contrast MR images of nu/nu nude mice with T6-17 flank tumors. 
Representative T2* weighted MR images in the axial plane prior to injection (pre-contrast) and 24 hours 
after injection (post-contrast) of native GC-SPIO (n=4), glycidol GC-SPIO (n=4) and dextran SPIO (n=3) 
nanoparticles. Tumor location is indicated by white arrows. 
 
The MR signal in the tumor regions of interest (ROIs) were also analyzed 
quantitatively (Figure 5B). For each animal, three matching axial slices were examined 
pre- and post-contrast. Variations in absolute signal from slice to slice, due to mouse or 
RF coil positioning, were accounted for by normalizing the tumor signal to that of 
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adjacent paraspinal muscle on a slice by slice basis. The native GC-SPIO nanoparticles 
yielded a contrast enhancement (relative signal intensity ratio) of 0.50. In this scale, 
lower values indicate greater contrast, with 1.0 corresponding to no contrast and 0 
indicating perfect contrast. Importantly, the contrast enhancement observed for native 
GC-SPIO nanoparticles was statistically different from that of glycidol GC and dextran 
SPIO, which had RSI ratios of 0.86 and 0.84, respectively.  
 
Figure 5.9 Quantitative analysis of MR images of native GC-SPIO (n=4), glycidol GC-SPIO (n=4) and 
dextran SPIO (n=3). Signal intensity of each tumor was normalized to adjacent paraspinal muscle. For 
contrast measurement, the relative signal intensity, RSI, was calculated as the quotient of the post-contrast 
to pre-contrast normalized tumor intensity. For t-test statistical analysis of the groups, statistically 
significant values of p<0.05 are indicated with single asterisk and p<0.005 with double asterisk.  
 
Interestingly, the RSI ratio obtained for these native GC-SPIO nanoparticles was 
comparable to that obtained in a study of actively targeted SPIO nanoparticles injected at 
the same concentration and directed against the same tumor cell line.32 While many 
variables influence the contrast enhancement observed in vivo, it is encouraging to see 
that the pH-titratable native GC-SPIO nanoparticles can deliver contrast enhancement on 
the same order as actively targeted agents.  
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Tumor Delivery and Blood Circulation 
To specifically examine the amount of nanoparticle delivery to the tumor, as well 
as investigate blood circulation profiles, the nanoparticle formulations were designed 
with unique lanthanide metal tracers that can be detected by ICP-MS. Immediately after 
the post-contrast images were acquired, each animal was sacrificed and the flank tumors 
removed. By comparing the amount of lanthanide tracer present in the excised tumors to 
the amount of lanthanide present in the original intravenous injection, the amount of 
nanoparticle delivery can be quantified as a percent of injected dose per gram of tumor 
tissue (Figure 5.10). Also, these data can be converted into absolute iron concentrations 
since the amount of injected material is known. The nanoparticle iron concentrations in 
the tumor were thus calculated as 2.5, 4.2, and 6.7 µg/mL for dextran, glycidol, and 
native GC-SPIO, respectively.  
 
Figure 5.10 Quantitative tumor delivery of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO. 
Percent injected dose per gram of tumor tissue was calculated by measuring the concentration of lanthanide 
tracer in excised tumors using ICP-MS. For the native GC-SPIO, this converts to approximately 6.7 µg Fe / 
mL. For t-test statistical analysis of the groups, statistically significant values of p<0.05 are indicated with 
single asterisk and p<0.005 with double asterisk. 
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Interestingly, even though MR imaging yielded similar contrast enhancement for 
the glycidol GC-SPIO and dextran SPIO, there was significantly more nanoparticle 
delivery for the glycidol GC-SPIO. The contrast enhancement observed in MR images 
reflects the combination of many variables, including, but not limited to: concentration of 
agent in the tumor, MR pulse sequence parameters (e.g. TE), and nanoparticle relaxation 
characteristics (e.g. R2). Specifically, the nanoparticles have a dynamic concentration 
range in which they linearly decrease the tissue’s relaxation time. For the SPIO used in 
this study the dynamic range, determined during in vitro relaxation measurements, was 1 
– 50 µg/mL (Figure 5.11). Little contrast may be observed with nanoparticle 
concentrations at the low end of this range, significant improvements in contrast occur 
near the middle of the range, and saturation occurs at the top. It is likely that the 
nanoparticle concentrations achieved by dextran and glycidol GC-SPIO are very near the 
bottom of the dynamic range, still not high enough to generate significant contrast with 
the pulse sequence parameters used.  
 
Figure 5.11 MR signal response profile for native GC-SPIO. At T2 values lower than 5 ms, the signal 
becomes saturated and a T2 values greater than 900 ms, the signal is not discernibly different from baseline 
medium (A). The linear dynamic range of the native GC-SPIO, therefore, falls roughly between 1 – 50 µg 
Fe / mL (B). 
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The animals injected with native GC-SPIO nanoparticles showed a further 
significant increase in tumor delivery from the glycidol GC-SPIO. Importantly, this pH-
mediated increase in nanoparticle delivery was sufficient to reach a concentration 
providing much more MR contrast. This demonstrates the importance of optimizing and 
maximizing nanoparticle delivery, since the incremental improvement in delivery (i.e. 
from glycidol GC-SPIO to native GC-SPIO) has the possibility to yield significant 
contrast improvement. It is envisioned that while a completely passive agent might not 
reach a concentration detectable on an MR image, the additional improvement in delivery 
obtained by a pH-sensitive agent could result in detectable MR contrast. 
It has been well established that entirely passive tumor delivery of nanoparticles 
via EPR is a function of the pharmacodynamics of their blood circulation20-23. The two 
GC based formulations are of similar size, have a similar (although not exactly identical) 
zeta potential at the physiologic pH = 7.4, and have a surface coat constructed from the 
same polymer. These two formulations, therefore, were expected to have very similar 
blood circulation profiles. This important hypothesis was validated by using ICP-MS to 
measure the blood concentration for each nanoparticle as a function of time (Figure 5.12). 
As anticipated, the native GC-SPIO and glycidol GC-SPIO were found to have very well 
overlapped blood circulation profiles. Importantly, the small difference between the 
native GC-SPIO and glycidol GC-SPIO surface charge at physiologic pH did not alter 
their blood clearance. Therefore, it can be concluded that the incremental improvement in 
delivery that native GC-SPIO exhibits over glycidol GC-SPIO represents pH-mediated 
delivery, not attributable to EPR. 
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Figure 5.12 Blood clearance of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO (-20 mV) as 
measured by concentration of lanthanide tracer in the blood. 
 
In order to see how the pH-enhanced tumor delivery of native GC-SPIO compares 
to the EPR that could be obtained with surface charges (other than neutral), it is helpful to 
examine the tumor delivery of the dextran SPIO nanoparticles at -20 mV and other zeta 
potentials. This can also rule out the possibility native GC-SPIO is simply adopting some 
positive charge, within its titration range, that would have produced high delivery even if 
the nanoparticle were fixed at that particular charge. Dextran SPIO with pH-independent 
zeta potentials of approximately -12 mV, -5 mV, +4 mV, +10 mV and +14 mV were 
intravenously administered to animals bearing T6-17 flank tumors Chapter 4.24 Like the -
20 mV dextran SPIO nanoparticles in this study, none of the pH-insensitive dextran SPIO 
nanoparticles accumulated as well as native-GC SPIO (i.e. statistically significant inferior 
delivery for every dextran SPIO nanoparticle, Figure 5.13). The lower delivery observed 
for the -20 mV and other charge dextran formulations correlated with their shorter blood 
residence times (Figure 5.12), characteristic of delivery by EPR. Importantly, the dextran 
SPIO with strongly positive surface charge accumulated especially poorly at the tumor 
site. It is, therefore, important for the mechanism of native GC-SPIO delivery that the 
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nanoparticles not constitutively display a large positive surface charge – rather only after 
entering the tumor microenvironment.  
 
 
Figure 5.13 Tumor delivery of native GC-SPIO compared to glycidol blocked GC-SPIO and dextran 
SPIO formulations with a wide range of pH-insensitive zeta potentials. 
 
Finally, in addition to the pathological environment of a tumor, other groups 
investigating pH-responsive agents have demonstrated that there are physiologically 
normal sites of pH < 7.4, such as the renal tubular system.34-36 Therefore, the delivery of 
native GC and control SPIO nanoparticles to the kidneys was examined. At 24 hours 
post-injection, the average renal concentrations, expressed as percent of injected dose per 
gram of kidney tissue, were found to be 4.49, 2.40, and 1.02 for native GC-SPIO, 
glycidol GC-SPIO and dextran SPIO (-20 mV), respectively (Figure 5.14). Given the 
longer blood residence times for the two GC based formulations, it is not surprising to 
observe a greater renal concentration at 24 hours for those formulations compared to the 
dextran SPIO. Interestingly, though, the renal concentration of the native GC-SPIO was a 
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statistically significant 87% higher than that of the glycidol GC-SPIO, despite very 
similar blood circulation profiles and identical blood concentrations at the 24 hour time 
point. Furthermore, the native GC-SPIO nanoparticles are not simply being deposited to a 
higher extent in all organs, since the concentrations of all three nanoparticles in the liver 
at 24 hours were not statistically distinct from one another. Despite the lack of statistical 
significance, the native-GC SPIO nanoparticles had a trend towards less accumulation in 
the liver (33.3 versus 44.9 and 37.9 for the glycidol GC and dextran SPIO, respectively, 
Figure 5.14). 
 
 
Figure 5.14 Kidney and liver concentrations of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO 
(-20 mV), 24 hours post-injection. Asterisk indicates statistical significance (p<0.05) between native GC-
SPIO kidney uptake and either control nanoparticle. 
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5.5 Conclusion 
The biocompatible and biodegradable polymer glycol chitosan can be used to impart pH-
responsiveness to superparamagnetic iron oxide nanoparticles. The resulting material 
demonstrates a pH-dependent surface charge, allowing it achieve long blood circulation 
at physiologic pH = 7.4 and then transition to a cationic and adhesive form upon entering 
an acidic microenvironment pH < 7.0. These native GC-SPIO nanoparticles exhibited 
significantly improved accumulation in a murine tumor model, compared to nanoparticles 
with similar physical properties, but lacking pH-responsiveness. Higher levels of SPIO 
accumulation in the tumor also resulted in a clear and quantifiable improvement in 
magnetic resonance contrast, as shown on T2*-weighted images. Generally, it is believed 
glycol chitosan could be used to exploit the metabolic profile of a wide range of 
malignancies and improve the tumor delivery of imaging or therapeutic agents, provided 
that synthesis of such agents preserves the pH-responsive amino group. 
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Chapter 6: Summary Discussion, Future Directions and 
Concluding Remarks 
6.1 Summary Discussion 
6.1.1 ICP-MS Multiplexing Analysis Applied in vivo 
 Since it was first used to analyze amino acids in 1958,1 mass spectrometry (MS) 
has become an extremely powerful tool in the investigation of biological samples. For 
example, mass spectrometry, combined with powerful computational methods, plays a 
critical role in the field of proteomics and metabolomics.2 MS can facilitate the 
identification of protein bands on gels using peptide mass fingerprinting3 and can be used 
for de novo peptide sequencing.4 When MS is coupled to a very high temperature plasma 
source (ICP-MS) elemental analysis of complex biological samples becomes possible. 
Recently, it was recognized that unique elemental isotopes (e.g. of lanthanides) could be 
used to “tag” biomolecules for identification and quantitation by ICP-MS.5 Given the 
very large window of atomic masses not normally observed in biological samples, very 
high order multiplex analysis becomes possible. This remarkable capability was very 
recently (May 2011) combined with flow cytometry to yield a technique dubbed “mass 
cytometry”.6 Specifically, conjugated metal isotopes were used to simultaneously 
measure the binding of 31 antibodies to single cells. This detailed level of analysis (3 – 4 
times more powerful than state of the art multi-color flow cytometry) revealed previously 
unappreciated cell signaling and phosphorylation responses in human hematopoietic 
cells. The objective of this thesis was to demonstrate the applicability of ICP-MS 
multiplex analysis to supra-molecular assemblies (i.e. nanoparticles), and more 
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importantly, pave the way for high-order multiplexing of in vivo data such as 
pharmacokinetics and biodistribution. 
 Firstly, lanthanide metals were used to tag superparamagnetic iron oxide (SPIO), 
a promising and widely-researched T2-weighted magnetic resonance contrast agent. A 
synthetic protocol to stably incorporate the lanthanide metals into the core of SPIO 
nanoparticles, without abolishing their magnetic properties, was developed. The 
lanthanide dopant can be used as a unique tracer atom, allowing the sensitive and 
quantitative detection of the entire nanoparticle by ICP-MS, both in vitro and in vivo, 
without interference from endogenous signals. When distinct lanthanide metals are 
incorporated into nanoparticles with distinct physicochemical properties, ICP-MS allows 
for the concentration of each nanoparticle formulation to be measured independently of 
other formulations that may be present in the solution or tissue of interest. As a proof of 
principle, this ICP-MS multiplex approach was used to evaluate the effect of nanoparticle 
size and surface charge on tumor delivery, biodistribution, and blood clearance in vivo. 
The results obtained were consistent with the general literature consensus about these 
properties and only required a small number of experimental animals, due to the inherent 
and robust statistical power of a multiplex (ratiometric) approach. Furthermore, it is 
envisioned that the ICP-MS multiplex analysis could prove to be a powerful future 
research tool in the investigation of other less well-characterized physicochemical 
properties. 
Secondly, more generalizable methods of lanthanide incorporation were pursued. 
It was found that in addition to precipitating lanthanide metals into the core of SPIO 
nanoparticles, it is also possible to incorporate lanthanides into liposomes, 
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polymersomes, and dendrimeric formulations using either encapsulation or chelation. 
Therefore, it is envisioned that any nanoparticle formulation amenable to labeling with a 
metal radionuclide would also be suitable for labeling with an ICP-MS metal tracer. 
Some other types of nanoparticles (e.g. gold and silver nanoparticles) inherently contain 
an ICP-MS metal tracer, without any further need for labeling. In addition to providing a 
quantitative method of detection with high sensitivity, ICP-MS tracers provide two 
potential benefits over conventional radiolabeling. Namely, they have the ability to easily 
multiplex a large number of signals in a single fluid or tissue sample while avoiding the 
hazards of handling radioactivity. Consequently, ICP-MS based multiplex analysis can be 
applied to a very wide variety of nanoparticle and macropharmaceutical formulations and 
allows for “higher throughput” evaluation of the pharmacokinetics and biodistribution of 
such agents in animals models. 
 Since active targeting of pathologies in vivo at the molecular level is an extremely 
promising and actively pursued strategy in nanotechnology, we sought to demonstrate 
how ICP-MS multiplexing could be exploited to streamline the evaluation of actively 
targeted nanoparticles in vivo. Specifically, SPIO nanoparticles were synthesized with a 
variety of lanthanide tracer metals and all had overlapping size distributions, so that they 
exhibit equal levels of passive tumor accumulation. These Ln-SPIO formulations were 
then be subsequently functionalized with active targeting ligands, such that each targeting 
ligand is associated with a specific lanthanide tracer. The binding of these nanoparticles 
to two tumor cell lines, with varying expression levels of three specific receptors, was 
examined in vitro with conventional methods such as flow cytometry. Then ICP-MS 
analysis was used to independently quantify the cell labeling of each nanoparticle, 
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compared to a non-targeted formulation, in a single sample. Therefore, it should become 
feasible in a single study to investigate in vivo many nanoparticle active targeting and 
negative control formulations, collecting data such as nanoparticle blood residence time, 
tumor delivery, and biodistribution. This represents a powerful tool for nanotechnology 
investigators to more thoroughly evaluate a greater number of nanoparticle formulations 
in vivo, while reducing experiment time, cost, and number of animals. 
6.1.2 Development of pH-Responsive SPIO 
Another major avenue of investigation in this thesis was the design of a novel 
pH-sensitive SPIO nanoparticle for relative pH imaging of acidic tumor 
microenvironments. Such an approach provides a complimentary approach to 
absolute pH imaging by MRS (where the pH is determined by the chemical shift of 
the probe) or CEST (where changes in pH influence the chemical exchange kinetics). 
With a relative pH probe, the goal is to detect regions of relatively abnormal pH by 
designing agents that preferentially accumulate in these regions. That is, the identity 
of the signal is not influenced by pH, but the biodistribution of the agent is influenced 
by pH. In this respect, such an agent has much in common with a classic 
receptor/ligand actively targeted molecule; the agent washes into the tumor through 
the enhanced permeability of the tumor vasculature and then is preferentially retained 
at the tumor site through pH mediated alterations in the nanoparticle’s 
physicochemical properties. 
It was found that the biocompatible and biodegradable polymer glycol chitosan 
can be used to impart pH-responsiveness to superparamagnetic iron oxide nanoparticles. 
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The resulting material demonstrates a pH-dependent surface charge, allowing it achieve 
long blood circulation at physiologic pH = 7.4 and then transition to a cationic and 
adhesive form upon entering an acidic microenvironment pH < 7.0. These native GC-
SPIO nanoparticles exhibited significantly improved accumulation in a murine tumor 
model, compared to nanoparticles with similar physical properties, but lacking pH-
responsiveness. Higher levels of SPIO accumulation in the tumor also resulted in a clear 
and quantifiable improvement in magnetic resonance contrast, as shown on T2*-weighted 
images. Generally, it is believed glycol chitosan could be used to exploit the metabolic 
profile of a wide range of malignancies and improve the tumor delivery of imaging or 
therapeutic agents, provided that synthesis of such agents preserves the pH-responsive 
amino group. 
6.2 Future Directions 
6.2.1 Completion of Active Targeting Comparison in vivo 
 In chapter 4, we used ICP-MS multiplex analysis to evaluate cell labeling of 
multiple actively targeted SPIO nanoparticles, compared to a non-targeted formulation, 
all in a single in vitro measurement. The final logical experiment, clearly, is to complete 
the in vivo characterization of these nanoparticles. Specifically, the HER2-SPIO, RGD-
SPIO, LDS-SPIO, and Blank-SPIO will be pooled into a single sample and administered 
intravenously to tumor bearing mice. Optimally, the animal subjects will bear both the 
“receptor-high” T6-17 tumors and “receptor low” HeLa tumors on opposite flanks. This 
will allow blood clearance of the four Ln-SPIO formulations, as well as tumor delivery to 
both cell lines, to be evaluated in a single animal. 
183 
 
6.2.2 Future Applications of in vivo ICP-MS Multiplex Analysis 
This thesis only begins to explore the possibilities of what information can be 
obtained from in vivo use of ICP-MS multiplex analysis. For example, the effect of SPIO 
nanoparticle size and charge on passive tumor delivery and biodistribution were assessed, 
so that the results obtained could be compared to the general literature consensus of these 
effects.7-10 However, there are many other physicochemical properties (e.g. shape, surface 
chemistry, elasticity, and other mechanical properties) that can affect nanoparticle tumor 
delivery and biodistribution, all of which are less fully understood and could be 
investigated using this method.  
Additionally, the ICP-MS multiplex method could aid in the evaluation of more 
nuanced questions in the field of nanoparticle active targeting. Specifically, the ICP-MS 
multiplex approach could be used to compare variations of a given actively targeted 
nanoparticle. For example, different ligand types, such as an antibody, single chain 
antibody fragment (scFv), or small affinity peptide could be quantitatively compared. Or, 
within a given class of ligand, different specific sequences could be compared (i.e. 
several affinity peptide sequences obtained from phage display). Furthermore, it is being 
appreciated that optimal cell binding and in vivo delivery is not necessarily achieved by 
coating a nanoparticle with the maximum possible ligand density. Thus, ICP-MS 
multiplex analysis presents a powerful tool to evaluate the effect of ligand density. Also, 
active targeting of nanoparticles displaying ligands for two or more targets could be 
compared against more conventional single ligand formulations.  
The ICP-MS multiplex approach could also be adapted to more specialized 
research questions. For example, nanoparticle trafficking and metabolism could be 
probed by labeling different components of the nanoparticle with different lanthanides 
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(e.g. encapsulating one metal within a liposome core and chelating another metal to the 
lipid membrane component). Or chelation stability could be evaluated in vivo by 
constructing a given nanoparticle formulation but using different chelators to incorporate 
the metal. In general, it is envisioned the ICP-MS multiplex method could be exploited to 
answer any research question involving the in vivo comparison of two or more agents that 
are amenable to lanthanide labeling. 
Furthermore, it is envisioned that the spatial distribution of each nanoparticle 
within an organ or other tissue sample could also be obtained with the use of laser 
ablation ICP-MS.11 With LA-ICP-MS, the tissue sample is directly vaporized, layer-by-
layer, with a pulsed laser and transported into the mass analyzer.12 Another potential 
advantage of LA-ICPS-MS is the ability to process microgram samples sizes, which 
could be required for the analysis of smaller organs or specialized tissue (e.g. lymph 
nodes, adrenal glands). 
6.2.3 Use of ICP-MS Multiplex Analysis to Generate Standardized 
Data 
Another promising application of this multiplex ICP-MS method is the potential 
to generate standardized data that can be compared between studies and between 
laboratories. With so many research groups engaged in the development of nanoparticles, 
a myriad of different formulations have been synthesized for both imaging and 
therapeutic applications.13 Even when nanoparticle (payload) delivery is quantitatively 
reported, it is difficult for one group to ascertain whether their formulation resulted in 
better delivery than another’s, given the numerous variables, known and unknown, 
involved in an in vivo study. This is a particularly significant problem in the nanoparticle 
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field, and one that hinders the progress of nanoparticles into clinical evaluation.14 
However, if a rigorously standardized and highly reproducible lanthanide-doped 
nanoparticle (such as a G5 dendrimer with tightly chelated lanthanide) were available, 
each group could co-inject the standardized nanoparticle along with their investigational 
one. The delivery of the investigational agent could, therefore, be reported not only in 
absolute terms, but also as a ratio to the standardized particle. Such a ratiometric 
approach could facilitate accurate comparisons between various investigational agents.  
6.2.4 Future Applications of pH-Responsive Glycol Chitosan and 
SPIO 
 Chapter four of this thesis demonstrated the success of using a glycol chitosan 
(GC) coating to increase the tumor delivery of SPIO nanoparticles based on tumor 
acidity. There are a number of possible ways to improve and adapt this approach for 
future investigational agents. For example, glycol chitosan is only one of a number of 
pH-responsive polymers or peptides that could be used to sense relative changes in pH. 
Future work could focus on using GC or another polymer to optimize the nanoparticle’s 
titration curve, with respect to starting zeta potential at physiologic pH, the pH at which 
charge transition begins to occur, and the steepness of the charge switch. Such studies 
could lead to an agent capable of sensing smaller deviations in pH while further reducing 
background accumulation at physiologic pH values. 
 Secondly, GC itself could be investigated as a pH sensor for imaging and 
therapeutic platforms in addition to SPIO. For example, a T1-weighted MR contrast agent 
could be developed by decorating a fraction of GC’s functional amino groups with small 
generation dendrimers, each carrying many gadolinium chelates. Similarly, incorporation 
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of 64Cu chelates could produce a novel pH-sensitive PET probe. Beyond imaging 
applications, GC could be incorporated into the design of drug-carrying nanoparticle 
formulations (e.g. polymeric micelles or nanovesicles) in order to facilitate 
chemotherapeutic delivery to tumors. 
 Finally, it may be possible to use the pH-dependent titration of GC to make 
measurements of absolute pH using chemical exchange saturation transfer (CEST). That 
is, the amine protons of the glycol chitosan should exhibit variable chemical exchange 
kinetics depending on the pH of their local environment. If a lower molecular weight 
form of GC were administered with large enough concentration, a saturation pulse could 
be applied on its N-H resonance, and the rate of saturation transfer to bulk water could be 
used as a pH meter in vivo. 
6.3 Concluding Remarks 
 Over the last two decades, the development of quantitative high-throughput 
analytical methods has revolutionized the process of molecular discovery and 
characterization in vitro. ICP-MS is increasing being used in these kinds of parallel 
processing of biological samples in vitro, as evidenced by the recent development of 
mass cytometry. In the future, we envision that “higher-throughput” evaluation of agents 
at the in vivo level using ICP-MS multiplex analysis may constitute a powerful tool to 
accelerate their pre-clinical evaluation in animal models. Further improvements to 
modularity and automation of lanthanide labeling (i.e. massively parallel conjugation of 
preformed metal-chelate complexes to macropharmaceuticals in robotically controlled 
reactions) would facilitate the use of in vivo ICP-MS multiplex analysis on a wider scale.  
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